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ABSTRACT 
 
 
In this work, a broad spectrum of novel platinum(II) complexes bearing various ketoxime and 
aldoxime ligands was prepared and characterized by elemental analysis, IR and electrospray 
ionization mass spectrometry (ESI-MS), multinuclear (1H, 13C, and 195Pt) NMR spectroscopy 
and, in some cases, X-ray crystallography. Further, evaluation of their cytotoxic potency was 
carried out. 
Initially, in order to study the effect of the leaving group as well as of the carbon chain length 
of the coordinated ketoxime ligand (both in neutral dichlorido and cationic diammino 
complexes) on the cytotoxicity, a number of structural modifications of the “parent” acetone 
oxime platinum(II) complex [PtCl2(Me2C=NOH)2] was performed. For this purpose, cis/trans-
couples of [PtX2(R2C=NOH)2] [X = Cl, Br, I; R = Me, Et, n-Pr, i-Pr] and 
[Pt(NH3)2(R2C=NOH)2](NO3)2 [R = Me, Et, n-Pr] were synthesized and characterized. The 
cytotoxicities of the novel species were studied in cisplatin-sensitive ovarian carcinoma (CH1) 
and inherently cisplatin-resistant colon carcinoma (SW480) cancer cells. Astonishingly, the 
dihalogenido complexes showed similar IC50 values in both tumor cell lines, therefore 
possessing a promising potential to circumvent cisplatin resistance. Changing the chlorido 
ligands for bromides in cis/trans-[PtX2(Me2C=NOH)2] resulted in the expected decrease of the 
cytotoxic potency, while the diiodido complexes exhibited an enhanced activity as compared 
to dibromido species, which could be explained by their increased lipophilicity facilitating 
cellular accumulation. As the dichlorido complexes cis/trans-[PtCl2(R2C=NOH)2] are 
concerned, the cytotoxicity depends on the substituent R as follows: Me ≈ i-Pr ≈ n-Pr > Et. 
The cationic species cis/trans-[Pt(NH3)2(R2C=NOH)2](NO3)2 proved to be less or insignificantly 
cytotoxic, which corresponds to the classical structure-activity rules postulating inactivity of 
charged complexes lacking leaving groups. Interestingly, a more pronounced cytotoxicity of 
the trans-configuration was confirmed for two more platinum(II)(oxime) cis/trans-couples. 
The second project is devoted to the generation of relatively inert platinum species (potential 
prodrugs) being capable of activation in the slightly acidic microenvironment of solid tumors. 
For this purpose, a series of zwitterionic diam(m)ine(3-hydroxy-2-(oxidoimino)propan-1-olato-
к2N,O)platinum(II) complexes [diam(m)ine = (ammonia)2, (ethylamine)2, ethane-1,2-diamine, 
and (R,R)-cyclohexane-1,2-diamine] featuring an N,O-chelate was generated, followed by the 
protonation of the oximato group by HCl and consequent opening of the chelate ring. The 
antiproliferative effect of the prepared compounds under physiological conditions (pH 7.4) 
was evaluated in vitro in three human cancer cell lines (CH1, SW480, and A549), 
demonstrating IC50 values in the medium or even low micromolar range. The solution 
behavior of a series of complexes featuring the ethane-1,2-diamine ligand was studied by 1H 
NMR spectroscopy at pH 7.4, 6.0, and exemplarily 5.0, correlating well with the pH-dependent 
cytotoxicity; activation of the chelated complex under slightly acidic conditions was observed. 
 
 
 
Furthermore, with the aim of increasing the aqueous solubility of the platinum(II)(oxime) 
species, aldoxime ligands E/Z-R(H)C=NOH were applied instead of ketoximes (R2C=NOH), 
resulting in trans-[PtCl2{(Z)-R(H)C=NOH}2] and trans-[PtCl2{(E)-R(H)C=NOH}{(Z)-
R(H)C=NOH}] [R = Me, Et]. As a next step, dimerization of the novel platinum(II)(aldoxime) 
species as well as of previously reported trans-[PtCl2(R2C=NOH)2] [R = Me, Et] complexes 
was performed leading to the corresponding dimers [PtCl(μ-RR’C=NO)(RR’C=NOH)]2 [R = Me, 
Et; R’ = H, Me, Et]. All compounds were completely characterized, including X-ray diffraction 
for two monomeric and two dimeric species. Interestingly, the crystal structure of an oximato-
bridged trimer featuring three platinum coordination units connected in a chain manner was 
determined. Additionally, solution behavior of trans-[PtCl2{(Z)-Me(H)C=NOH}2] and its 
respective dimer was studied at pH 7.4 and physiological NaCl concentration by 1H NMR 
spectroscopy, expectedly resulting in nearly identical equilibrium mixtures. Further, hydrolysis 
of the platinum(II)(aldoxime) complexes was studied exemplarily with trans-[PtCl2{(Z)-
Me(H)C=NOH}2] under the same conditions in absence of NaCl. The complex was ultimately 
converted into a new species, supposed to possess a ring-shaped oximato-bridged trimeric 
structure. Finally, the cytotoxic potency of the monomers and the corresponding dimers was 
studied in cisplatin-sensitive CH1 and intrinsically cisplatin-resistant SW480 and A549 cells. It 
was revealed that dimerization leads to a significant (1.3−6.6 times) enhancement of the 
cytotoxicity. Intriguingly, the novel complexes were found to be not cross-resistant to cisplatin 
in the SW480 cell line. 
 
 
 
 
 
ZUSAMMENFASSUNG 
 
 
Im Zuge dieser Dissertation wurde ein breites Spektrum an neuartigen Oximplatin(II) 
Komplexverbindungen synthetisiert und mittels Elementaranalyse, IR- und Elektrospray-
Ionisation Massenspektrometrie (ESI-MS), 1H, 13C, und 195Pt NMR-Spektroskopie und, in 
einigen Fällen, Röntgenstrukturanalyse charakterisiert. Weiterhin wurde die Zytotoxizität aller 
hergestellten Komplexe mittels MTT-Assay bestimmt.  
Zur Beurteilung der Auswirkung der Abgangsgruppe sowie der Kohlenstoffkettenlänge des 
Oximliganden auf die Zytotoxizität, wurden cis/trans-Paare [PtX2(R2C=NOH)2] [X = Cl, Br, I; R 
= Me, Et, n-Pr, i-Pr] und [Pt(NH3)2(R2C=NOH)2](NO3)2 [R = Me, Et, n-Pr] synthetisiert und 
vollständig charakterisiert. Die Zytotoxizität wurde in Cisplatin-sensitiven Ovarialkarzinom 
(CH1) und intrinsisch Cisplatin-resistenten Kolonkarzinom (SW480) Krebszellen untersucht. 
Da die Dihalogenidokomplexe ähnliche IC50-Werte in den beiden Tumorzelllinien zeigten, 
besitzen sie ein vielversprechendes Potential zur Überwindung der Cisplatin Resistenz. 
Austausch der Chlorido- gegen Bromidoliganden in cis/trans-[PtX2(Me2C=NOH)2] führte zu 
der erwarteten Verringerung der zytotoxischen Wirksamkeit, während die Diiodidokomplexe 
eine verstärkte Aktivität im Vergleich zu den Dibromidospezies zeigten. Dies ist erklärbar 
durch die erhöhte Lipophilie, die zu einer erhöhten zellulären Akkumulation führt. Bei den 
Dichloridokomplexen cis/trans-[PtCl2(R2C=NOH)2] hängt die Zytotoxizität von dem Substituent 
R wie folgt ab: Me ≈ i-Pr ≈ n-Pr > Et. Die kationischen Spezies cis/trans- 
[Pt(NH3)2(R2C=NOH)2](NO3)2 erwiesen sich als wenig zytotoxisch; dies entspricht den 
klassischen Struktur-Aktivitäts-Regeln. Zusätzlich wurde eine höhere Zytotoxizität der trans-
Konfiguration für zwei weitere Oximplatin(II) cis/trans-Paare bestätigt. 
Das zweite Projekt ist der Synthese von relativ inerten Platinspezies (potentiellen Prodrugs), 
die in der leicht saueren Mikroumgebung solider Tumoren aktivierbar sind, gewidmet. Zu 
diesem Zweck wurde eine Reihe von zwitterionischen Diam(m)in(3-hydroxy-2-
(oxidoimino)propan-1-olato-к2N,O)platin(II)-Komplexen [Diam(m)in = (Ammoniak)2, 
(Ethylamin)2, Ethan-1,2-diamin und (R,R)-Cyclohexan-1,2-diamin], gefolgt von der 
Protonierung der Oximato Gruppe mittels HCl und der anschließenden Öffnung des 
Chelatringes, synthetisiert. Die antiproliferative Wirkung der hergestellten Verbindungen unter 
physiologischen Bedingungen (pH 7.4) wurde in vitro in drei humanen Krebszelllinien (CH1, 
SW480 und A549) untersucht. Die IC50-Werte waren im mittleren oder sogar niedrigen 
mikromolaren Bereich. Das Verhalten der Ethan-1,2-diamin-Komplexserie in wässriger 
Lösung wurde mittels 1H-NMR-Spektroskopie bei pH 7.4, 6.0 und exemplarisch bei pH 5.0 
untersucht. Die Ergebnisse korrelieren gut mit der pH-abhängigen Zytotoxizität; eine 
Aktivierung des Chelatkomplexes unter leicht sauren Bedingungen wurde beobachtet. 
Zur Erhöhung der Wasserlöslichkeit der Oximplatin(II) Spezies, wurden Aldoxim Liganden 
E/Z-R(H)C=NOH anstelle der Ketoxime R2C=NOH für die Synthese von trans-[PtCl2{(Z)-
 
 
 
R(H)C=NOH}2] und trans-[PtCl2{(E)-R(H)C=NOH}{(Z)-R(H)C=NOH}] [R = Me, Et] verwendet. 
Als nächster Schritt wurde die Dimerisierung der neuen Aldoximplatin(II) Spezies sowie der 
trans-[PtCl2(R2C=NOH)2] [R = Me, Et] Komplexe durchgeführt und die entsprechenden 
Dimere [PtCl(μ-RR'C=NO)(RR'C=NOH)]2 [R = Me, Et, R' = H, Me, Et] erhalten. Alle 
Verbindungen wurden vollständig, einschließlich Einkristall-Röntgenstrukturanalyse für zwei 
monomere und zwei dimere Spezies, charakterisiert. Zusätzlich wurde die Kristallstruktur des 
Oximato-verbrückten Trimers mit drei kettenförmig verbundenen Platinkoordinationseinheiten 
bestimmt. Weiters wurde das Verhalten des trans-[PtCl2{(Z)-Me(H)C=NOH}2] Komplexes 
sowie des entsprechenden Dimers in wässriger Lösung bei pH 7.4 und physiologischer NaCl-
Konzentration mittels 1H-NMR-Spektroskopie untersucht. Erwartungsgemäß waren die 
Gleichgewichtsmischungen nahezu identisch. Zusätzlich wurde die Hydrolyse des 
Aldoximplatin(II)-Komplexes, trans-[PtCl2{(Z)-Me(H)C=NOH}2], unter den gleichen 
Bedingungen ohne Zusatz von NaCl untersucht. Schließlich wurde die zytotoxische Wirkung 
der Monomere und der entsprechenden Dimere in humanen CH1, SW480 und A549-
Tumorzellen bestimmt. Es zeigte sich, dass die Dimerisierung zu einer signifikanten (1.3- bis 
6.6-fachen) Steigerung der Zytotoxizität führte. Interessanterweise konnte für die neuen 
Komplexe keine Cisplatin-Kreuzresistenz in SW480-Zellen festgestellt werden.  
 
 
 
 
ABBREVATIONS 
 
 
Am    am(m)ine 
BOC    tert-butyloxycarbonyl 
DACH    diaminocyclohexane or cyclohexanediamine 
DMF    dimethylformamide 
DNA    deoxyribonucleic acid 
ESI-MS    electrospray ionization mass spectrometry 
Et    ethyl group 
5’-GMP    guanosine monophosphate 
gDNA    genomic deoxyribonucleic acid 
HMG    high mobility group 
IC50    half maximal inhibitory concentration 
IR    infrared (spectroscopy) 
Me    methyl group 
Me-pip    methylpiperidine 
MMR    mismatch repair 
mtDNA    mitochondrial deoxyribonucleic acid 
NER    nucleotide excision repair 
NMR    nuclear magnetic resonance 
NSCLC    nonsmall-cell lung cancer 
pdn    pyridazine 
4-phe-1,2,3-trz   4-phenyl-1,2,3-triazolate 
pmn    pyrimidine 
Pr    propyl group 
pz    pyrazolate 
pzn    pyrazine 
RNA    ribonucleic acid 
SCLC    small-cell lung cancer 
ta    tetrazolate 
TPA    trans-platinum planar amine complex 
1,2,3-trz   1,2,3-triazolate 
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I. INTRODUCTION 
 
 
Cancer, or malignant neoplasm, is a general term giving definition to a broad spectrum of 
diseases that can affect any part of the body (more than 100 different types of cancer are 
known). Cancer is notable for an uncontrolled growth of a group of abnormal cells and 
penetration into nearby tissues leading to their destruction. On the later stages, the tumor 
cells are spread to other parts in the body through the lymphatic or blood system resulting in 
the formation of metastases.   
 
 
Figure 1. Distribution of causes of deaths in Austria (WHO, 2010).1 
 
Cancer represents the second most prevailing cause of death in Austria, being inferior 
solely to the cardiovascular diseases (Figure 1).1  As provided by GLOBOCAN 2008,2  it 
accounted for about 12.7 million cases and 7.6 million deaths (around 13% of all deaths) 
worldwide in 2008. The predominant types of cancer are lung (1.4 million deaths), stomach 
(740 000 deaths), liver (700 000 deaths), colorectal (610 000 deaths) and breast (460 000 
deaths) cancer, however, it should be noted that the statistical data differ depending on the 
sex of patients. WHO evaluations for the near future show that the number of deaths caused 
by cancer worldwide is projected to continue rising, with estimated over 11 million deaths in 
2030. These facts explain an extremely high importance of cancer research. 
 
 
1. CLASSICAL PLATINUM-BASED ANTICANCER THERAPY 
 
1.1. Cisplatin: discovery and mode of action 
 
Cisplatin (1, Figure 2) is the first platinum-based anticancer agent, which became one of the 
most widely used antitumor drugs in cancer chemotherapy worldwide. The tumor-inhibiting 
3
  
 
properties of cisplatin have been serendipitously revealed over 40 years ago by the physicist 
Barnett Rosenberg at the Biophysical Department of the Michigan State University (USA).3 
Investigating the influence of an electric field on the growth of Escherichia coli cells, he 
observed unexpected filamentation of the bacteria. As it turned out, the fascinating biological 
effect was caused by compounds formed due to the chemical reaction: platinum from 
electrodes reacted with ammonium chloride from the culture medium under the influence of 
light. Thus, cis-[PtIICl2(NH3)2] (cis-diamminedichloridoplatinum(II), or cisplatin, 1), and cis-
[PtIVCl4(NH3)2] (cis-diamminetetrachloridoplatinum(IV), 2) were found to be responsible for this 
intriguing effect, whereas the corresponding trans-analogues (3 and 4) were proved to be 
significantly less active (Figure 2). The cis-complexes 1 and 2 were able to stop the cell 
division, leading to filamentous growth of bacteria; subsequent in vivo tests disclosed their 
antitumor activity.4 Finally, in 1978 the most active complex, cisplatin, was approved by the 
US Food and Drug Administration (FDA). 
 
Cl
Cl
Pt
NH3
NH3
Cl
Cl
Pt
NH3
NH3
Cl
Cl
Cl
H3N
Pt
Cl
NH3 Cl
H3N
Pt
Cl
NH3
Cl
Cl
1 2
3 4  
Figure 2. Structures of the cis-configured complexes responsible for complete cessation of 
cell division (1 and 2) as well as their nonactive trans-analogues (3 and 4). 
 
Cisplatin is especially effective in the case of testicular cancer, exhibiting cure rates over 
90%.5 Alone or in combination with other antitumor agents, it is applied for the treatment of 
ovarian, cervical, head and neck, esophageal and nonsmall-cell lung cancer.6−9 Cisplatin is 
administered intravenously. Due to a relatively high concentration of chloride ions in the blood 
(100 mM), the hydrolysis of cisplatin is suppressed and it stays in the intact neutral form. 
Cisplatin enters the cell basically by passive diffusion, but also by an active transport 
mechanism mediated by copper transport proteins (e.g. Ctr1) and/or organic cation 
transporters.10−12 The considerably diminished chloride concentration inside the cell (4–20 
mM) favors the hydrolysis of the drug resulting in the formation of aqua- and hydroxido 
species (Figure 3).   
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Figure 3. Behavior of cisplatin in aqueous solution. 
 
There is strong evidence that genomic DNA is the primary target of cisplatin. 13 − 15  Via 
exchange of chlorido by aqua ligand(s), the activation of the drug occurs, so that it can readily 
bind to N7 of the imidazole ring of guanine and to a significantly lesser extend of adenine. 
Cisplatin was shown to form 1,2-intrastrand cross-links involving adjacent guanine bases (cis-
GG), comprising 47–50% of all adducts formed, or guanine and adenine bases (cis-AG), 
comprising another 23−28%. Additionally, 8−10% of 1,3-interstrand cross-links involving 
nonadjacent guanines were detected, as well as 2−3% of monofunctional adducts. It is worth 
mentioning that in all cases platinum proved to be bound to the N7-atom of a purine base. 
1,2-Intrastrand cross-links were found to be the major DNA adducts formed by cisplatin and 
they are believed to be responsible for its anticancer activity. 16,17 The binding of cisplatin to 
DNA distorts its structure by bending and unwinding, which prevents its replication and 
transcription, ultimately leading to apoptosis (programmed cell death). Additionally, the drug 
forms a high amount of adducts in mitochondrial DNA (6- and 4-fold higher proportion of 
adducts in mtDNA as compared with gDNA adducts was found). Considering the fact that 
mitochondria are incapable of nucleotide excision repair (NER), a major pathway to remove 
cisplatin-DNA adducts, mitochondrial DNA could be an important pharmacological target for 
cisplatin as well.15 Furthermore, it was observed that the complex is able to bind to RNA, 
which may play a significant role in its mode of action.18 
DNA adducts formed by cisplatin are mainly repaired through the nucleotide excision repair 
(NER) mechanism,15, 19  which involves recognition of DNA damage, binding of specific 
proteins (e.g. XPA, RPA) individually and selectively to the cisplatin-modified DNA, followed 
by excision of the damaged DNA fragment. Finally, the proteins dissociate and DNA 
polymerases and ligases fill in and close the gap. 
Another significant repair mechanism proved to participate in processing of cisplatin-DNA 
adducts is the mismatch repair pathway (MMR).15,19 It is performed by MMR proteins, 
5
  
 
recognizing mismatched or unmatched DNA base pairs and initiating the excision of the 
damaged area, subsequently resynthesized by DNA polymerases. It was shown that cisplatin-
DNA adducts are effectively recognized by MMR proteins, interfering with normal MMR 
activity and preventing repair from being completed, which ultimately leads to apoptosis.20 
Further, a large family of high mobility group (HMG) domain proteins is worth to mention as 
an important class of proteins capable of specific binding to cisplatin-modified DNA adducts. 
Moreover, it was demonstrated that HMG-domain proteins selectively bind to 1,2-intrastrand 
adducts, but not to 1,3-interstrand or monofunctional adducts produced by cisplatin.21,22 There 
are two main hypotheses for how those proteins could influence the sensitivity of cells to 
cisplatin. Hence, cisplatin-DNA adducts could hijack the HMG-domain proteins from their 
normal binding sites, leading to the disruption of the cellular function. Alternatively, they could 
shield cisplatin-DNA adducts from damage recognition necessary for initiating the repair 
mechanisms, ultimately resulting in cell death. It should be noticed, that these two models do 
not exclude each other and could work jointly, affecting the biological activity of cisplatin.23,24 
In spite of the high therapeutic potential of cisplatin, the treatment is accompanied by severe 
side effects such as nephrotoxicity, being a dose-limiting factor, as well as neurotoxicity, 
ototoxicity and myelosuppression. Nephrotoxicity, or reduced kidney function and damage, 
can be diminished through hydration therapy and diuresis. 25 Moreover, some tumors are 
characterized by intrinsic or acquired resistance to cisplatin, which are caused by (i) an 
insufficient amount of the drug binding to DNA owing to reduced cell accumulation,26,27 (ii) an 
increased level of intracellular thiols28 , 29  (e.g. glutathione, methionine or metallothionein), 
reacting with cisplatin and leading to its deactivation, as well as (iii) a failure of apoptosis 
induction after formation of platinum-DNA adducts due to enhanced DNA repair and 
tolerance.30 Therefore, the search for novel anticancer agents capable of overcoming the 
drawbacks of cisplatin-based chemotherapy is indispensable.  
 
1.2. Carboplatin and oxaliplatin − advantages and drawbacks 
 
Followed by the discovery of cisplatin and its consequent approval by the FDA, thousands of 
platinum complexes have been synthesized and screened for their biological properties. 
However, nearly 40 of them have entered the clinical trials, resulting in the worldwide 
approval of carboplatin and oxaliplatin (5 and 6, Figure 4) in 1989 and 2004, respectively.  
A second-generation platinum drug carboplatin (5), or cis-diammine(1,1-
cyclobutanedicarboxylato)platinum(II), differs from the parent cisplatin solely by the leaving 
group, comprising the 1,1-cyclobutanedicarboxylato chelate instead of two chlorido ligands in 
cisplatin. Due to the bidentate coordination of the leaving ligand, carboplatin is kinetically 
more inert, resulting in substantially reduced side-effects, which enables application of the 
drug in significantly higher doses. Thus, it proved to be less toxic to the kidney and nervous 
system and caused less nausea and vomiting than cisplatin, providing an improved quality of 
6
  
 
life to cancer patients. However, the spectrum of activity of carboplatin is identical to that of 
the parent drug, which is explainable by the same pattern of Pt-DNA adducts formed.31 
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5 6  
Figure 4. Structures of carboplatin (5) and oxaliplatin (6). 
 
In the third generation platinum drug oxaliplatin (6), or {(1R, 2R)-
cyclohexanediamine}oxalatoplatinum(II), the platinum center bears a bulky bidentate 
cyclohexanediamine carrier ligand (DACH) as well as a chelated oxalato leaving group. 
Oxaliplatin was proved to form the same type of interstrand and 1,2-intrastrand DNA cross-
links between adjacent guanosine residues as cis- and carboplatin, whereas exhibiting a 
completely different spectrum of anticancer activity and a lack of cross-resistance with the 
classical anticancer agents. 32 , 33  This is in accord with the fact that recognition of the 
oxaliplatin-DNA adducts by MMR and HMG1 proteins was found to be substantially less 
effective as compared to the DNA adducts produced by cis- and carboplatin.34,35 
Oxaliplatin in combination with 5-fluorouracil and leucovorin has been approved worldwide for 
the treatment of metastatic colorectal cancer, 36  while the investigation of its anticancer 
potential in other tumors is still ongoing. Besides neurotoxicity, which is the dose-limiting 
factor, side-effects of oxaliplatin include hematologic and gastrointestinal tract toxicity. As 
compared to cisplatin, it causes significantly less nausea and vomiting as well as milder 
nephrotoxicity, permitting administration of oxaliplatin without prehydration.37 Interestingly, the 
following structure-activity relationships for the (cyclohexanediamine)oxalatoplatinum(II) steric 
isomers were observed: complexes containing the trans-1R,2R-DACH ligand were found to 
be the most cytotoxic, followed by species comprising coordinated trans-1S,2S-DACH, 
completing the sequence with the complex bearing cis-1R,2S-DACH being the least 
cytotoxic.38,39 A significance of chirality of the DACH carrier ligand in mediating interactions 
between oxaliplatin and DNA was additionally proved by X-ray crystallography.40  
 
1.3. Regionally approved platinum(II) antitumor drugs  
 
Besides the three platinum-based drugs in worldwide clinical use, there are some complexes 
which received regionally limited approval for cancer treatment, e.g., nedaplatin (Japan) (7), 
lobaplatin (China) (8) and heptaplatin (the Republic of Korea) (9) (Figure 5). Nedaplatin41,42 
features two ammine carrier ligands along with glycolato leaving group. The complex was 
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selected based on the enhanced anticancer effect it showed in preclinical studies. In general, 
nedaplatin is less toxic as compared to cisplatin: it is characterized by reduced nephrotoxicity, 
but increased myelosuppression, being a dose-limiting factor. However, the platinum drug 
was proved to be cross-resistant with cisplatin in the L1210R leukemia model. In Japan, 
nedaplatin is approved for application against head and neck, testicular, lung, oesophagel, 
ovarian, and cervical cancer. 
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Figure 5. Structures of regionally approved nedaplatin (7), lobaplatin (8) and heptaplatin (9). 
 
Lobaplatin42,43 represents an isomeric mixture of two diastereomers containing coordinated 
1,2-bis(aminomethyl)cyclobutane and a lactato leaving group. The drug appeared to be 
similarly or even higher cytotoxic/active as compared to cisplatin both in vitro and in vivo, 
exhibiting a preclinical toxicity profile analogous to carboplatin. Thrombocytopenia was found 
to be dose-limiting. Furthermore, lobaplatin was observed to be noncross-resistant with 
cisplatin in a human embryonal cell line in vitro and in the P388 murine leukemia in vivo. The 
drug has been approved in China for the treatment of chronic myelogenous leukemia, 
inoperable metastatic breast cancer and small-cell lung cancer.44 
Heptaplatin45,46 features a (4R,5R)-bis(aminomethyl)-2-isopropyl-1,3-dioxolane carrier ligand 
and a bidentate malonato leaving group. It demonstrated similar to cisplatin cytotoxicity and 
antitumor activity, being significantly less toxic. Hepatotoxicity, nephrotoxicity and 
myelosuppression appeared to be dose-limiting factors. Moreover, heptaplatin was shown to 
be active against cisplatin-resistant L1210 leukemia cells. Currently the drug is applied in the 
Republic of Korea against advanced gastric and lung cancer.47 
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2. NONCLASSICAL CYTOTOXIC PLATINUM COMPLEXES 
 
2.1.  Cisplatin and transplatin. Early structure-activity relationships 
 
Inability of transplatin, or trans-diamminedichloridoplatinum(II), (3, Figure 2) to induce 
filamentation in Escherichia coli bacteria was revealed in the Barnett Rosenberg’s 
experiments at the same time as the opposite effect of cisplatin was observed followed by 
elucidation of its anticancer activity.3,4 Differently, transplatin was recognized to lack the 
tumor-inhibiting properties in vivo and proved to be significantly less cytotoxic in vitro as 
compared to cisplatin.  
Due to the general differences in the chemical structures of cis- and transplatin, the first 
aquation step is much faster in the case of trans-configuration. It can be explained by a higher 
trans-labilizing effect of the Cl situated trans to the leaving chlorido ligand in transplatin as 
compared with NH3 ligand in cisplatin (Figure 6).  
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Figure 6. Strepwise hydrolysis of transplatin. 
 
As a consequence, transplatin is more reactive compared to its cis-analogue, being involved 
into the undesired side-reactions on the way to its pharmacological target to a higher extent, 
which leads to its deactivation and results in a lower amount of the complex reaching DNA. 
On the contrary, the second step of hydrolysis of transplatin occurs extremely slowly due to a 
considerably weaker trans-effect of H2O, being trans-located to the second leaving chlorido 
ligand, versus NH3 in cisplatin. This is in accord with the lower rate of bisadducts formation 
found for transplatin.48,49 As far as transplatin-DNA monoadducts are concerned, they could 
be much easier repaired simply by a chemical pathway reacting with trans-labilizing 
nucleophiles present in the cell, e.g., thiourea, glutathione, whereas repair of the cisplatin-
DNA conjugates might involve an enzymatic mechanism (Figure 7).  
Owing to its stereochemistry, transplatin is not capable of forming 1,2-intrastrand cross-links, 
which predominate for cisplatin and are believed to determine its anticancer activity. 
Differently, it was shown to form mainly 1,3-intrastrand and interstrand cross-links proved to 
change less significantly the stability and structure of DNA.50 The high mobility group protein 
HMG1, effectively recognizing cisplatin-DNA adducts and thereby altering the cellular 
sensitivity to the drug, was observed to be incapable of recognizing the adducts produced by 
transplatin.51 It correlates with the fact that the transplatin-DNA adducts are more rapidly 
repaired. 
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Figure 7. Reaction of cisplatin-(above) and transplatin-DNA monoadduct (below) with 
thiourea. 
 
After the fascinating anticancer effect of cisplatin was disclosed, a wide variety of analogous 
platinum(II) complexes was tested for their tumor-inhibiting properties, resulting in some 
general structure-activity rules drawn by Cleare and Hoeschele. 52,53  Hence, the following 
prerequisites for anticancer activity of platinum-based species were established: (i) the 
complex should have two leaving groups located in cis-position to each other; (ii) the 
compound has to be uncharged; (iii) the leaving groups should be bound moderately to the 
platinum center, since complexes exhibiting too labile leaving groups proved to be toxic 
whereas tightly bound leaving groups result in low activity; (iv) the complexes featuring fewer 
alkyl substituents should be more active. 
 
2.2.  Activation of trans-geometry 
 
The early structure-activity relationships postulated inactivity of trans-configured species, 
leading to the consequence that platinum complexes of trans-geometry have been ignored for 
decades. However, over the last twenty years several classes of trans platinum compounds 
exhibiting cytotoxicity at least similar or even higher than their cis-isomers were 
published,54−56 breaking the classical structure-activity rules.52,53 A general interest for these 
complexes could be explained by their potential to overcome resistance towards the classical 
cis-configured platinum drugs: trans-configuration allows the formation of completely different 
Pt-DNA adducts, resulting in a new spectrum of activity which could be complementary to that 
of the cisplatin-like antitumor agents used in clinics. The cytotoxic platinum(II) species of 
trans-geometry can be classified into the following groups:  
 
2.2.1. Platinum(II) complexes bearing planar amines 
 
Replacement of one or two ammine ligands in transplatin by sterically demanding planar 
amine(s) led to complexes of the general formula trans-[PtCl2(L)(L’)] (L = NH3, L’ = pyridine, 
picoline, quinoline, isoquinoline, or thiazole; L = L’ = pyridine, thiazole) (10 and 11, Figure 
8).56 The use of sterically hindered ligands resulted in reduced hydrolysis rates, decreasing 
deactivation of the drug before the pharmacological target is reached. Generally, the trans-
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platinum planar amine (TPA) complexes exhibit cytotoxicity comparable with their cis-
analogues and similar to cisplatin, whereas being substantially more cytotoxic than transplatin. 
Analysis of the novel class of platinum-based compounds in the NCI human tumor panel 
identified this group as having in comparison to the clinically used agents a different 
cytotoxicity profile and activity in cisplatin- and oxaliplatin-resistant cell-lines.57 It was found 
that the TPA complexes form significantly more intrastrand cross-links in comparison with the 
“parent” compound transplatin. In general, the distribution of platinum-DNA adducts was 
carrier-ligand dependent, e.g., in the particular case of thiazole the ratio of intra-, interstrand 
cross-links and monofunctional adducts was nearly equal.58 Interestingly, the monofunctional 
adducts of TPA compounds were proved to be extremely stable, converting very slowly to a 
bifunctional mode. 59  Additionally, the complexes were found to produce single-stranded 
protein-associated DNA strand-breaks in cells, which offers an attractive potential for the 
design of selective DNA-protein cross-linkers.60, 61 Moreover, the anticancer activity of TPA 
complexes has been proved in an in vivo model: trans-[PtCl2(NH3)(tz)] demonstrated a 
moderate activity against P388 leukemia.62  
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Figure 8. Trans-planar amine complexes (TPAs). 
 
In order to increase the aqueous solubility of the TPA species, carboxylato leaving groups 
were introduced resulting in complexes of general formula trans-[Pt(O2CR2)(L)(L’)].63,64 Indeed, 
the carboxylato derivatives were found to be very water-soluble and stable to hydrolysis, 
showing cytotoxicity similar to their dichlorido analogues. An increased cellular uptake even in 
cisplatin and oxaliplatin-resistant cells was observed.  
 
2.2.2. Platinum(II) compounds with piperazine and piperidine 
 
Positively charged trans-platinum(II) complexes with monodentately bound piperazine (pz) of 
general formula [PtCl2(Am)(pz)] (Am = NH3, 4-picoline, n-butanamine, isopropanamine) (12, 
Figure 9) exhibiting a good aqueous solubility were prepared by protecting one of the amines 
of pz by tert-butyloxycarbonyl (BOC).65 The cytotoxicity of the synthesized piperazine species 
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was screened on three pairs of cisplatin-sensitive and cisplatin-resistant tumor cell lines: 
A2780/A2780cisR, 41M/41McisR and CH1/CH1cisR, giving especially low IC50 values in the 
cisplatin-resistant ovarian cancer cell line. Binding of the novel complexes to DNA occurs 
more rapidly with respect to cisplatin, while the reaction with cellular proteins, e.g., ubiquitine, 
myoglobine, proceeds much slower. Moreover, complexes containing piperazine and n-
butanamine ligands (12c) as well as piperidino-piperazine and ammine (13) appeared to be 
the first platinum complexes of trans-configuration displaying antiparasitic activity, inducing 
cell-cycle arrest in G2/M and giving rise to cell death through apoptotic mechanism.66  
Further, neutral species containing the monofunctional piperidine ligand (14, Figure 9) were 
prepared and their cytotoxic potential was tested together with complex containing both 
piperazine and 4-picoline ligands (12b) in human ovarian carcinoma (OV-1063) and colon 
carcinoma cells (C-26). The latter compound proved to show the lowest IC50 values from the 
group, however, still being 4-10-fold higher as compared to cisplatin.67 These complexes were 
demonstrated to effectively platinate the cellular DNA, inducing apoptosis in ovarian, but not 
in colon cancer cells.68,69 
The interaction of the selected piperidine and piperazine complexes with DNA was 
investigated.70 The formation of stable 1,3-interstrand cross-links between guanine bases to a 
significantly higher extent with respect to cis- and transplatin was detected. The produced Pt-
DNA adducts were shown to be removed by NER mechanism less effectively than those of 
cisplatin. 
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Figure 9. Platinum(II) complexes with piperazine (12), piperidino-piperazine (13), piperidine 
(14) and methylpiperidine (15−17). 
 
Additionally, three isomeric complexes with methylpiperidine (Me-pip) ligands (15−17, Figure 
9) were synthesized and in vitro evaluated in cisplatin-sensitive cells A2780, 41M, and CH1, 
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as well as in the corresponding cisplatin-resistant tumor cells A2780cisR, 41McisR and 
CH1cisR. 71  Surprisingly, no considerable difference in IC50 values of the isomers was 
observed; however, the compound containing 2-Me-pip reacted with glutathione and ubiquitin 
slower than its analogues probably due to steric reasons. 
 
2.2.3. Platinum(II) complexes with aliphatic amines 
 
Another intriguing class of trans-configured platinum(II) complexes demonstrating enhanced 
cytotoxicity with respect to their cis-analogues represent platinum(II) dichlorido complexes 
featuring asymmetric aliphatic amines trans-[PtCl2(Am)(isopropylamine)] (Am = NH3, N,N-
dimethylamine, propanamine, butanamine) (18, Figure 10).72,73 
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Figure 10. Platinum(II) complexes containing aliphatic amines 
 
The complexes were screened in vitro in a series of tumor cell lines, exhibiting similar or even 
lower IC50 values compared to cisplatin both against cisplatin-sensitive (Jurat, Hela, Vero) and 
-resistant (CH1cisR, HL-60, Pam212-ras) cancer cells. An apoptotic cell death initiation was 
confirmed in the case of trans-[PtCl2(Me2NH)(Me2CHNH2)] (18b) in Pam212-ras and in 
CH1cisR cells and for trans-[PtCl2(n-BuNH2)(Me2CHNH2)] (18d) both in Pam212-ras and 
A2780cisR cell lines. Moreover, complex 18b demonstrated a lack of cross-resistance with 
cisplatin in both A2780cisR and CH1cisR cells and was shown to form mostly interstrand 
cross-links between complementary guanidine and cytosine residues. However, no in vivo 
antitumor activity in human ovarian carcinoma xenografts in mice was detected, probably, due 
to a high binding rate towards plasma proteins.74,75 
Furthermore, trans-platinum(II) complexes containing an ammine ligand along with more 
sterically demanding branched amines trans-[PtCl2(NH3)(Am)] (Am = 2-methylbutanamine or 
sec-butanamine) (19, Figure 10), demonstrated outstanding cytotoxic properties, being more 
active than cisplatin both in cisplatin-sensitive and resistant cancer cell lines. 76  The 
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compounds were found to form mainly interstrand cross-links (40−50%) and monofunctional 
DNA lesions (30−40%).  
 
2.2.4. Platinum(II) complexes with iminoether ligands 
 
The following class of active platinum-based compounds of trans-geometry represent 
platinum(II) complexes featuring one or two iminoether ligands HN=C(OR)Me (R = Me, Et) 
reported by the group of Coluccia and Natile (20−22, Figure 11).77−79 Addition of an alcohol to 
a platinum-bound nitrile results in the formation of a coordinated Z-iminoether, which can be 
further converted into the corresponding E-analogue under basic conditions.80 
In general, the complexes are characterized by a considerably enhanced cellular 
accumulation as compared to that of cisplatin in ovarian cancer cells A2780 and A278cisR, 
probably due to their increased lipophilicity. Moreover, trans-iminoether complexes exhibit an 
increased degree of DNA platination. As opposed to cis- and transplatin, they demonstrated a 
low tendency to intrastrand DNA cross-linking, forming preferentially stable monofunctional 
adducts at guanine residues, which proved to be more resistant towards reactions with sulfur-
donor ligands than the DNA adducts produced by transplatin. 81 , 82  Monofunctional DNA 
adducts formed by trans-(iminoether)platinum(II) complexes can readily react with proteins 
resulting in the formation of specific DNA-protein cross-links supposed to be responsible for 
the tumor-inhibiting properties of iminoether complexes.  
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Figure 11. Trans-platinum(II) complexes comprising iminoethers (20−23) as well as cyclic 
iminoether-mimiking ligands (24 and 25). 
 
A comparative in vitro study of trans-[PtCl2{HN=C(OMe)Me}2] isomers featuring ZZ-(20a), EZ- 
(21a) and EE-ligands (22a) elucidated that the former complex (20a) possessed the highest 
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cytotoxic potency. Furthermore, 20a demonstrated a significant antitumor activity in vivo 
against P388 and P388cisR leukemia, being better tolerated by animals as compared to 
cisplatin.  
Considering ethoxy analogues, EE-complex (22b) appeared to be more cytotoxic than its ZZ–
isomer (22a) in a panel of human tumor cell lines (ovarian, colon, lung, and breast cancer), 
revealing opposite structure-activity relationships compared to the methoxy complexes.78 
Interestingly, both ethoxy compounds proved to be noncross-resistant with cisplatin in 
A2780cisR cells. However, in vivo tests carried out in the murine P388 leukemia system 
showed a slightly enhanced antitumor effect in case of the ZZ–isomer (20b). 
Exchange of one ammine in transplatin for an iminoether ligand resulted in a dramatic 
increase of the cytotoxic potency (23, Figure 11), especially in the case of ovarian and colon 
tumor cells.79 In addition, 23 appeared to be active in vivo against SK-OV-3 human cancer 
cell xenografts in nude mice and in the murine P388 leukemia system. 
Finally, two compounds with cyclic ligands mimicking iminoethers were prepared in order to 
unable E↔Z isomerization (24 and 25, Figure 11). 83  The IC50 values for both of the 
complexes were lower than those of 20−23 in a panel of human tumor cells (colon, ovary, 
lung, and breast). Interestingly, complex 25 was shown to be more cytotoxic as compared to 
24. 
 
2.2.5. Acetonimine platinum(II) complexes 
 
As next, platinum(II) complexes containing one or two acetonimine ligands have been 
prepared by condensation of platinum-coordinated ammine with acetone (26−29, Figure 
12).84  
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Figure 12. Platinum(II) complexes with acetonimine ligand(s). 
 
A clear evidence for the activation of trans-geometry was demonstrated: while the cytotoxicity 
of the cis-configured acetonimine species (27 and 29) proved to be lower with respect to 
cisplatin in a panel of human ovarian, colon, lung, and breast cancer cells, the opposite 
dependence between the trans-isomers (26 and 28) and transplatin was observed. 
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Interestingly, in the case of cis-geometry the bisacetonimine complex 27 appeared to be less 
active than ammine/acetonimine compound 29, whereas the trans-bisacetonimine species 26 
exhibited enhanced cytotoxic properties compared to the corresponding trans-
ammine/acetonimine complex 28. Ability to circumvent either partially or completely the 
resistance to cisplatin was demonstrated for acetonimine-containing complexes of trans-
geometry. 
 
2.2.6. Oxime platinum(II) complexes 
 
Very recently a novel and intriguing class of cytotoxic trans-configured platinum species was 
published, namely, platinum(II) complexes containing oxime ligands. In the last few years two 
independent working groups reported on remarkable in vitro results for three acetone oxime 
containing complexes (30−32, Figure 13). Firstly, Navarro-Ranninger et al. comparatively 
examined the cytotoxicity and ability to induce cell death via either apoptotic or necrotic 
mechanism of trans-[PtCl2(Me2C=NOH)(Me2CHNH2)] complex (30) and the cis-configured 
counterpart (31) in rat renal tubular cells (NRK-52E) and human hepatoma cells (HepG2). 
Unlike cis-[PtCl2(Me2C=NOH)2] (31), the complex of trans-geometry (30) was shown to cause 
apoptosis, although being less cytotoxic.85 
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Figure 13. Structures of platinum(II) complexes bearing oxime ligands. 
 
Almost at the same time, Keppler et al. reported on a cis/trans couple of platinum(II) 
complexes featuring two acetone oxime ligands (31 and 32). 86  Fascinatingly, trans-
[PtCl2(Me2C=NOH)2] (32) was found to be more cytotoxic than its cis-isomer (31) not only in 
cisplatin-sensitive ovarian carcinoma cell line (CH1), but also in cisplatin-resistant colon 
carcinoma cells (SW480), moreover, being by a factor of 15 more potent than cisplatin in 
SW480 cells. It was demonstrated that the novel complex of trans-geometry binds slowly to 
5’-dGMP as compared to cisplatin (τ½ = 50 h versus 8.9 h, respectively), exhibits low reactivity 
towards DNA and influences insignificantly the secondary structure of DNA. Moreover, no Pt-
DNA interstrand cross-links could be detected. All these facts indicate a completely different 
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mechanism of antitumor action of trans-[PtCl2(Me2C=NOH)2] as compared with that 
characterizing the classical anticancer platinum drugs.  
 
2.3.  Synthesis of platinum(II) complexes with trans-configuration 
 
There are several methods for the preparation of platinum(II) complexes exhibiting trans-
geometry. The first pathway includes two steps and is widely used for the synthesis of 
symmetric (Am1 = Am2) and asymmetric diamine trans-[PtCl2(Am1)(Am2)] species (Figure 14). 
Initially, the cis-isomer is converted into the cationic tetramine compound, followed by thermal 
decomposition or addition of concentrated HCl, which results in the target trans-dichlorido 
complex. At the second step, after one amine ligand is substituted for chloride, the trans-
located amine is exchanged due to the higher trans-labilizing effect of Cl as compared to 
am(m)ines.87 For instance, this pathway was applied to prepare trans-platinum(II) complexes 
with planar88,89 and aliphatic amines.72 
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Figure 14. 
 
Another possible way for the synthesis of trans-configured platinum(II) species is 
isomerization of the corresponding cis-complex into its trans-analogue carried out either in an 
appropriate solvent or in the solid state. The direction of the conversion is determined by a 
higher thermodynamic stability. For instance, dissolution of cis-[PtCl2(cyclobutylamine)2] in 
acetone leads to its conversion into the trans-isomer. 90  An additional example, trans-
configured (oxime)platinum(II) complexes are prepared by thermal isomerization of their cis-
analogues either in solution in nitromethane or in the solid state.91  
Furthermore, cis-[PtCl2(L)2] is used as a starting complex as well, being firstly converted into 
the dichlorido-bridged dimer [Pt(μ-Cl)Cl(L)]2 via reaction with platinum(II) chloride, followed by 
addition of the amine ligand L’ to obtain the desired trans-[PtCl2(L)(L’)] complex (Figure 15). 
This pathway was applied for the synthesis of platinum(II) complexes with aliphatic amines73 
as well as various asymmetric compounds.92,93 
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Figure 15. 
 
For the generation of trans-diacetato complexes trans-[Pt(OAc)2(L1)(L2)], the corresponding 
trans-dihalogenido species are treated with two equivalents of silver acetate either in DMF 
(for the low soluble dichlorido complexes) or in acetone (in the case of diiodido species) 
(Figure 16). This pathway was used for the preparation of trans-configured compounds 
featuring 3-picoline or 4-picoline ligands as well as for complexes containing pyridine, 
quinoline, or isoquinoline.63,64  
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Figure 16. 
 
 
2.4. Multinuclear platinum(II) compounds 
 
Multinuclear platinum(II) complexes represent an individual class of platinum-based cytotoxic 
agents, differing from the classical compounds used in the clinics both by their structure and 
mode of biological action. A broad and the most extensively studied family consists of 
complexes comprising two or more platinum coordination units PtCln(NH3)3-n connected to 
each other in a chain manner by various linkers, e.g., flexible NH2(CH2)nNH2 or more rigid 
4,4’-dipyrazolylmethane. 94  Interestingly, the more flexibility the compounds displayed the 
higher activity they demonstrated.  
The most promising representative appeared from this class which was already investigated 
in clinical trials is [trans-diamminechloridoplatinum(II)][(μ-trans-diamminedihexanediamine-
N,N’)platinum(II)] nitrate, denominated as BBR3464 (33, Figure 17), a trinuclear compound 
with an overall charge of +4. The complex was shown to be taken up by both cisplatin-
sensitive and resistant cancer cells much faster and in higher amounts as compared to 
cisplatin. 95 , 96  Owing to the positive charge, BBR3464 is pre-associated on the polymer 
backbone of DNA, resulting in a faster DNA binding.97−99 The complex was shown to produce 
long-range intra- and interstrand DNA adducts, characterized by a high flexibility.100−102 In in 
vitro studies, BBR3464 demonstrated IC50 values up 1000-fold lower than those of cisplatin in 
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cisplatin-sensitive cells. Additionally, the compound appeared to be capable of overcoming 
cisplatin resistance in a broad spectrum of cancer cells (small-cell lung cancer (SCLC), 
nonsmall-cell lung cancer (NSCLC), melanoma, glioma, neuroblastoma, osteosarcoma, 
astrocytoma, cervical, ovarian and prostatic). However, BBR3464 demonstrated severe toxic 
effects, neutropenia and gastro-intestinal toxicity being the dose-limiting factors. 103  The 
complex reached clinical phase II for gastric, ovarian, SCLC and NSCLC but the trials were 
abandoned due to lack of activity.104,105 Phase II studies in locally advanced or metastatic 
pancreatic cancer are ongoing. 
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Figure 17. Structure of BBR3464. 
 
Furthermore, several classes of multinuclear platinum(II) complexes displaying intriguing 
cytotoxic properties in vitro were reported in the literature. Firstly, dinuclear platinum-
bisphosphonate complexes were prepared by Natile et al. in order to attain a specific 
accumulation of the drugs at the bone tissue (34, Figure 18).  
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Figure 18. Dimeric platinum-bisphosphonate complexes. 
 
Loading of the complexes comprising ethane-1,2-diamine into a silica-xerogel was performed 
with the aim to obtain a hybrid inorganic matrix releasing active platinum species for the 
treatment of bone tumors.106 The presence of calcium in the matrix was found to influence the 
loading capacity, stability of the formulations and the nature of platinum complexes released. 
Further, complexes containing two ammine ligands or cis-cyclohexane-1,4-diamine along with 
R’ = 
+H3NCH2 or +H3NCH2CH2 were prepared and evaluated in a set of 13 tumor cell lines of 
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multiple origin.107 The new cationic compounds were found to be capable of overcoming 
cisplatin resistance in A431/Pt and C13* cells, in general exhibiting IC50 values similar to 
those of carboplatin. Finally, diammine and cis-cyclohexane-1,4-diamine complexes featuring 
neutral amines as R’ were synthesized, showing a modest cytotoxicity, which was explained 
by a slow and inadequate hydrolysis.108 
As next class, a series of hydroxo- and azolato-bridged platinum(II) complexes (35, Figure 19) 
has been prepared. OH− acts as a leaving group, providing a bifunctional coordination to 
DNA.109 The cytotoxic potential of the compounds featuring a bridging pyrazolate (pz) or 
1,2,3-triazolate (1,2,3-trz) was investigated in several human tumor cell lines, e.g., melanoma, 
breast, colon, ovarian, renal, and nonsmall-cell lung cancer.110 The species featuring two 
ammine ligands were found to be up to 37 times higher cytotoxic than cisplatin, while those 
containing trans-cyclohexane-1,2-diamine were found to be moderately active. Further, a 
complex featuring a bridging 4-phenyl-1,2,3-triazolate (4-phe-1,2,3-trz) ligand along with the 
previously mentioned ammine-containing species was tested in both cisplatin-sensitive and 
resistant L1210 murine leukemia cell lines, exhibiting the ability to overcome acquired 
cisplatin-resistance in the cases of μ-1,2,3-trz or μ-4-phe-1,2,3-trz. 111  Additionally, two 
isomeric platinum(II) dimers containing bridging tetrazolato (ta) ligands coordinated to the 
platinum centers either via N1 and N2 or through N2 and N3 were synthesized (35, Figure 
19).112 The latter complex appeared to be double as cytotoxic as either cisplatin or its N1, N2-
ligated isomer toward the H460 human NSCLC cell line. Moreover, it showed strikingly high 
antitumor efficacy in the pancreatic tumor PANC-1 xenograft, demonstrating markedly 
improved activity compared with gemcitabine, a front-line therapy for pancreatic cancer. 
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Figure 19. Platinum(II) dimers bridged by azolato ligands. 
 
Additionally, isomeric azines, e.g., pyrazine (pzn), pyrimidine (pmn), and pyridazine (pdn) 
were applied as bridging ligands for novel dinuclear platinum(II) complexes (36, Figure 20).113 
The compounds demonstrated high specificity for the IGROV and WIDR cell lines in vitro. The 
pyrazine-bridged complex showed the best results being as cytotoxic as cisplatin in L1210 
leukemia cells and exhibiting the highest potential to circumvent acquired resistance to 
cisplatin in L1210cisR. Generally, the azine-bridged platinum(II) dimers (36) appeared to be 
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less cytotoxic as compared to the azolato-bridged complexes (35), which could be explained 
by a significantly slower reactivity of the latter species upon binding to nucleic acids.111  
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Figure 20. Azine-bridged dinuclear platinum(II) complexes. 
 
Further, a dimeric platinum(II) complex with a bridging 4, 4’-dipyrazolylmethane ligand was 
prepared and in vitro evaluated in A2780 and A2780cisR human ovarian cancer cells (37, 
Figure 21),114 being significantly less cytotoxic than cisplatin with IC50 values of 100 and 60 
μM, respectively. 
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Figure 21. 
 
An extraordinary example of a dinuclear platinum(II) compound represents a diplatinum(II) 
tetracarboxylate complex, having a dimeric carboplatin structure (38, Figure 22).115 The novel 
complex proved to be more cytotoxic  than carboplatin  in all malignant tumor cell lines tested 
(up to 8 times in HL60 cells), moreover, demonstrating in vivo a remarkably lower general 
toxicity in comparison with the parent clinical drug.  
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Figure 22. Dimeric carboplatin analogue. 
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2.5. Activation strategies of platinum-based prodrugs at the tumor site 
 
Whereas the normal differentiated cells generate energy via mitochondrial oxidative 
phosphorylation, cancer cells were shown to rely on glycolysis (“the Warburg effect”, Otto 
Warburg, 1924).116,117 It results in an increased production of lactic acid, which cannot be 
always quickly removed due to the rapid growth and the poorly organized vasculature of the 
solid tumors. In the course of tumor growing, the oxygen concentration within the tumor 
decreases as compared to the normal tissue; the phenomenon is termed “hypoxia”118,119 and 
is explained by an insufficient tumor blood supply. For this reasons the shift to an anaerobic 
cellular metabolism is favored, leading to a significantly acidic extracellular pH (pHe) (acidosis). 
Thus, pHe of solid tumors was found in the range between 5.5 and 7.3, 120−122 while in the 
case of the normal tissue pHe is at approximately 7.4. 
An acidic pH value as well as a reductive environment within solid tumors could be 
beneficially used: relatively inert anticancer agents (prodrugs) could be introduced being 
capable of activation at the tumor site either by reduction or protonation, leading to the 
formation of active species. This approach could help to significantly improve the therapeutic 
index defined as ratio of the drug efficacy to its toxicity. 
 
2.5.1. Activation by reduction: platinum(IV) complexes 
 
The ability of a platinum(IV) complex cis-[PtCl4(NH3)2] (2, Figure 1) to induce the anticancer 
effect was disclosed simultaneously with the discovery of the tumor-inhibiting properties of 
cisplatin in Barnett Rosenberg’s experiments.3,4 However, the biological properties of 2 
proved to be substantially weaker, resulting in a major focus on platinum(II) species. The 
crucial feature of platinum(IV) complexes is their greater kinetic inertness as compared to 
platinum(II) analogues leading to an extremely low rate of ligand-exchange reactions. 
Although the aquation of platinum(IV) species could be observed, it appeared to be much too 
slow to cause any biological consequences. To be activated, they have to be reduced into the 
corresponding platinum(II) analogues (so-called activation by reduction), playing thus a role of 
prodrugs (Figure 23).123,124  
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Figure 23. The two-electron reduction of octahedral platinum(IV) to square-planar platinum(II) 
complex, accompanied by a loss of axial ligands. 
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The rate of reduction in biological media was shown to be much higher than that of aquation. 
125  This fact explains the primary importance of the reduction potential for platinum(IV) 
compounds, which is mainly determined by the nature of the axial ligands. Additionally, it is 
worth to mention that there are no structure-activity relationships for platinum(IV) anticancer 
agents except that the respective platinum(II) complex should be active. 
To date, there are several platinum(IV) complexes that have entered the clinical trials, e.g., 
tetraplatin (39), iproplatin (40), JM216 or satraplatin (41) and LA-12 (42) (Figure 24). 
Tetraplatin ([PtCl4(trans-cyclohexane-1,2-diamine)]) (39) demonstrated promising results in 
preclinical studies, however, was found to cause severe peripheral neuropathy in treated 
patients and was abandoned after phase I trials.126 Due to its high reduction potential owing to 
the axial chlorido ligands, tetraplatin is easily reduced being activated on the way to its 
pharmacological target, which results in a high general toxicity. 
On the contrary, iproplatin (cis,trans,cis-[PtCl2(OH)2(isopropylamine)2]) (40), featuring axial 
hydroxido ligands and therefore being characterized by a more negative reduction potential, 
stays mostly unchanged resulting in insufficient activity. The complex was abandoned after 
phase III clinical trials.127,128 
 
H2
N
N
H2
Pt
Cl
Cl
Cl
Cl
H2
N
N
H2
Pt
Cl
Cl
OH
OH
H2N
N
H2
Pt
Cl
Cl
OCOCH3
OCOCH3
H2N
HN
Pt
Cl
Cl
OCOCH3
OCOCH3
39 424140
 
Figure 24. Platinum(IV) complexes entered clinical studies: tetraplatin (39), iproplatin (40), 
JM216 or satraplatin (41), and LA-12 (42). 
 
JM-216 or satraplatin (cis,trans-[PtCl2(OAc)2(NH3)(cyclohexylamine)]) (41), is a lipophilic 
complex which was rationally designed to allow oral administration. 129 , 130  Bearing axial 
acetato ligands, satraplatin exhibits an intermediate reduction potential, providing an optimal 
reduction rate in biological media. The drug was recently in phase III clinical trials but the 
trials were abandoned based on the lack of improvement over the anticancer agent already 
used in the clinics. 
Lately, Kozubik et al. reported on a novel platinum(IV) drug candidate: LA-12 (42, Figure 24), 
featuring a bulky 1-adamantylamine ligand, is a highly lipophilic platinum(IV) complex, 
capable of overcoming acquired resistance to cisplatin in vitro in human ovarian A2780cisR 
cells. 131 The complex demonstrated promising results in preclinical mouse studies: an oral 
activity was shown in a murine ADJ/PC6 plasmacytoma and human A2780 ovarian carcinoma 
tumor model.132 LA-12 entered phase I clinical trials. 
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Figure 25. 
 
Two works of particular interest in the field of antineoplastic platinum(IV) compounds are 
based on utilization of bioactive moieties in axial positions, targeting specific molecular 
features of a tumor and being released after reduction of Pt(IV) to Pt(II). For instance, in order 
to target platinum to estrogen receptor positive breast cancer cells, a conjugation of estradiol 
3-benzoate ligands axially to a platinum core was performed by Lippard et al. (43, Figure 
25).133 
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Figure 26. 
 
Alternatively, attachment of ethacrynate to platinum(IV) was carried out by Dyson et al. with 
the aim to inhibit glutathione-S-transferase exhibiting increased levels in some cisplatin-
resistant cancer cells (44, Figure 26).134  
Very recently, a novel class of platinum(IV) compounds was reported: three dihydroxido 
complexes of the general formula trans, trans, trans-[PtCl2(OH)2(Am1)(Am2)] exhibiting trans-
configured equatorial amine ligands were published (45, Figure 27). 135 , 136  The cellular 
properties of trans, trans, trans-[PtCl2(OH)2(Me2NH)(Me2CHNH2)] (45a) were evaluated in 
comparison with its platinum(II) counterpart in pairs of cisplatin-sensitive and –resistant cell 
lines (A2780/A2780cisR, CH1/CH1cisR, and 41M/41McisR).135 It was demonstrated that 
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acquired cisplatin resistance was circumvented by platinum(IV) complex 45a both in CH1cisR 
and 41McisR, but solely in CH1cisR cells by its platinum(II) counterpart. Moreover, only the 
platinum(IV) complex displayed activity in vivo in CH1 human ovarian carcinoma xenografts in 
mice, which was explained by its lower rate of binding to plasma proteins decreasing 
extracellular inactivation as compared with its platinum(II) analogue. 
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Figure 27. Platinum(IV) complexes of trans-geometry. 
 
Later, two further trans-platinum(IV) complexes (45b and 45c) were synthesized and their 
cytotoxic properties were examined.136 Interestingly, trans-platinum(IV) compounds were 
demonstrated to be similarly or even higher cytotoxic than their platinum(II) congeners, 
although displaying considerably negative reduction potentials (between −666 and −770 mV), 
usually associated with resistance to reduction and high IC50 values. The authors suggested 
that it could be related to the trans-location of the chlorido ligands, which are reduced much 
easier. 
 
2.5.2. Activation under mildly acidic conditions 
 
There are several classes of pH-sensitive platinum(II) complexes being capable of activation 
in the acidic microenvironment found in solid tumors.137 Firstly, Schilling et al. reported on the 
synthesis and biological properties of alkyldithiocarbonatoplatinum(II) complexes (46, Figure 
28) exhibiting enhanced cytotoxicity at pH 6.8 as compared to pH 7.4 due to opening of a 
rather kinetically inert chelate cycle leading to formation of an active form (47, Figure 
28). 138 , 139  Thioplatin, or bis-(O-ethyldithiocarbonato)platinum(II) (46, R = Et), the most 
exhaustively studied representative of this class, was shown to platinate DNA with a 
substantially higher efficiency at pH 6.8 than at pH 7.4 as well as to dramatically improve its 
cytotoxic properties in slightly acidic milieu (IC50 in HeLa cells: 5 μM at pH 6.8 versus 51 μM at 
pH 7.4). In vivo efficacy of thioplatin was evaluated in a human small-cell lung carcinoma 
(H16) and a colorectal carcinoma (SW707) xenograft in athymic nude mice, demonstrating 
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5−10 times better therapeutic index as compared to cisplatin.138 To set up the structure-
activity relationships, over 20 derivatives of thioplatin were prepared and their antitumor 
properties were investigated in a panel of six human tumor cell lines, demonstrating up to 7 or 
25 times enhanced cytotoxicity as compared to thioplatin or cisplatin, correspondingly. 
Moreover, complexes featuring secondary xanthates (R = CH(R1)2 or CHR1R2) appeared to 
be significantly more active than those containing primary ligands (R = CH2R1). 139 
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Figure 28. Activation of alkyldithiocarbonatoplatinum(II) complexes at acidic pH values. 
 
Another fascinating class of pH-dependent platinum(II) species represent 
bis(aminoalcoholato)platinum(II) complexes (48, Figure 29). 140 − 142  The compounds are 
capable of intramolecular ligand-exchange reactions, leading to the conversion of a relatively 
stable doubly ring-closed species (48) into the more reactive and consequently higher 
cytotoxic mono ring-closed (49) and ring-opened (50) forms.  
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Figure 29. pH-dependent intramolecular ligand-exchange reaction of 
bis(aminoalcoholato)platinum(II) complexes. 
 
Binding of the complexes to the DNA model nucleotide 5’-guanosine monophosphate (5’-
GMP) at pH 7.4 and 6.0 was investigated both by NMR spectroscopy 143  and capillary 
electrophoresis, 144 − 146  demonstrating a significantly higher reactivity under slightly acidic 
conditions (Table 1). For the corresponding doubly ring-closed (48) and ring-opened (50) 
complexes nearly identical half times were observed, being in good agreement with an 
adjustment of a pH-dependent equilibrium. Moreover, a comparative evaluation of the 
cytotoxic potency in the human nonsmall-cell lung cancer cell line (A549) at different proton 
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concentrations showed substantially improved IC50 values at pH 6.0 as compared to those at 
pH 7.0 (Table 1).147 
 
Table 1. Half times for the reaction of platinum(II) complexes 48a, 50a and 48b with 5’-GMP 
as well as their cytotoxicity in the human nonsmall-cell lung cancer cell line (A549).137 
 Half time of 5’ GMP binding 
[h] 
Cytotoxicity in A549 cells 
[μM] 
pH 7.4 pH 6.0 pH 7.0 pH 6.0 
48a 32.5 4.5 115 41.2 
50a 28.5 4.5 110 45.6 
48b 80.0 18.7 182 55.0 
 
 
In addition, a new class of potential platinum(II)-based prodrugs able to be converted into the 
corresponding active species at lower pH values represent mixed-ligand complexes of cis-
geometry featuring various amines along with aminoalcohol ligands (51, Figure 30).148 The 
cytotoxic properties of the complexes were studied in human ovarian carcinoma cell lines 
sensitive (A2780) and resistant (A2780R) to cisplatin. Among the novel compounds, 
complexes comprising R1 = Me, R2 = H (51a) and R1 = i-Pr, R2 = H (51b) showed the most 
promising IC50 values, being however cross-resistant with cisplatin in A2780R cells. 
Additionally, both 51a and 51b were tested in the mouse leukemia cell lines L1210 and 
L1210R, demonstrating slightly higher IC50 values as compared to cisplatin and ability to 
partially overcome cisplatin resistance. However, no pH-dependent studies were reported. 
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Figure 30. pH-sensitive mixed-ligand platinum(II) complexes. 
 
Finally, a broad series of platinum(II) complexes with L-alanine and other α-amino acids was 
patented by Shaw et al. (53, Figure 30),149,150 shown to be more active under slightly acidic 
conditions that proved to accompany solid tumors and exhibiting lower activity at pH values 
found in normal tissues (pH 7.2−7.4). 
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Figure 30. Activation of (aminocarboxylato)platinum(II) complexes. 
 
 
3. FINAL REMARKS 
 
In spite of incontestable achievements in the field of classical platinum-based anticancer 
therapy, there are enough shortcomings to be improved. Hence, there is still a need in 
developing novel antitumor agents characterized by a mode of action dissimilar to that of 
cisplatin. Thereby, a circumvention of resistance exhibited intrinsically by some tumors toward 
the antineoplastic platinum drugs used in the clinics or acquired in the course of treatment 
could be enabled. It would offer a solution of the main problem associated with the classical 
platinum-based anticancer therapy. 
Platinum(II) acetone oxime complexes of trans-geometry reported recently represent 
promising candidates of nonclassic cytotoxic agents. In particular, trans-[PtCl2(Me2C=NOH)2] 
was shown to display an enhanced cytotoxicity as compared both with cis-analogues and 
cisplatin as well as ability to overcome intrinsic cisplatin-resistance in vitro in SW480 cells. 
Deeper investigations of the complex, e.g., binding to 5’-GMP, reactivity to DNA and influence 
on DNA secondary structure, point to a mode of action absolutely dissimilar to those platinum 
drugs used in the clinics. For this reason, it appears to be crucial to broaden the class of 
platinum(II)(oxime) compounds in order to draw and optimize structure-activity relationships. 
Moreover, it would help to obtain a deeper understanding of the mechanism behind their 
cytotoxic action. 
This work contributes to the research on the synthesis, characterization, solution behavior, 
mode of action and cytotoxicity of novel platinum(II) oxime complexes. 
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Novel Cis- and Trans-Configured Bis(oxime)platinum(II) Complexes: Synthesis,
Characterization, and Cytotoxic Activity
Yulia Yu. Scaffidi-Domianello,† Kristof Meelich,† Michael A. Jakupec,†,‡ Vladimir B. Arion,†
Vadim Yu. Kukushkin,§ Markus Galanski,*,† and Bernhard K. Keppler*,†,‡
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University of Vienna, W€ahringer Strasse 42, A-1090 Vienna, Austria, and §Department of Chemistry,
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Novel cis- and trans-configured bis(oxime)platinum(II) complexes have been synthesized and characterized
by elemental analyses, IR, electrospray ionization mass spectrometry, multinuclear (1H, 13C, and 195Pt) NMR
spectroscopy, and, in five cases, by X-ray diffraction. Their cytotoxicity was studied in the cisplatin-sensitive CH1 cell
line as well as in inherently cisplatin-resistant SW480 cancer cells. Remarkably, every single dihalidobis(oxime)platinum-
(II) complex (with either a cis or trans configuration) shows a comparable cytotoxic potency in both cell lines, indicating
a capacity of overcoming cisplatin resistance. Particularly strong cytotoxicities were observed in the case of trans-
[PtCl2(R2CdNOH)2] (R = Me, n-Pr, i-Pr) with IC50 values in the high nanomolar concentration range in both CH1 and
SW480 cancer cells. These complexes are as potent as cisplatin in CH1 cells and up to 20 times more potent than
cisplatin in SW480 cells. In comparison to transplatin, the novel compounds are up to 90 (CH1) and 120 times
(SW480)more cytotoxic. The previously reported observation that the trans geometry yields a more active complex in
the case of [PtCl2(Me2CdNOH)2] could be confirmed for at least two structural analogues.
Introduction
Over 40 years have passed since the serendipitous discov-
ery of the biological activity of cisplatin,1 which has become
oneof themost usedanticancer drugs today. Since then, great
efforts have been concentrated on the development of novel
platinum drugs possessing therapeutic properties compar-
able to those of cisplatin but showing reduced side effects
along with a broader spectrum of activity.2-4 The search for
ever new drug candidates among the complexes complying
with the classical structure-activity relationships5,6 led to
the achievements of carboplatin and oxaliplatin but then
seemed tobecomegradually exhausted. Therefore, nowadays
more investigators turn their attention toward nonclassic
structures7-11 that may help to overcome the drawbacks of
platinum-based chemotherapy. Moreover, the development
of platinum compounds being structurally different from
cisplatin and forming different types of Pt-DNAadductsmay
lead to a drug with a spectrum of clinical activity different
from those of classic platinum drugs.
For decades, trans-configured platinum complexes at-
tracted little interest because of the classic structure-activity
relationships according to Cleare and Hoeschele,5,6 based on
cisplatin/transplatin and their analogues. The presence of
two monodentate or one bidentate exchangeable ligand(s)
(leaving groups) coordinated in cis geometry was declared a
requirement for antitumor activity. The significantly lower
cytotoxicity of transplatin compared to that of cisplatin in
vitro as well as its inactivity in vivo has been ascribed to its
disfavored chelation reactions with DNA due to the trans-
standing leaving groups. Consequently, the formation of 1,2-
intrastrand cross-links, the predominant DNA adducts
formed by cisplatin and believed to account for its cytotoxic
activity, is greatly hindered.12 It was shown that transplatin-
DNA adducts are more rapidly repaired and cannot be
*To whom correspondence should be addressed. E-mail: markus.
galanski@univie.ac.at (M.G.), bernhard.keppler@univie.ac.at (B.K.K.).
Phone: þ43-1-4277-52603 (M.G.), þ43-1-4277-52602 (B.K.K.). Fax: þ43-
1-4277-52680 (M.G.), þ43-1-4277-52680 (B.K.K.).
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recognized by the high-mobility group proteins HMG1,
recognizing specifically 1,2-intrastrand cross-links and
shielding them from repair. Moreover, the higher reactivity
of transplatin compared to that of cisplatin may favor its
deactivation, resulting in the lack of anticancer activity.
In the past fewyears, some exceptions from the classic rules
have been reported. Several classes of trans complexes
exhibiting higher cytotoxicity than or at least equal to that
of the corresponding cis isomer are (i) platinum(II)13-16/
platinum(IV)17 complexes with pyridine-like ligands, (ii) plati-
num(II) complexes with iminoether ligands,18-21 (iii) plati-
num(II) complexes with nonplanar heterocyclic ligands, such
as piperidine or piperazine,22-25 (iv) platinum(II)26-28/
platinum(IV)29,30 complexes with aliphatic amines, (v) plati-
num(II) carboxylato complexes with planar amines,31,32
azole and isopropylamine,33 azole and ammine ligands,34 (vi)
platinum(II) complexes containing various phosphoric
groups,35,36 and (vii) platinum(II) complexes with acetimine
ligands.37 Interestingly, most of the listed complexes are
similarly or even more cytotoxic than cisplatin and all of
them proved to be non-cross-resistant to cisplatin in cellular
models of acquired cisplatin resistance. Furthermore, for the
first four of the above-mentioned classes, the antitumor
activity was confirmed in an in vivo model. Moreover, some
of the complexes even displayed a lack of cross-resistance to
cisplatin in vivo.20,29
Very recently, a new intriguing class of trans-configured
platinum compounds exhibiting antitumor activity was re-
ported. Almost simultaneously two independent groups of
researcher published the fascinating results of in vitro bio-
logical investigations for two acetoxime-containing plati-
num(II) complexes, namely, trans-[PtCl2(Me2CdNOH)(NH2-
CH(CH3)2)]
38 as well as trans-[PtCl2(Me2CdNOH)2].
39
According to these investigations, the former complex, but
not its cis isomer, causes cell death by apoptosis, even though
the overall cytotoxicity was found to be higher for the cis-
configured complex.Differently, trans-[PtCl2(Me2CdNOH)2]
was found to be 16 times more cytotoxic than its cis isomer
and as cytotoxic as cisplatin in cisplatin-sensitive ovarian
carcinoma cells (CH1). Moreover, it appeared to be 15 times
more cytotoxic than both cisplatin and its cis isomer
in intrinsically cisplatin-resistant colon carcinoma cells
(SW480).
In this context, it is worthwhilementioning that oximes are
attractive ligands in view of their potential to act as donors or
acceptors for hydrogen bonds or even serve as weak acids
(pKa 3-8),40 which could play an important role in the
binding of platinum compounds to DNA.41 In addition,
the biological relevance of oximes appreciably favors their
use as ligands for potential metal-based drugs, which may
yield increased cytotoxicity by virtue of synergistic effects
between the platinum center and the coordinated oxime. For
instance, it was reported that oxime complexes and other
species bearing the oxime functional group caused biological
effects such as endothelium-independent relaxation in blood
vessels,42 an increase in the targeting of specific nuclear bases
of DNA,43 and oxidative DNA cleavage.44
On the basis of the promising results obtained with
trans-[PtCl2(Me2CdNOH)2] and with the aim to estab-
lish structure-activity relationships, we report on a series
of novel dihalidobis(oxime)platinum(II) complexes, i.e.,
trans-[PtX2(R2CdNOH)2] (X = Cl, Br, I; R = Me, Et, n-
Pr, i-Pr), of which at least two exhibit higher cytotoxicity
than the corresponding cis species in both CH1 and SW480
cells. Moreover, the corresponding cis/trans couples of
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[Pt(NH3)2(R2CdNOH)2](NO3)2 (R = Me, Et, n-Pr) were
synthesized and investigated. In accordance with the classic
structure-activity relationships, stating that platinum com-
plexes with four nitrogen donor ligands are devoid of
cytotoxicity, the IC50 values of the diamminebis(oxime) series
were proven to be very high.
Experimental Section
Solvents were obtained from commercial sources and used
as received. Acetone oxime was purchased fromFluka, while
3-pentanone, 4-heptanone, and 2,4-dimethyl-3-pentanone
for the synthesis of the corresponding oximes were obtained
from Aldrich. The complexes cis- and trans-[PtBr2(Me2Cd
NOH)],53 cis-[PtI2(NH3)2]
54, and trans-[PtCl2(NH3)2]
55 were
prepared according to the published methods. For thin-layer
chromatography (TLC), Merck UV 254 SiO2 plates were
used. Fluka silica gel 60 (220-440mesh) was used for column
chromatography. C, H, and N elemental analyses were car-
ried out by theMicroanalytical Laboratory of the University
of Vienna and are within (0.4% of the calculated values,
confirming their g95% purity. Melting points were deter-
mined with a B€uchi B-540 melting point apparatus and
are uncorrected. Electrospray ionization mass spectrometry
(ESI-MS) spectra were obtained with a Bruker Esquire 3000
instrument. Mid-infrared (MIR; 4000-400 cm-1) spectra
were recorded with a Perkin-Elmer Fourier transform infra-
red (FTIR) instrument in KBr pellets. 1H, 13C, and 195Pt
NMR spectra were measured with a Bruker Avance III
500 MHz NMR spectrometer at 500.32 (1H), 125.81 (13C),
and 107.55 MHz (195Pt), correspondingly, at 298 K. 195Pt
chemical shifts are given relative to external K2[PtCl4], and
the half-height line width is given in parentheses.
Synthesis of Ligands. 3-Pentanone oxime, 4-heptanone
oxime, and 2,4-dimethyl-3-pentanone oxime were synthesized
by known procedures45-47 with some modifications: the corres-
ponding ketones were treated with hydroxylamine hydrochloride
in a MeOH/H2O mixture (1:1), while K2CO3 was used for
neutralization. The reaction mixture was stirred at 65-70 C
for 24 h, and then the solvent was removed and the product
purified by column chromatography (1:4 ethyl acetate/hexane,
first fraction). The yields were 87-92%.
SynthesisofComplexes. (SP-4-2)-Bis(acetoneoxime-KN )dibro-
midoplatinum(II) (2c). The complex was prepared according to the
publishedmethod fromK2[PtCl4] (191 mg, 0.46mmol), an excess of
KBr (274 mg, 2.30 mmol), and 2 equiv of acetoxime (67 mg, 0.92
mmol) inwater.53Yield: 138mg (60%).Anal. (C6H14N2Br2O2Pt) C,
H,N.IRinKBr(selectedbands):ν1656m(νCdN) cm
-1. 1HNMRin
D2O: δ 2.69 (s, 3H, CH3), 2.22 (s, 3H, CH3) ppm. ESI-MS
þ in
MeOH:m/z 524 [Mþ Na]þ, 560 [Mþ HClþ Na]þ.
(SP-4-1)-Bis(acetone oxime-KN )dibromidoplatinum(II) (2t).
The synthesis was performed by thermal isomerization of the
corresponding cis complex.53 2c (175mg, 0.35mmol)was kept at
140 C for 6 h; the resulting gray powder was suspended in 2mL
of acetone and filtered through a small amount of SiO2, which
was washed three times with 2 mL of acetone. Then the solvent
was partially evaporated under reduced pressure, and bright
yellow crystals of the product were formed. The crystals were
collected, washed with 0.5 mL of acetone, and dried in vacuo.
Yield: 35 mg (20%). Anal. (C6H14N2Br2O2Pt) C, H, N. IR in
KBr (selected bands): ν 1664 m (νCdN) cm
-1. 1H NMR in
acetone-d6: δ 2.62 (s, 3H, CH3), 2.19 (s, 3H, CH3) ppm. ESI-
MSþ in MeOH: m/z 524 [M þ Na]þ, 560 [M þ HCl þ Na]þ.
(SP-4-2)-Bis(acetone oxime-KN )diiodidoplatinum(II) (3c).
Potassium iodide (406 mg, 2.45 mmol) was added to a solution
of K2[PtCl4] (203 mg, 0.49 mmol) in 2 mL of H2O, and the
mixture was stirred at room temperature for 2 h. After the
addition of acetone oxime (72 mg, 0.98 mmol), the reaction
mixture was left to stand at the same temperature without
stirring for 2 days, and the crystals of 3c were filtered off,
washed twice with 0.5 mL of ice-cold water, and dried in vacuo.
Yield: 233 mg (80%). Anal. (C6H14N2I2O2Pt) C, H, N. ESI-
MSþ in acetone:m/z 545 [M-Me2CdNOHþNa]þ, 618 [Mþ
Na]þ, 634 [M þ K]þ. ESI-MS- in acetone: m/z 521 [M -
Me2CdNOH - H]-, 594 [M - H]-. Mp 220 C (dec). TLC
[10:1 (v/v) CHCl3/Me2CO]: Rf = 0.52. IR in KBr (selected
bands): ν 3242 s (νOH), 1653 m (νCdN) cm
-1. 1H NMR in
acetone-d6: δ 2.65 (s, 3H, CH3), 2.19 (s, 3H, CH3) ppm.
13C{1H}
NMR in acetone-d6: δ 164.6 (CdN), 24.6 (CH3), 17.9 (CH3)
ppm. 195Pt NMR in acetone-d6: δ-1729 (600Hz) ppm. Crystals
for X-ray study were obtained by slow evaporation of an
aqueous solution.
(SP-4-1)-Bis(acetone oxime-KN )diiodidoplatinum(II) (3t).
The powder of 3c (230 mg, 0.39 mmol) was refluxed in 5 mL
of MeNO2 at 95-100 C for 3 h. A small amount of a brown
precipitate was filtered off, and the yellow filtratewas reduced to
1.5 mL at 40 C using a rotary evaporator, resulting in the
precipitation of a yellow solid. The precipitate was collected by
filtration, washed twice with 1 mL of MeNO2, and dried in
vacuo. Yield: 114 mg (50%). Anal. (C6H14N2I2O2Pt) C, H, N.
ESI-MSþ in acetone:m/z 618 [MþNa]þ.Mp 200 C (dec). TLC
[15:1 (v/v) CHCl3/Me2CO]: Rf = 0.50. IR in KBr (selected
bands): ν 3329 s (νOH), 1661m (νCdN) cm
-1. 1HNMR inDMF-
d7: δ 11.88 (s, br, 1H, OH
a), 11.71 (s, br, 1H, OHb), 2.72 (s, 3H,
CH3
b), 2.68 (s, 3H, CH3
a), 2.39 (s, 3H, CH3
b), 2.32 (s, 3H, CH3
a)
ppm. 13C{1H} NMR in DMF-d7: δ 164.8 (CdN
b), 162.6
(CdNa), 24.87 (CH3
b), 24.86 (CH3
a), 17.9 (CH3
b), 17.5 (CH3
a)
ppm. 195Pt NMR in DMF-d7: δ -1800 (320) ppm. Crystals for
X-ray study were obtained by slow evaporation of an acetone
solution.
(SP-4-2)-Dichloridobis(3-pentanone oxime-KN )platinum(II)
(4c) and (SP-4-1)-Dichloridobis(3-pentanone oxime-κN )plati-
num(II) (4t). 3-Pentanone oxime (113mg, 1.12mmol) was added
to a solution ofK2[PtCl4] (239mg, 0.58mmol) in 1.5mLofH2O,
and themixture was stirred at 70 C for 0.5 h. Then, the reaction
mixture was left to stand without stirring at room temperature
for 2 days, resulting in the formation of pale-yellow crystals. The
precipitate was filtered off, washed twice with 1 mL of ice-cold
water, and dried at room temperature in air, whereupon isomers
4c and 4t were separated by column chromatography [8:1 (v/v)
CHCl3/Me2CdO] and dried in vacuo.Yields: 148mg (55%) and
108 mg (40%), respectively.
4c. Anal. (C10H22N2Cl2O2Pt) C, H, N. ESI-MS
þ in MeOH:
m/z 491 [M þ Na]þ, 507 [M þ K]þ, 533 [M þ Et2CdNOH -
Cl]þ. ESI-MS- in MeOH: m/z 330 [M - Et2CdNOH -HCl -
H]-, 467 [M - H]-. Mp 153 C (dec). TLC [7:1 (v/v) CHCl3/
Me2CO]: Rf = 0.46. IR in KBr (selected bands): ν 3255 s (νOH),
1649m (νCdN) cm
-1. 1HNMR inCDCl3: δ 9.04 (s, br, 1H,OH),
3.18 (q, 2H, CH2,
3JH,H = 7.6 Hz), 3.60 (q, 2H, CH2,
3JH,H =
7.6 Hz), 1.26 (t, 3H, CH3,
3JH,H = 7.6 Hz), 1.09 (t, 3H, CH3,
3JH,H= 7.6Hz) ppm.
13C{1H}NMR inCDCl3: δ 176.2 (CdN),
29.8 (CH2), 23.4 (CH2), 10.9 (CH3), 10.3 (CH3) ppm.
195Pt
NMR in CDCl3: δ -441 (380 Hz) ppm. Crystals for X-ray
study were obtained by slow evaporation of a chloroform/ethyl
acetate solution.
4t. Anal. (C10H22N2Cl2O2Pt) C, H, N. ESI-MS
þ in MeOH:
m/z 491 [M þ Na]þ. ESI-MS- in MeOH: m/z 330 [M - Et2Cd
NOH-HCl-H]-, 366 [M- Et2CdNOH-H]-. Mp: 204 C
(dec). TLC [7:1 (v/v) CHCl3/Me2CO]: Rf = 0.54. IR in KBr
(selected bands): cm-1: ν 3254 s (νOH), 1658m (νCdN).
1HNMR
inCDCl3:δ 3.10 (q, 2H,CH2,
3JH,H=7.6Hz), 2.58 (q, 2H,CH2,
3JH,H= 7.6 Hz), 1.33 (t, 3H, CH3,
3JH,H= 7.6 Hz), 1.13 (t, 3H,
(45) Portela-Cubillo, F.; Lymer, J.; Scanlan, E. M.; Scott, J. S.; Walton,
J. C. Tetrahedron 2008, 64, 11908–11916.
(46) Alcalde, E.; Mesquida, N.; Alvarez-Rua, C.; Cuberes, R.; Frigola, J.;
Garcia-Granda, S.Molecules 2008, 13, 301–318.
(47) Wang, K.; Fu, X.; Liu, J.; Liang, Y.; Dong, D. Org. Lett. 2009, 11,
1015–1018.
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CH3,
3JH,H = 7.6 Hz) ppm.
13C{1H} NMR in CDCl3: δ 176.2
(CdN), 29.6 (CH2), 23.5 (CH2), 11.0 (CH3), 10.3 (CH3) ppm.
195Pt NMR in CDCl3: δ -462 (450 Hz) ppm.
(SP-4-1)-Dichloridobis(4-heptanone oxime-KN )platinum(II)
(5t). 4-Heptanone oxime (182 mg, 1.41 mmol) was added to a
solution of K2[PtCl4] (292 mg, 0.70 mmol) in 2 mL of H2O, and
the mixture was stirred at 85 C for 2 h. Then, the heating was
switched off, and the reaction mixture was stirred at room
temperature for 2 days, resulting in the formation of a large
amount of lemon-yellow precipitate. The precipitate was filtered
off, washed twice with 1 mL of H2O, and dried at room
temperature in air, whereupon it was purified by column
chromatography [10:1 (v/v) CHCl3/Me2CdO] and then dried
in vacuo.Yield: 240mg (65%).Anal. (C14H30N2Cl2O2Pt) C,H,N.
ESI-MSþ in MeOH: m/z 452 [M - HCl - Cl]þ, 525 [M þ H]þ,
547 [MþNa]þ, 584 [MþHClþNa]þ. ESI-MS- inMeOH:m/z
358 [M - Pr2CdNOH -HCl -H]-, 394 [M - Pr2CdNOH -
H]-. Mp: 173 C (dec). TLC [10:1 (v/v) CHCl3/Me2CO]: Rf =
0.48. IR in KBr (selected bands): ν 3299 s (νOH), 1672 m (νCdN)
cm-1. 1H NMR in CDCl3: δ 7.42 (s, br, 1H, OH), 3.04 (m, 2H,
CH2), 2.54 (m, 2H, CH2), 1.78 (m, 2H, CH3CH2), 1.58 (m, 2H,
CH3CH2), 1.12 (t, 3H, CH3,
3JH,H = 7.3 Hz), 0.98 (t, 3H, CH3,
3JH,H=7.3Hz) ppm.
13C{1H}NMR in CDCl3: δ 173.8 (CdN),
38.4 (CH2), 32.1 (CH2), 20.2 (CH3CH2), 19.5 (CH3CH2), 14.3
(CH3), 13.9 (CH3) ppm.
195Pt NMR in CDCl3: δ-453 (350 Hz)
ppm. Crystals for X-ray study were obtained by slow evapora-
tion of a chloroform/ethyl acetate solution.
(SP-4-1)-Dichloridobis(2,4-dimethyl-3-pentanone oxime-KN)-
platinum(II) (6t). The synthesis and purification were carried out
as described for 4t, using K2[PtCl4] (153 mg, 0.37 mmol) and 2,4-
dimethyl-3-pentanone oxime (95 mg, 0.74 mmol). Yield: 104 mg
(60%). Anal. (C14H30N2Cl2O2Pt) C, H, N. ESI-MS
þ in acetone:
m/z 452 [M - HCl - Cl]þ, 510 [M - HCl þ Na]þ, 547 [M þ
Pr2CdNOH - Cl]þ. ESI-MS- in acetone: m/z 358 [M - Pr2Cd
NOH - HCl - H]-, 394 [M - Pr2CdNOH - H]-, 487 [M -
HCl - H]-. Mp: 185 C (dec). TLC [10:1 (v/v) CHCl3/Me2CO]:
Rf = 0.45. IR in KBr (selected bands): ν 3330 s (νOH), 1662 m
(νCdN) cm
-1. 1H NMR in CDCl3: δ 4.28 (m, 2H, 2CH), 2.67 (m,
2H, 2CH), 1.28 (d, 6H, 2CH3,
3JH,H=6.9Hz), 1.23 (d, 6H, 2CH3,
3JH,H = 6.9 Hz) ppm.
13C{1H} NMR in CDCl3: δ 180.7 (CdN),
37.1 (CH), 29.7 (CH), 18.9 (2CH3), 18.5 (2CH3) ppm.
195PtNMR
in CDCl3: δ -441 (420 Hz) ppm.
(SP-4-2)-Bis(acetone oxime-KN )diammineplatinum(II)Dini-
trate (7c). cis-[PtI2(NH3)2] (72 mg, 0.15 mmol) and AgNO3
(51mg, 0.30 mmol) were suspended in 2mL of H2O, whereupon
the mixture was stirred at room temperature overnight. The
yellow precipitate of AgI was filtered off, and acetone oxime
(22 mg, 0.30 mmol) was added. After the reaction mixture was
stirred at the same temperature for 10 h, the clear colorless
solution was reduced to 0.5 mL and 15 mL of acetone was
added, inducing the precipitation of a white solid. The precipi-
tate was filtered off, washed with acetone (2 1 mL), and dried
in vacuo. Yield: 41mg (55%). Anal. (C6H20N6O8Pt 3H2O) C,H,
N. ESI-MSþ in H2O/MeOH: m/z 357 [M - NH3 - HNO3 -
NO3]
þ, 374 [M-HNO3-NO3]þ, 696 [2M- 3NH3- 3HNO3-
NO3]
þ, 713 [2M- 2NH3- 3HNO3-NO3]þ, 730 [2M-NH3-
3HNO3 - NO3]þ, 747 [2M - 3HNO3 - NO3]þ. Mp: 147 C
(dec). IR in KBr (selected bands): ν 3194 s (νOH), 1666 m (νCdN)
cm-1. 1H NMR in D2O: δ 2.52 (s, 3H, CH3), 2.12 (s, 3H, CH3)
ppm. 13C{1H} NMR in D2O: δ 172.5 (CdN), 23.8 (CH3), 18.2
(CH3) ppm.
195Pt NMR in D2O: δ -907 (1000 Hz) ppm.
(SP-4-1)-Bis(acetone oxime-KN )diammineplatinum(II)Dini-
trate (7t). trans-[PtCl2(NH3)2] (81 mg, 0.27 mmol) and AgNO3
(92 mg, 0.54 mmol) were suspended in 2.5 mL of H2O, where-
upon the mixture was stirred at 60 C overnight. The white
precipitate of AgCl was filtered off, and acetone oxime (40 mg,
0.54 mmol) was added. After the reaction mixture was stirred at
room temperature overnight, the clear yellowish solution was
reduced to 0.5mLand 10mLof acetonewas added, inducing the
precipitation of a white solid. The precipitate was filtered off,
washed with acetone (2  1 mL) and ether (3 mL), and dried in
vacuo. Yield: 88 mg (65%). Anal. (C6H20N6O8Pt) C, H, N. ESI-
MSþ in H2O/MeOH: m/z 267 [M - 2NH3 - Me2CdNOH -
HNO3-NO3]þ, 340 [M- 2NH3-HNO3-NO3]þ, 357 [M-
NH3-HNO3-NO3]þ, 374 [M-HNO3-NO3]þ, 639 [2M-
Me2CdNOH- 2NH3- 3HNO3-NO3]þ, 657 [2M-Me2Cd
NOH-NH3- 3HNO3-NO3]þ, 696 [2M- 3NH3- 3HNO3-
NO3]
þ, 713 [2M- 2NH3- 3HNO3-NO3]þ, 747 [2M- 3HNO3-
NO3]
þ. Mp: 234 C (dec). IR in KBr (selected bands): ν 3211 s
(νOH), 1667 m (νCdN) cm
-1. 1H NMR in D2O: δ 4.27 (s, br, 3H,
NH3), 2.58 (s, 3H,CH3), 2.19 (s, 3H,CH3) ppm.
13C{1H}NMRin
D2O: δ 172.2 (CdN), 23.4 (CH3), 18.0 (CH3) ppm.
195Pt NMR in
D2O: δ -907 (800 Hz) ppm. Crystals for X-ray study were
obtained by slow evaporation of an aqueous solution.
(SP-4-2)-Diamminebis(3-pentanone oxime-KN)platinum(II)
Dinitrate (8c). cis-[PtI2(NH3)2] (109mg, 0.23mmol) andAgNO3
(77 mg, 0.45mmol) were suspended in 2mL ofH2O, whereupon
the mixture was stirred at room temperature overnight. The
yellow precipitate of AgI was filtered off, and 3-pentanone
oxime (50 μL, 0.45 mmol) in 2 mL of THF was added. After
the reaction mixture was stirred at the same temperature for 2
days, the solvent was removed and the crude product was dried
in vacuo. Then, the white solid was suspended in 10 mL of
acetone, filtered off, washed with acetone (2 1 mL), and dried
in vacuo. Yield: 53 mg (42%). Anal. (C10H28N6O8Pt) C, H, N.
ESI-MSþ in H2O/MeOH: m/z 396 [M - 2NH3 - HNO3 -
NO3]
þ, 413 [M - NH3 - HNO3 - NO3]þ, 430 [M - HNO3 -
NO3]
þ, 606 [2M - 2Et2CdNOH - 3NH3 - 3HNO3 -NO3]þ,
690 [2M-Et2CdNOH- 4NH3- 3HNO3-NO3]þ, 724 [2M-
Et2CdNOH - 2NH3 - 3HNO3 - NO3]þ, 808 [2M - 3NH3 -
3HNO3 - NO3]þ, 825 [2M - 2NH3 - 3HNO3 - NO3]þ, 843
[2M -NH3 - 3HNO3 - NO3]þ, 859 [2M - 3HNO3 -NO3]þ.
Mp: 158 C (dec). IR in KBr (selected bands): ν 3194 s (νOH),
1666 m (νCdN) cm
-1. 1H NMR in D2O: δ 3.00 (m, 2H, CH2),
2.53 (m, 2H, CH2), 1.12 (t, 3H, CH3,
3JH,H = 7.6 Hz), 0.99 (t,
3H, CH3,
3JH,H= 7.6 Hz) ppm.
13C{1H} NMR in D2O: δ 178.9
(CdN), 29.5 (CH2), 22.9 (CH2), 9.9 (CH3), 9.3 (CH3) ppm.
195Pt
NMR in D2O: δ -897 (1050 Hz) ppm.
(SP-4-1)-Diamminebis(pentanone oxime-KN)platinum(II)
Dinitrate (8t). trans-[PtCl2(NH3)2] (105 mg, 0.35 mmol) and
AgNO3 (118 mg, 0.70 mmol) were suspended in 4 mL of H2O,
whereupon themixturewas stirred at 60 Covernight. Thewhite
precipitate of AgCl was filtered off, and 3-pentanone oxime
(77 μL, 0.70 mmol) in 2 mL of THF was added. After the
reaction mixture was stirred at room temperature overnight, the
solvent was removed and the yellowish solid was suspended in
10 mL of acetone; the precipitate was then filtered off, washed
with acetone (2  1 mL) and diethyl ether (3 mL), and dried in
vacuo. Yield: 54 mg (45%). Anal. (C10H28N6O8Pt) C, H, N.
ESI-MSþ in H2O/MeOH: m/z 396 [M - 2NH3 - HNO3 -
NO3]
þ, 413 [M - NH3 - HNO3 - NO3]þ, 430 [M - HNO3 -
NO3]
þ, 724 [2M-Et2CdNOH- 2NH3- 3HNO3-NO3]þ, 808
[2M- 3NH3 - 3HNO3 - NO3]þ, 859 [2M -3HNO3 - NO3]þ.
Mp: 213 C (dec). IR in KBr (selected bands): ν 3270 s (νOH),
1645m(νCdN) cm
-1. 1HNMRinD2O:δ4.30 (s, br, 3H,NH3), 3.02
(m, br, 2H, CH2), 2.58 (m, br, 2H, CH2), 1.17 (t, 3H, CH3,
3JH,H=
7.7 Hz), 1.03 (t, 3H, CH3,
3JH,H = 7.6 Hz) ppm.
13C{1H} NMR
in D2O: δ 180.2 (CdN), 29.3 (CH2), 23.0 (CH2), 10.0 (CH3), 9.3
(CH3) ppm.
195Pt NMR in D2O: δ-914 (1500 Hz) ppm.
(SP-4-2)-Diamminebis(4-heptanone oxime-KN )platinum(II)
dinitrate (9c). The synthesis was carried out as described for
7c, using 203 mg (0.42 mmol) of cis-[PtI2(NH3)2], 143 mg (0.84
mmol) of AgNO3, and 122 μL (0.84 mmol) of 4-heptanone
oxime. Yield: 39 mg (15%). Anal. (C14H36N6O8Pt 3H2O) C, H,
N. ESI-MSþ in H2O/MeOH: m/z 340 [M - NH3 - n-Pr2Cd
NOH - HNO3 - NO3]þ, 452 [M - 2NH3 - HNO3 - NO3]þ,
470 [M - NH3 - HNO3 - NO3]þ, 486 [M - HNO3 - NO3]þ,
774 [2M - n-Pr2CdNOH - 4NH3 - 3HNO3 - NO3]þ, 791
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[2M - n-Pr2CdNOH - 3NH3 - 3HNO3 - NO3]þ, 808 [2M -
n-Pr2CdNOH- 2NH3- 3HNO3-NO3]þ, 920 [2M- 3NH3-
3HNO3 - NO3]þ, 937 [2M - 2NH3 - 3HNO3 - NO3]þ, 955
[2M - NH3 - 3HNO3 -NO3]þ, 972 [2M - 3HNO3 - NO3]þ.
Mp: 155 C (dec). IR in KBr (selected bands): ν 3316 s (νOH),
1645 m (νCdN) cm
-1. 1H NMR in D2O: δ 2.94 (t, 2H, CH2,
3JH,H=8.0Hz), 2.51 (t, br, 2H, CH2), 1.55 (m, br, 2H, CH3CH2),
1.45 (m, br, 2H,CH3CH2), 0.96 (t, 3H,CH3,
3JH,H=7.4Hz), 0.84
(t, 3H,CH3,
3JH,H=7.2Hz) ppm.
13C{1H}NMR inD2O: δ 177.8
(CdN), 38.3 (CH2), 31.7 (CH2), 19.5 (CH3CH2), 18.9 (CH3-
CH2), 13.34 (CH3), 13.32 (CH3) ppm.
195Pt NMR in D2O: δ
-882 (1050 Hz) ppm.
(SP-4-1)-Diamminebis(4-heptanone oxime-KN)platinum(II)
Dinitrate (9t). trans-[PtCl2(NH3)2] (200 mg, 0.67 mmol) and
AgNO3 (227 mg, 1.34 mmol) were suspended in 5 mL of H2O,
whereupon themixturewas stirred at 60 Covernight. Thewhite
precipitate of AgCl was filtered off, and 4-heptanone oxime
(173 mg, 1.34 mmol) in 1 mL of THF was added. After the
reactionmixture was stirred at room temperature for 3 days, the
yellowish solution was filtered from a small amount of a gray
precipitate. Then the solvent was removed, and the solid was
suspended in 10mLof acetone; the white precipitate was filtered
off and washed with acetone (2 1 mL) and ether (3 mL). After
that, the solid was suspended in 5 mL of EtOH, filtered off, and
then washed three times with 1 mL of EtOH. The filtrates were
combined, the volume was reduced to 0.5 mL, and 5mL of Et2O
was added, inducing the precipitation of a white solid. After
filtration, the product was washed with 0.5 mL of Et2O and
dried in vacuo. Yield: 123 mg (30%). Anal. (C14H36N6-
O8Pt 3H2O) C, H, N. ESI-MS
þ in H2O/MeOH: m/z 452 [M -
2NH3-HNO3-NO3]þ, 469 [M-NH3-HNO3-NO3]þ, 486
[M - HNO3 - NO3]þ. Mp: 211 C (dec). IR in KBr (selected
bands): ν 3202 s (νOH), 1657m (νCdN) cm
-1. 1HNMR inD2O: δ
4.30 (s, br, 3H, NH3), 2.96 (s, br, 2H, CH2), 2.56 (t, 2H, CH2,
3JH,H = 8.0 Hz), 1.63 (m, br, 2H, CH3CH2), 1.49 (m, br, 2H,
CH3CH2), 1.00 (t, 3H, CH3,
3JH,H = 7.3 Hz), 0.87 (t, 3H, CH3,
3JH,H = 7.4 Hz) ppm.
13C{1H} NMR in D2O: δ 178.2 (CdN),
38.1 (CH2), 31.8 (CH2), 19.6 (CH3CH2), 18.9 (CH3CH2), 13.4
(CH3), 13.2 (CH3) ppm.
195Pt NMR in D2O: δ -906, -914
(950 Hz) ppm.
Crystallographic Structure Determination. X-ray diffraction
measurements were performed with a Bruker X8APEX II CCD
diffractometer at 100 K. Single crystals were positioned at 40,
40, 40, 40, 40, and 35mm from the detector, and 930, 2109, 1575,
804, and 1869 frames were measured, each for 5, 30, 30, 50, and
3 s over 1 scan width for 3c, 3t, 4c, 5t, and 7t, respectively. The
data were processed using the SAINT software package.48
Crystal data, data collection parameters, and structure refine-
ment details for 3c, 3t, 4c, 5t, and 7t are given in Table 1. The
structures were solved by direct methods and refined by full-
matrix least-squares techniques. Non-hydrogen atoms were
refined with anisotropic displacement parameters. Hydrogen
atoms were placed at calculated positions and refined as riding
atoms in the subsequent least-squares model refinements. The
isotropic thermal parameters were estimated to be 1.2 times
the values of the equivalent isotropic thermal parameters of the
non-hydrogen atoms to which the hydrogen atoms were
bonded. SHELXS-9749 was used for structure solution and
SHELXL-9750 for refinement, molecular diagrams were pro-
duced with ORTEP,51 and appropriate scattering factors were
used.52
Cell Lines and Culture Conditions. Human CH1 (ovarian
carcinoma) and SW480 (colon carcinoma) cells were kindly
provided by Lloyd R. Kelland (CRC Centre for Cancer Ther-
apeutics, Institute of Cancer Research, Sutton, U.K.) and
Brigitte Marian (Institute of Cancer Research, Department of
Medicine I, Medical University of Vienna, Austria), respec-
tively. Cells were grown in 75 cm2 culture flasks (Iwaki/Asahi
Technoglass,Gyouda, Japan) as adherentmonolayer cultures in
a complete culture medium, i.e., a minimal essential medium
(MEM) supplemented with 10% heat-inactivated fetal bovine
serum, 1 mM sodium pyruvate, and 4 mM L-glutamine (all
purchased fromSigma-Aldrich, Vienna,Austria). Cultures were
maintained at 37 C in a humidified atmosphere containing 5%
CO2 and 95% air.
Cytotoxicity Tests in Cancer Cell Lines. Cytotoxicity was
determined bymeans of a colorimetricmicroculture assay [MTT
Table 1. Crystal Data and Details of Data Collection for 3c, 3t, 4c, 5t, and 7t
3c 3t 4c 5t 7t
empirical formula C6H14I2N2O2Pt C6H14I2N2O2Pt C10H22Cl2N2O2Pt C14H30Cl2N2O2Pt C6H20N6O8Pt
fw 595.08 595.08 468.29 524.39 499.37
space group P21/c P212121 P1 Pnma P1
a, A˚ 7.9315(2) 9.0055(4) 9.1808(2) 8.0268(6) 6.3713(4)
b, A˚ 17.4453(5) 9.0841(3) 9.4940(3) 16.3958(13) 7.6065(5)
c, A˚ 9.6186(2) 16.5477(5) 9.5723(3) 14.4299(12) 8.4282(6)
λ, deg 79.582(3) 91.570(4)
β, deg 101.752(2) 79.141(2) 105.325(4)
γ, deg 72.957(2) 101.662(3)
V, A˚3 1303.00(6) 1353.72(9) 776.38(4) 1899.1(3) 384.39(4)
Z 4 4 2 4 1
R, A˚ 0.710 73 0.710 73 0.710 73 0.710 73 0.710 73
Fcalcd, g cm-3 3.033 2.920 2.003 1.834 2.157
crystal size, mm 0.25  0.10  0.08 0.12  0.05  0.03 0.21  0.15  0.08 0.20  0.06  0.06 0.21  0.12  0.10
T, K 100 100 100 100 100
μ, cm-1 154.85 149.05 93.74 76.75 91.73
R1a 0.0250 0.0144 0.0174 0.0187 0.0195
wR2b 0.0543 0.0309 0.0354 0.0400 0.0385
GOFc 1.034 0.990 1.010 0.989 1.000
aR1=
P
||Fo|- |Fc||/
P
|Fo|.
bwR2={
P
[w(Fo
2-Fc2)2]/
P
[w(Fo
2)2]}1/2. cGOF={
P
[w(Fo
2-Fc2)2] /(n- p)}1/2, where n is the number of reflections
and p is the total number of parameters refined.
(48) SAINT-Plus, version 7.06a, and APEX2; Bruker-Nonius AXS Inc.:
Madison, WI, 2004.
(49) Sheldrick, G. M. SHELXS-97, Program for Crystal Structure Solu-
tion; University of G€ottingen: G€ottingen, Germany, 1997.
(50) Sheldrick, G. M. SHELXS-97, Program for Crystal Structure Re-
finement; University of G€ottingen: G€ottingen, Germany, 1997.
(51) Johnson, C. K. Report ORNL-5138; Oak Ridge National Labora-
tory: Oak Ridge, TN, 1976.
(52) International Tables for X-ray Crystallography; Kluwer Academic
Press: Dordrecht, The Netherlands, 1992; Vol. C, Tables 4.2.6.8 and 6.1.1.4.
(53) Kukushkin, V. Yu.; Tudela, D.; Izotova, Y. A.; Belsky, V. K.; Stash,
A. I. Polyhedron 1998, 17, 2455–2461.
(54) Dhara, S. C. Indian J. Chem. 1970, 8, 193–194.
(55) Kauffman, G. B.; Cowan, D. O. Inorg. Synth. 1963, 7, 239–245.
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assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide]. For this purpose, CH1 and SW480 cells
were harvested from culture flasks by trypsinization and seeded
in 100 μL aliquots in MEM supplemented with 10% heat-
inactivated fetal bovine serum, 1 mM sodium pyruvate, 4 mM
L-glutamine, and 1% nonessential amino acids (100) (all
purchased fromSigma-Aldrich) into 96-wellmicroculture plates
(Iwaki/Asahi Technoglass, Gyouda, Japan) in cell densities of
1.5  103 and 2.5  103 cells well-1, respectively, in order to
ensure exponential growth of untreated controls throughout
drug exposure. For 24 h, cells were allowed to settle and resume
exponential growth, followed by the addition of dilutions of
the test compounds in aliquots of 100 μL well-1 in the same
medium. Only for the less water-soluble compounds 5t and 6t,
stock solutions had to be prepared in a dimethyl sulfoxide
(DMSO)/H2O mixture (the stability of the compounds in a
DMSO solution was proven by 1H NMR spectroscopy). The
DMSO content in the actually tested dilutions did not exceed
0.5%. After continuous exposure for 96 h, drug solutions were
replaced by a 130 μL well-1 RPMI 1640 culture medium
(supplemented with 10% heat-inactivated fetal bovine serum
and 4 mM L-glutamine) plus 20 μL well-1 MTT solution in
phosphate-buffered saline (5 mg mL-1). After incubation for
4 h, the medium/MTT mixtures were removed, and the for-
mazan crystals formed by viable cells were dissolved in 150 μLof
DMSOper well. Optical densities at 550 nmweremeasuredwith
a microplate reader (Tecan Spectra Classic), using a reference
wavelength of 690 nm to correct for unspecific absorption. The
quantity of vital cells was expressed in terms of T/C values by
comparison to untreated control microcultures, and 50% in-
hibitory concentrations (IC50) were calculated fromconcentration-
effect curves by interpolation. Evaluation is based onmeans fromat
least three independent experiments, each comprising three repli-
cates per concentration level.
Results and Discussion
Recently, we reported on the intriguing biological proper-
ties of an isomeric couple cis/trans-[PtCl2(Me2CdNOH)2]
(1c/1t).39 In order to establish and learn more about their
structure-activity relationships, a series of novel oximepla-
tinum(II) analogues were prepared: (i) cis/trans couples of
[PtX2(Me2CdNOH)2], where X = Br (2c/2t)
53 or I (3c/3t),
with the aim of understanding the role of the ionic leaving
ligands and the configuration of the complexes for their
cytotoxic properties, (ii) [PtCl2(R2CdNOH)2], where R = Et
(4c/4t), n-Pr (5t), and i-Pr (6t), to elucidate the influence
of increased lipophilicity and/or steric hindrance, and (iii)
complexes of the type [Pt(NH3)2(R2CdNOH)2](NO3)2, where
R = Me (7c/7t), Et (8c/8t), and n-Pr (9c/9t), which were
anticipated to be inactive (Figure 1).
Synthesis and Characterization of Dihalidobis(oxime)-
platinum(II) Complexes. Synthesis of the target cis-diio-
didoplatinum(II) complex 3c was carried out in analogy to
corresponding dibromido species 2c.53 The reaction be-
tween K2[PtI4], obtained in situ by the addition of KI to
an aqueous solution ofK2[PtCl4], and acetoxime proceeded
in an aqueous solution at room temperature and led to
precipitation of 3c. Corresponding trans isomer 3t was
obtained via thermal isomerization of 3c in a MeNO2
solutionat 95-100 Cfor3h.Thepreparationofdichlorido
species 4c and 4t-6t was performed by a one-step reaction
of K2[PtCl4] and 2 equiv of the corresponding oxime in an
aqueous solution at 75-85 C; a higher temperature was
needed to increase the solubility of the oximes in water. The
formation of a cis/trans isomeric mixture was observed
exclusively in the case of the n-pentanone oxime complex
(4c/4t), and these isomers could be separated by column
chromatography. The reactions with n-heptanone oxime as
well as with 2,4-dimethyl-3-pentanone oxime resulted, be-
cause of steric reasons, solely in isomerically pure trans
compounds 5t and 6t, respectively. The final products were
obtainedas pale-yellow solids andwere isolated inmoderate
to good yields (40-65%).
Complexes 3c, 4c, and 3t-6t were characterized by C,
H, and N elemental analyses, 1H, 13C{1H}, and 195Pt
NMR and IR spectroscopy, ESI-MS, and also X-ray
crystallography (for 3c, 3t, 4c, and 5t). All compounds
gave satisfactory C, H, and N elemental analyses. ESI-
MS spectra displayed the fragments [MþNa]þ and [Mþ
K]þ in the positivemode as well as [M- oxime-H]- and
[M -H]- in the negative mode, having isotopic patterns
that were in good agreementwith the calculated ones. The
IR spectra of 3c, 4c, and 3t-6t showed strong-intensity
νOH (3242-3330 cm-1) and medium-intensity νCdN
(1649-1672 cm-1) stretching vibrations. Interestingly,
only in the case of the trans-configured complex 3t,
displaying sterically demanding iodido ligands, two sets
of CH3 signals were detected in the
1H NMR spectrum.
This circumstance is explainable by a hindered rotation of
the oxime ligands around the Pt-N bonds as proven via
Figure 1. Platinum(II) oxime complexes under investigation.
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the acquisition of 1HNMRspectra at different temperatures
(278-335 K; Figure S1 in the Supporting Information).
Synthesis and Characterization of Diamminebis-
(oxime)platinum(II) Dinitrate Complexes. For the pre-
paration of cis- and trans-[Pt(NH3)2(R2CdNOH)2]-
(NO3)2 (7c/7t-9c/9t), the well-known cis-[PtI2(NH3)2]54
and trans-[PtCl2(NH3)2]
55 complexes were used as start-
ing materials. First, halide abstraction of the starting
complex by using AgNO3 was carried out in an aqueous
solution at room temperature in the case of the cis species
and at 60 C for the corresponding trans-configured
complexes. The elevated temperature in the latter case
was necessary for the second chlorido ligand to be
abstracted31 after the first chloride was already ex-
changed by a water molecule (aqua ligands are known
for their extremely weak trans effect56). After the formed
AgX (X=Cl, I) precipitate was filtered off, 2 equiv of the
corresponding oxime was added to the in situ generated
cis/trans-[Pt(NH3)2(H2O)2]
2þ species, leading to the for-
mation of the desired complexes (7c/7t-9c/9t). The com-
pounds were obtained in moderate to good yields
(15-65%) via either precipitation (7c, 7t, and 9c; the
addition of acetone to the aqueous solution) or solvent
removal and suspension in acetone (8c, 8t, and 9t).
Complexes 7c/7t-9c/9t gave satisfactory elemental
analyses and expected molecular ion/fragmentation pat-
terns in the ESI-MS spectra. The presence of a broad
range of peaks was recognized in the positive mode (see
Experimental Section). Complexes 7c/7t-9c/9t were
characterized by IR spectroscopy; characteristic νOH
(3194-3316 cm-1) and νCdN (1645-1667 cm
-1) bands
were observed. With respect to the 1H NMR spectra in
D2O of the trans-[Pt(NH3)2(R2CdNOH)2](NO3)2 com-
plexes 7t, 8t, and 9t, it is worthmentioning that the proton
signals become broader with the increased length ofR. In
turn, in the 195Pt NMR spectra, the platinum signal of 8t
was broader than that for 7t (the half-height widths were
1500 and 800 Hz, respectively), turning into two signals
(a broad signal with a shoulder) in the case of 9t, which is
most probably the result of a hindered rotation of the
sterically demanding ligands. To clarify that fact, 195Pt
(Figure 2) and 1H NMR (Figure S2 in the Supporting
Information) spectra weremeasured at different tempera-
tures for 9t. At 283 K, two platinum signals at -914 and
-926 ppm were observed; upon an increase in the tem-
perature to 343 K, only one signal was detected, showing
that the complex exists in temperature-dependent con-
formations.
An analogous behavior was monitored in the proton
resonance spectra, measured at the same temperatures
(Figure S2 in the Supporting Information). However, for
the NMR spectra of the corresponding cis-configured
[Pt(NH3)2(R2CdNOH)2](NO3)2 complexes 7c, 8c, and
9c, no such features were observed.
X-ray Crystal Structures. The structures of cis-[PtI2-
(Me2CdNOH)2] (3c), trans-[PtI2(Me2CdNOH)2] (3t),
cis-[PtCl2(Et2CdNOH)2] (4c), trans-[PtCl2(n-Pr2CdNOH)2]
(5t), and trans-[Pt(NH3)2(Me2CdNOH)2](NO3)2 (7t) were
determinedbyX-raydiffraction (Table 1 andFigures 3-5).
In 3c, 3t, 4c, and 5t, the metal center is bound by two
oximic nitrogen atoms and two halogenido ligands, being
in the cis (3c and 4c) or trans (3t and 5t) positions. In 7t,
two ammonia and two oxime ligands are mutually trans.
In the coordinated oximes, the CdN bond lengths
[1.270(7)-1.292(7) A˚] are similar within 3σ and corres-
pond to previously reported distances in metal-bound
oximes [1.268-1.324 A˚].53,57-60 The platinumatom in the
square-planar complex 3t is slightly displaced out of the
Figure 2. Temperature-dependent 195PtNMR spectra of 9t (the region between-1100 and-700 ppm is shown). At low temperatures, the rotation of the
ligands is slowed down, resulting in a splitting of the platinum resonances.
(56) Chval, Z.; Sip, M.; Burda, J. V. J. Comput. Chem. 2008, 29, 2370–
2381.
(57) Kukushkin, V. Yu.; Nishioka, T.; Tudela, D.; Isobe, K.; Kinoshita, I.
Inorg. Chem. 1997, 36, 6157–6165.
(58) Kukushkin, N. V.; Ketrush, P. M.; Haukka, M. Acta Crystallogr.
2007, E63, m1286.
(59) Manivannan, V.; Kumar, B.; ChandanKumar Pal, D.; Chakravorty,
A. Inorg. Chem. 1997, 36, 1526–1528.
(60) Ebeling, G.; Gruber, A. S.; Burrow, R. A.; Dupont, J.; Lough, A. J.;
Farrar, D. H. Inorg. Chem. Commun. 2002, 5, 552–554.
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meanplane throughN1-I1-N2-I2, by 0.01 A˚, whereas in
the case of 3c, it lies ideally within the corresponding
N1-I1-N2-I2 plane (Figure 3).
The Pt-I bond distances in complexes 3c and 3t were
found in the range of 2.5819(4)-2.6104(2) A˚. These
distances agree well with those of previously published
platinum(II) iodide compounds.61-63 The Pt-N dis-
tances in the case of cis-configured 3c at 2.041(4) and
2.055(4) A˚ for Pt-N1 and Pt-N2, respectively, are
significantly longer than those found in 3t [Pt-
N1, 2.002(3) A˚; Pt-N2, 2.007(3) A˚] because of the
more pronounced trans influence of the coordinated
iodide.56
In dichloridoplatinum(II) complexes 4c and 5t (Figures
4 and 5), deviation of the platinum atom from the mean
planes through N1-Cl1-N2-Cl2 and N1-Cl1-N1-
I1-Cl2 is not larger than 0.04 A˚. The Pt-Cl bond
distances in 4c and 5t vary from 2.2821(9) to 2.3208(8) A˚,
which falls into the range of typical Pt-Cl dis-
tances.64,65 The Pt-N1 bond length in 4c at 2.0049(19) A˚
is in the expected range for platinum complexes with a cis
configuration.53,57 Of note is the relatively long distance
Pt-N2 at 2.0249(19) A˚, displaying a 7σ difference from the
Pt-N1 bond length. The N1-Pt-N2 angle at 92.08(8) in
4c is larger than that in 3c [N1-Pt-N2, 89.03(17)], depen-
ding on the coordinated halogenido ligand (chlorido versus
iodido).
The Pt-N1 bond of trans-configured 5t at 2.006(2) A˚ is
well comparable with Pt-N distances found in 3t and 7t
at 2.002(3) and 2.006(2) A˚, respectively. In contrast, the
Pt-N2 distance (coordinated ammine ligand) in 7t at
2.045(2) A˚ is significantly longer.
Cytotoxicity and Structure-Activity Relationships.The
cytotoxic potencies of the halogenido oxime complexes
2c-4c and 2t-6t, as well as the diamminebis(oxime) com-
pounds 7c/7t-9c/9t, were compared to those of cisplatin
and transplatin in the cisplatin-sensitive ovarian carcinoma
cell line CH1 and the intrinsically cisplatin-resistant colon
carcinoma cell line SW480 by means of the colorimetric
MTT assay. IC50 values are listed in Table 2. In general,
both cell lines are similarly sensitive to the halogenido
oxime compounds 2c-4c and 2t-6t, while CH1 cancer
cells are considerably more sensitive to the cationic
diamminebis(oxime) complexes 7c-9c as well as 7t and
9t than SW480 cells; complex 8t showed no antiprolifera-
tive effect at all.
Specific structural modifications of the previously re-
ported cis/trans-[PtCl2(Me2CdNOH)2] complexes 1c and
1t39 were made in order to investigate the structure-
activity relationships with respect to the effect of (i) the
leaving group, (ii) the carbon chain length of coordinated
oximes in the case of the chlorido complexes, as well as
(iii) an increasing oxime carbon chain length in cationic
diamminebis(oxime) complexes.
i. Effect of the Leaving Group. Substitution of the
chlorido ligands in 1c/1t for bromides, yielding 2c/2t,
dramatically decreases the cytotoxic potencies by factors
of 9-39. These results were expected and can be explained
by the lower reactivity of bromido complexes compared
to chlorido analogues.6 Still, the trans isomer 2t is more
cytotoxic than its cis analogue 2c. However, this trend is
not continued in the iodido counterparts. 3c and 3t
proved to be more cytotoxic than, or at least similarly
cytotoxic to the corresponding bromido species 2c and 2t,
despite a higher stability [hard and soft acids and bases
(HSAB) principle]. This might be caused by the higher
lipophilicity of 3c and 3t, facilitating cellular accumula-
tion of the complexes. Thus, the order of cytotoxicity of
Figure 3. ORTEP diagram of 3c (left) and 3t (right) displaying thermal ellipsoids at 50% probability. Selected bond lengths (A˚) and angles (deg) for 3c:
Pt-N1, 2.041(4); Pt-N2, 2.055(4); Pt-I1, 2.5819(4); Pt-I2, 2.5963(4);N1-C2, 1.292(7); N2-C5, 1.270(7); N1-Pt-N2, 89.03(17); N1-Pt-I1, 90.77(12);
N1-Pt-I2, 176.08(12). Selected bond lengths (A˚) and angles (deg) for 3t: Pt-N1, 2.002(3); Pt-N2, 2.007(3); Pt-I1, 2.5938(3); Pt-I2, 2.6104(2); N1-C2,
1.285(4); N2-C5, 1.291(4); N1-Pt-N2, 174.39(11); N1-Pt-I1, 90.69(8); N1-Pt-I2, 89.63(8).
Figure 4. ORTEP diagram of 4c displaying thermal ellipsoids at 50%
probability. Selected bond lengths (A˚) and angles (deg): Pt-N1,
2.0049(19); Pt-N2, 2.0249(19); Pt-Cl1, 2.2977(6); Pt-Cl2, 2.2957(6);
N1-C3, 1.290(3); N2-C8, 1.287(3); N1-Pt-N2, 92.08(8); N1-Pt-Cl1,
88.35(6); N1-Pt-Cl2, 178.14(5).
(61) Berger, I.; Nazarov, A. A.; Hartinger, Ch. G.; Groessl, M.; Valiahdi,
S.-M.; Jakupec, M. A.; Keppler, B. K. ChemMedChem. 2007, 2, 505–514.
(62) Rochon, F. D.; Bonnier, C. Inorg. Chim. Acta 2007, 360, 461–472.
(63) Rochon, F. D.; Buculei, V. Inorg. Chim. Acta 2004, 357, 2218–2230.
(64) Scaffidi-Domianello, Yu.; Nazarov, A. A.; Haukka, M.; Galanski,
M.; Keppler, B. K.; Schneider, J.; Du, P.; Eisenberg, R.; Kukushkin, V. Yu.
Inorg. Chem. 2007, 46, 4469–4482.
(65) Scaffidi-Domianello, Yu.; Haukka, M.; Kelly, P. F.; Galanski, M.;
Keppler, B. K.; Kukushkin, V. Yu.Z. Kristallogr.;NewCryst. Struct. 2006,
221, 226–228.
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[PtX2(Me2CdNOH)2]-type agents is dependent on the
halido ligandX as follows: I>Cl>Br (cis geometry) and
Cl> IgBr (trans geometry). Contrary to the chlorido (1c/
1t) and bromido (2c/2t) complexes, the cis isomer 3c is
slightly more cytotoxic than trans-configured 3t, reversing
the structure-activity relationships to a more cis/transpla-
tin-like behavior.
ii. Effect of the Oxime Carbon Chain in Dichlorido
Complexes. A series of complexes with chlorido ligands
and a systematically increased carbon chain of the oxime
ligand were investigated. Using n-pentanone oxime in
4c/4t instead of acetoxime in 1c/1t resulted in a 4-8.6-fold
decrease of cytotoxicity. Remarkably, the trans-config-
ured complex 4t is 8 timesmore cytotoxic than 4c. Further
increasing the length of the oxime carbon chain of the
trans complexes by either n-propyl (5t) or isopropyl (6t)
residues results in similarly enhanced cytotoxicity with
IC50 values in the high nanomolar concentration range in
both the cisplatin-sensitive CH1 and cisplatin-resistant
SW480 cells. Hence, the cytotoxicity of the trans-[PtCl2-
(R2CdNOH)2]-type complexes depends on the residues
R as follows: Me ≈ n-Pr ≈ i-Pr > Et.
iii. Effect of the Oxime Carbon Chain Length in Catio-
nic Diamminebis(oxime) Complexes. All six cationic dia-
mminedioxime complexes (7c/7t-9c/9t) displayed either
a low or a negligible cytotoxicity. This is in accordance
with the classic structure-activity relationships, accord-
ing to which complexes with four nitrogen donor ligands
(virtually no leaving groups66) or charged compounds
(low cellular accumulation but increased renal elimina-
tion6) are generally considered to be noncytotoxic. The
reason for the observed (albeit low) cytotoxicity of 7c
and 9t, especially in CH1 cells, is yet unclear.
In comparison to cisplatin, the cis-configured halido
complexes 1c-4c are considerably (up to 70 times) less
potent in the cisplatin-sensitive cell line CH1 but almost
completely retain their cytotoxicity in the cisplatin-resis-
tant SW480 cells, as indicated by a comparison of the
resistance factors (RF = IC50 in the cisplatin-resistant
cell line/IC50 in the cisplatin-sensitive cell line) of 1c-4c
(RF= 1.1-1.8; Table S1 in the Supporting Information)
with that of cisplatin (RF = 24).
In the case of trans-halido compounds 1t-6t, the
resistant factors of 0.4-1.4 show that the complexes are
not cross-resistant with cisplatin either. 1t, 5t, and 6t are
similarly cytotoxic as cisplatin in CH1 cells and up to 20
times more cytotoxic than cisplatin in SW480 cells. In
comparison to transplatin, 1t-6t are up to 90 (CH1) and
120 (SW480) times more cytotoxic.
Conclusions
A series of novel bis(oxime)platinum(II) complexes with
either cis or trans configuration have been synthesized,
characterized, and investigated in two human cancer cell
lines. Structure-activity relationships could be inferred from
these results. The observation that the trans geometry yields a
more active complex in the case of the prototypic oxime
complex [PtCl2(Me2CdNOH)2] could be confirmed for at
least two further structural analogues, [PtBr2(Me2Cd
NOH)2] and [PtCl2(Et2CdNOH)2]. Every single cis- or
trans-configured halido bis(oxime) complex showed compar-
able cytotoxic potency in both cell lines, the cisplatin-sensi-
tive CH1 and the inherently cisplatin-resistant SW480 cancer
cells. Particularly high cytotoxicities were revealed for the
three trans compounds with chlorido ligands, with IC50
values as low as 0.16-0.22 μM. Given these encouraging
results, their mechanism of action should be studied in more
detail in order to gain an understanding, which, in turn, may
help to optimize their anticancer activity.
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Figure S1. Temperature dependent 1H NMR spectra of 3t (region between 2.65 and 
2.74 ppm is shown). At 278 K, two separated signals in a ratio of about 1:5 were 
detected. Upon heating up to 335 K, only one broad signal was observed. 
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Figure S2. Temperature dependent 1H NMR spectra of 9t (region between -0.50 and 
4.00 ppm is shown). At 343 K, a doubled set of CH2 and CH3 resonances was 
detected, displaying a good resolution of each signal. During cooling down to 283 K, 
one set of signals became broader and at 283 K, the methylene protons CH2–CN 
additionally were split into two clearly separated signals. 
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Table S1. Resistance Factors of Platinum Oxime Complexes, IC50 (SW480, Cisplatin 
Resistant Cell Line) / IC50 (CH1, Cisplatin Sensitive Cell Line)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cis-configuration trans-configuration 
compound resistance factor compound resistance factor 
1c 1.3 1t 1.3 
2c 1.8 2t 0.4 
3c 1.1 3t 0.9 
4c 1.4 4t 1.4 
--- --- 5t 0.9 
--- --- 6t 1.1 
7c 27 7t --- 
8c --- 8t --- 
9c --- 9t 12 
cisplatin 24 transplatin 1.3 
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Table S2. Elemental Analyses of Platinum Oxime Complexes 
 
 
Calculated, % Found, % 
complex 
C H N C H N 
2с 14.38 2.82 5.59 14.76 2.80 5.36 
2t 14.38 2.82 5.59 14.67 2.70 5.53 
3c 12.11 2.37 4.71 12.03 2.18 4.66 
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8t 21.62 5.08 15.13 21.41 4.88 15.14 
9c·H2O 26.71 6.08 13.35 26.90 5.69 13.61 
9t·H2O 26.71 6.08 13.35 26.94 5.67 13.71 
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’ INTRODUCTION
Currently, there are three platinum-based anticancer drugs in
worldwide clinical use, viz., cisplatin and carboplatin—mainly
but not exclusively applied in the treatment of tumors of the
urogenital tract—and oxaliplatin, which is used in colorectal
cancer.15 In spite of important achievements of platinum-based
chemotherapy, one cannot deny a number of serious drawbacks
of platinum medicines, especially severe side eﬀects caused by
their unselective reaction with biomolecules. Therefore, devel-
opment of antitumor complexes attributed with an enhanced
selectivity for tumor tissue or increased reactivity at the tumor
site is a crucial goal of current cancer research.
Preferably, novel platinum drugs should attack exclusively
cancerous cells without aﬀecting the normal ones. However, this
bar is almost certainly unreachable in the case of such a complex
disease as cancer. Nevertheless, there is a possibility of approx-
imating the ideal situation, developing platinum-based prodrugs
almost innocent in the administered form and being activated
under certain conditions by conversion within the tumor tissue
to their cytotoxic/reactive analogues. Ideally, only the latter form
destroys cancer cells.
Several strategies for the design and application of platinum-based
drugswhich canbe activated in the tumor tissue have beendeveloped
so far (Figure 1). The ﬁrst and most abundant class of platinum-
based anticancer prodrugs are kinetically inert and unreactive
platinum(IV) complexes, which can be converted to more reactive
platinum(II) species, taking advantage of the reducing environment
in solid tumors (activationby reduction).2,610The secondpromising
platinum prodrug strategy pursues the development of platinum(IV)
species which can be photoactivated, implying that they are inactive
in the dark but can be photoreduced to cytotoxic platinum(II)
species by visible light,1119 with the advantage of external
initiation and control of the activation. Third, an intriguing class
of platinum-based antitumor prodrugs represents platinum com-
plexes that are inert at physiological pH but which can be
activated under slightly acidic pH values, converting platinum
species to their cytotoxic/activated form.2029
As far as the latter strategy is concerned, it is worthmentioning
that many solid tumors are characterized by a signiﬁcant acidity
Received: May 19, 2011
ABSTRACT:The reaction of 1,3-dihydroxyacetone oxime with
diam(m)minediaquaplatinum(II) under basic conditions produced
zwitterionic diam(m)mine(3-hydroxy-2-(oxidoimino)propan-1-
olato-k2N,O)platinum(II) complexes featuring the N,O-chelating
ligand. Upon reaction with hydrochloric acid, it was possible to
isolate either the singly protonated species still exhibiting the intact
N,O-chelate or the open-chain chlorido complex. All complexes
were characterized in detail with multinuclear (1H, 13C, and 195Pt)
NMR spectroscopy, ESI mass spectrometry, and in one case X-ray
diﬀraction. Cytotoxicity was investigated in three human cancer cell
lines (CH1, SW480, and A549). The obtained IC50 values are in
the medium or even low micromolar range, remarkable for platinum complexes having N3O or N3Cl coordination spheres. To study the
solution behavior of the prepared complexes at physiologically relevant proton concentrations, time-dependent 1H NMR measurements
were performed for the ethane-1,2-diamine-containing series at pH values of 7.4, 6.0, and exemplarily 5.0. While the zwitterionic complex
proved to be stable at both pH 7.4 and 6.0, the protonated species were deprotonated at pH 7.4, tending toward ring opening in slightly
acidic environments, as characteristic for many solid tumors. Finally, the open-chain form stayed intact at pH 6.0, being completely
converted into its chelated analogue at pH 7.4. A pH-dependent evaluation of antiproliferative eﬀects of the two latter complexes at pH 7.4
and pH 6.0 revealed an activation under slightly acidic conditions, which might be of interest for further in vivo studies.
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(pH 5.66.8),30 compared to the normal tissue (pH 7.4), due to
their poor blood perfusion, resulting in low oxygen availability.31
This promotes an increased metabolism of glucose and the
production of metabolic acids, such as lactic acid.32 An acidic milieu
within solid tumors could be beneﬁcially used for the application of
pH sensitive anticancer platinum drugs kinetically inert and nearly
inactive under physiological conditions (the unreactive or prodrug
form) and displaying increased cytotoxicity under mildly acidic pH
values in tumoral tissues (the activated or reactive form, Figure 1).
Up to now, only two small groups of platinum-based anticancer
compounds displaying pH-dependent antitumor activity have
been reported, viz., platinum(II) complexes bearing two chelating
O-alkyldithiocarbonato20,21 or aminoalcoholato ligands.2229
Both of them are, as many chelates, rather inert but can be
activated under acidic conditions via protonation and subsequent
opening of rather thermodynamically stable ﬁve-membered rings.
In view of our current interest in platinum(II) oxime
complexes3337 and their recently reported outstanding cytotoxic
properties, appreciably enhanced in the case of trans-geometry,3840
we focused our eﬀorts on the development of novel oxime-based
pH-sensitive platinum prodrugs. The scenario of this work was the
following: (i) to synthesize and characterize kinetically inert
platinum(II) complexes bearing a chelating oxime ligand; (ii) to
study their pH-dependent behavior, especially at physiologically
relevant pH values 7.4 (normal tissue) and 6.0 (tumor tissue); and
(iii) to evaluate the cytotoxic properties of these compounds in
three human tumor cell lines originating from ovarian carcinoma
(CH1), colon carcinoma (SW480), and nonsmall cell lung cancer
(A549), including a comparative investigation under standard pH
screening conditions (pH 7.4) and in an acidiﬁedmedium (pH 6.0)
to ﬁgure out whether the concept of pH-dependent activation also
works for this novel class of compounds.
’RESULTS AND DISCUSSION
Inspired by intriguing cytotoxic properties of (oxime)PtII
complexes,3840 we turned our attention to a commercially
available 1,3-dihydroxyacetone oxime (IUPAC name:41 1,3-
dihydroxypropan-2-one oxime) as a promising ligand for the
development of novel potentially tumor-inhibiting platinum
complexes that are rather inert but which can be activated at
acidic pH values. Owing to the presence of three hydroxo groups,
the ligand is able to formmultiple hydrogen bonds, being of great
importance for the binding of platinum compounds to DNA.42
Moreover, the 1,3-dihydroxyacetone oxime ligand is particularly
interesting because it is capable of a pH-dependent intramole-
cular chelation and ring opening (Figure 2). This reaction could
be crucial in view of the lower pH value in solid tumors. Thus, the
kinetically inert chelated compound might be applied as a
prodrug, being converted into the more (re)active open-chain
form at lower pH values in tumor tissues.
Synthesis, Characterization, and X-Ray Structure Deter-
mination of Platinum(II) Species with Chelated 1,3-Dihy-
droxyacetone Oxime. Synthesis of bischelate 1 proceeded in a
one-step reaction through the addition of 2 equiv of 1,3-dihydroxy-
acetone oxime to an aqueous solution of K2[PtCl4] at room
temperature. As a consequence, an equilibrium mixture of the
opened,mono-, and bischelated complexes was formed (Figure 3).
The latter species, notable for the lowest solubility, precipitated
from the aqueous solution and was isolated (45%) by filtration. An
additional portion of the product was formed after the addition of
1MNaOHsolution to the filtrate, resulting in a change of pH value
from 2.0 to 5.5 and giving an overall yield of 62%.
As starting materials for the preparation of the diam(m)-
ineplatinum(II) compounds bearing the 3-hydroxy-2-(oxidoimino)-
propan-1-olato ligand, we addressed the readily accessible com-
plexes cis-[PtX2A2], where X = chloride or iodide and A2 =
(ammine)2, (ethylamine)2, ethane-1,2-diamine (en), or (R,R)-
cyclohexane-1,2-diamine [(1R,2R)-chxn]. The precursors of target
species 25 (Scheme 1) were prepared by a one-step reaction of
K2[PtX4] with the corresponding am(m)ine or diamine by a
reported method.43,44 Further, halide abstraction using AgNO3 was
carried out in an aqueous solution at room temperature, where-
upon one equivalent of 1,3-dihydroxyacetone oxime was slowly
added in order to avoid/minimize the formation of a bis(oxime)-
platinum(II) species. As a next step, the reactionmixturewas treated
with a basic ion exchanger, leading to deprotonation of both the
side-chain and oximic hydroxo group and resulting in the formation
of zwitterionic oximato species 25. Finally, 24 were puriﬁed
by semipreparative HPLC yielding 2058% of the desired pro-
ducts, while 5 was isolated in 32% yield as a colorless precipitate
after concentration of the reaction mixture.
Figure 1. Strategies to activate rather unreactive platinum prodrugs in
the tumor tissue.
Figure 2. pH-Dependent intramolecular chelation and ring opening of
the ligated 1,3-dihydroxyacetone oxime.
Figure 3. pH-Dependent equilibrium mixture of the opened-, mono-,
and bischelated oximeplatinum species.
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Complexes 15were characterized by elemental analyses; 1H,
13C{1H}, and 195Pt NMR and IR spectroscopy; electrospray
ionization mass spectrometry (ESI-MS); and also X-ray crystal-
lography (in the case of 5). All compounds gave satisfactory C, H,
and N elemental analyses. The ESI-MS spectrum of 1 exhibited
the fragment [M  H], while in the spectra of 25, [M + H]+
and [M + Na]+ peaks were found. In all cases, the observed and
calculated isotopic patterns agreed well with each other.
The IR spectra of 15 displayed strong to medium ν(OH) and
ν(NH) (for 25) [28083474 cm1] and medium ν(CdN)
[16021630 cm1] stretching vibrations. Chelation of the 1,3-
dihydroxyacetone oxime ligandwas conﬁrmed (e.g., complex 4) via
acquisition of an 1H,195Pt-HMQC NMR spectrum (Figure 4).
Thus, for compound 4, three correlation peaks were detected,
derived from the coupling of the 195Pt nucleus with the protons of
the coordinated ethane-1,2-diamine as well as with one of the oxime
CH2 groups located within the chelate ring. The presence of the
latter cross-peak undoubtedly proved the fact of the ring closure.
The structure of 5 was determined by X-ray diﬀraction
(Table 1 and Figure 5). The platinum(II) atom has a slightly
distorted square-planar coordination geometry. It is coordinated
by two ligands, bidentate (R,R)-cyclohexane-1,2-diamine and a
doubly deprotonated 1,3-dihydroxyacetone oxime ligand acting
as a bidentate as well. Deviation of the platinum atom from the
mean plane through N1, N2, O1, N3 is at 0.011 Å. The bond
lengths PtN1 = 2.040(11) and PtN2 = 2.054(11) Å are
in a good agreement with those of oxaliplatin, (SP-42)-
((R,R)-cyclohexane-1,2-diamine)oxalato-platinum(II) [PtN1 =
2.06(2) Å, PtN2 = 2.04(2) Å].45 The PtN3 distance is
1.997(13) Å and correlates well with PtN bond lengths
in previously reported (oxime)Pt(II) complexes displaying an
N-bound ligand in the trans position to an oxime [1.9932.032
Å].4648 It is worth mentioning that no nitrate counteranions
were detected in the structure of 5, providing additional evidence
for the double deprotonation of the 1,3-dihydroxyacetone oxime.
The atomsO1 andO2 seem to be deprotonated, acting as proton
acceptors in hydrogen bonding interactions with cocrystallized
water molecules and the O3H group of the oxime ligand in the
adjacent molecule of 5.
Protonation of the Oximato Group and Opening of the
Oxime Chelate Ring. Above described complexes 4 and 5 were
Figure 4. 1H,195Pt HMQC NMR spectrum of 4.
Table 1. Crystal Data and Details of Data Collection for
5 3 2H2O
5 3 2H2O
empirical formula C9H23N3O5Pt
fw 448.39
space group P212121
a [Å] 7.3783(15)
b [Å] 8.3748(19)
c [Å] 22.125(5)
V [Å3] 1367.1(5)
Z 4
λ [Å] 0.71073
Fcalcd [g cm3] 2.178
cryst size [mm3] 0.40  0.02  0.01
T [K] 100
μ [mm1] 10.281
R1
a 0.0556
wR2
b 0.1145
GOFc 1.009
a R1 = ∑||Fo| |Fc||/∑|Fo|. b wR2 = {∑[w(Fo2 Fc2)2]/∑[w(Fo2)2]}1/2.
cGOF = {∑[w(Fo
2  Fc2)2]/(n  p)}1/2, where n is the number of
reﬂections and p is the total number of parameters reﬁned.
Figure 5. ORTEP view of 5 with the atom labeling scheme. The
thermal ellipsoids have been drawn at the 50% probability level. Selected
bond lengths (Å) and bond angles (deg): PtN1= 2.040(11), PtN2=
2.054(11), PtN3 = 1.997(13), PtO1 = 2.006(9); N1PtN2 =
83.4(4), O1PtN3 = 82.5(4).
Scheme 1
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converted into the corresponding cationic species by the addition
of an equivalent amount of hydrochloric acid (pH ≈ 2.5;
Scheme 1), whereupon the reaction mixture was immediately
frozen and lyophilized in order to avoid further protonation of
the ligated oxime and opening of the chelate ring. The com-
pounds 4a and 5a were isolated with nearly quantitative yields.
Opening of the oxime chelate ring was performed in an
analogous way, adding an excess of HClconc (about 4 equivs)
until a pH of 1 was reached to an aqueous solution of 4 or 5 and
stirring the mixture for 24 h at room temperature for completion
of the reaction (Scheme 1). Finally, products were isolated via
lyophilization, resulting in pale-yellow hygroscopic species 4b
and 5b, obtained in 65% and 72% yield, respectively. Unfortu-
nately, HCl addition to complexes 13 led to the formation of
highly unstable species which could not be isolated.
Complexes 4a, 4b, 5a, and 5b gave satisfactory elemental
analyses and the expected molecular ion/fragmentation patterns
in ESI-MS spectra. Thus, [M  Cl]+ and [M + H]+ peaks were
detected for 4a and 5a, whereas the ESI-MS spectra of 4b and 5b
exhibited [MHClCl]+ and [MCl]+ signals. The IR spectra
of the complexes displayed the characteristic ν(OH) and ν(NH)
[28623394 cm1] bands of strong intensity, as well as medium-
intensive ν(CdN) [16131675 cm1] bands. In the 1H NMR
spectra, the downﬁeld shifting of the oxime CH2 group signals as a
result of oximato group protonation and consequent chelate ring
opening could be clearly observed. Thus, the above-mentioned
proton signals appeared at 4.50 and 4.22 ppm for chelated oximato
species 4 and 5, changing to 4.60 and 4.28 ppm for protonated
cationic complexes 4a and 5a, and ﬁnally resonating at 4.98 and
4.60 ppm for open-chain compounds 4b and 5b. As expected, the
oximato group protonation hardly inﬂuenced the chemical shift of
the platinum signal in 195Pt NMR spectra (δPt =663 ppm for 4
vs666 ppm for 4a). In contrast, the oxime ring opening resulted
in a signiﬁcant shift of the platinum signal (δPt =978 ppm for 4b)
due to the change in the ligand sphere (Cl vs O). Additionally, the
presence of the oxime chelate ring for complexes 4a and 5a was
conﬁrmed by 1H,195Pt-HMQC NMR.
Time-Dependent NMR Studies Under Physiological and
Slightly Acidic Conditions. To elucidate the solution behavior
of the prepared complexes at physiologically relevant proton
concentrations, time-dependent 1H NMR measurements at pH
values of 7.4, 6.0, and in one case 5.0 were carried out with the
most water-soluble ethane-1,2-diamine complexes 4, 4a, and 4b.
For that purpose, a phosphate-buffered solution (pH 7.4 and pH
6.0) or a solution of DNO3 in D2O (pH 5.0) was used.
The zwitterionic complex 4 proved to be stable at both pH 7.4
and 6.0. Thus, no changes in the NMR spectra were observed
during a measurement time of 24 h at ambient temperature. In
contrast to 4, compound 4a, featuring the protonated oximic
group, was immediately deprotonated at pH 7.4 and stayed
unchanged for the next 24 h. Expectedly, at pH 6.0, no
deprotonation of 4a took place, but a partial opening of the
oximic chelate ring was observed. Hence, small signals of the
open-chain form 4b were visible already 5 min after dissolution
and increased with time, 17 h later reaching an equilibrium ratio
of 10 to 1 (4a versus 4b), or in other words ∼9% of conversion.
This diﬀerent behavior of 4a in comparison to 4 at a given pH
value is at ﬁrst sight astonishing but might be explainable due to
the presence of chloride ions in the case of 4a, having an inﬂuence
on the ring-opening reaction. Additional time-dependent mea-
surements were carried out also at pH 5.0, resulting in∼12% ring
opening after 8 h.
As far as complex 4b is concerned, chelate ring closure takes
place while keeping it at a pH of 7.4. Thus, the ﬁrst signals of 4
appeared within 5 min after dissolution, whereas the complete
conversion of 4b into 4 occurred 25 h later, proving the reversi-
bility of the ring-opening process. As expected, at pH 6.0, no
chelation was observed, and the open-chain complex 4b stayed
intact during the measurement time (24 h).
Cytotoxic Activity at Physiologically Relevant Proton Con-
centrations.The in vitro cytotoxicity of complexes 15, 4a, 4b, 5a,
and 5b was evaluated in three human cancer cell lines (CH1,
SW480, and A549), using the MTT assay (Table 2 and Figures
S1S3, Supporting Information) under standard screening condi-
tions at a pHof 7.4.Of all compounds, the bis(1,3-dihydroxyacetone
oxime) complex 1 displayed the lowest antiproliferative potency.
For example, in CH1 cells, the IC50 value of 1was 190 times higher
compared to the most potent complex in this series. Among
zwitterionic ring-closed compounds 25 (Figure S1, Supporting
Information), the nonleaving am(m)ine ligands have a distinct
influence on cytotoxic properties. Complexes with monodentate
amine ligands (NH3 in complex 2 or EtNH2 in complex 3) yielded
lower IC50 values in the CH1 cell line as compared to complexes 4
or 5 featuring bidentate ethane-1,2-diamine or (R,R)-cyclohexane-
1,2-diamine ligands. However, this cannot be generalized for other,
inherently cisplatin-resistant cell lines (such as SW480 andA549), as
the (R,R)-cyclohexane-1,2-diamine ligand (in complex 5) results
in a completely different sensitivity profile analogous to oxaliplatin.
Comparing analogues 4, 4a, and 4b (Figure S2, Supporting
Information) or 5, 5a, and 5b (Figures S3, Supporting In-
formation), oxidoimino complexes 4 and 5 showed the lowest
cytotoxic potency. A comparable or by trend slightly improved
antiproliferative behavior was found in the case of protonated
counterparts 4a and 5a, respectively, a circumstance which is not
explainable at the moment. Ring opening and formation of the
chloridoplatinum(II) species 4b and 5b was accompanied by a
noteworthy lowering of the IC50 values (increase in cytotoxicity)
down to 1 μM in CH1 cells. The antiproliferative potency is
signiﬁcantly lower compared to cisplatin. However, these
cytotoxicities in the low micromolar range are remarkable, taking
into account that 4b and 5b display three coordinated nitrogen
donor atoms (nonclassic platinum complexes). Similar structure
activity relationships were found in SW480 and A549 cells.
Table 2. Cytotoxicity of the (1,3-Dihydroxyacetone
Oxime)Platinum(II) Complexes in CH1, SW480, and A549
Cancer Cells (Exposure Time 96 h)
IC50 [μM]
compound CH1 SW480 A549
1 190( 20 571( 47 >640
2 3.9( 1.1 130( 23 302 ( 7
3 16 ( 5 277( 23 575 ( 86
4 33( 9 350( 34 >640
4a 15( 2 307( 6 >320
4b 1.0( 0.1 37( 9 63 ( 19
5 37( 10 33( 2 217 ( 36
5a 8.3( 3.2 12( 3 56 ( 13
5b 1.1( 0.2 0.97( 0.30 5.6 ( 1.6
cisplatin 0.14( 0.3 3.3( 0.4 1.3 ( 0.4
oxaliplatina 0.33( 0.09 0.30( 0.08
aData taken from ref 49.
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Not unexpectedly for complexes 14, the cytotoxic potency
was highest in the cisplatin sensitive cell line CH1 but decreased
signiﬁcantly in inherently cisplatin-resistant SW480 and A549
cells. Contrarily, IC50 values for the (R,R)-cyclohexane-1,2-
diamine derivatives 5, 5a, and 5b, were comparable in CH1
(ovarian carcinoma) and SW480 (colon carcinoma) cells. As
mentioned above, this pattern is analogous to oxaliplatin, which
is clinically approved for the treatment of colorectal cancer
(compare with IC50 values of oxaliplatin, Table 2).
Protonation and/or ring opening of complexes 25 in an
acidic environment (as observed in many solid tumors) should
be accompanied by an enhanced cytotoxic eﬀect. Therefore,
ethane-1,2-diamine compound 4a and its open-chain analog 4b
were exemplarily investigated in SW480 and A549 cells under
standard screening conditions at a pH of 7.4 and in an acidiﬁed
cell culture medium at a pH of 6.0 (Table 3). Note that the drug
exposure time was only 24 h, followed by incubation in a drug-
free medium at a pH of 7.4 for a further 72 h; consequently, the
IC50 values are higher in comparison to experiments with 96 h of
exposure. Expectedly, antiproliferative activity was improved
under acidic conditions in both cell lines for 4a as well as for 4b.
Binding of Complex 5b to 50-GMP. Monodentately bound
oxime in 4b and 5b may act as a leaving or nonleaving group,
leading to either bis- or monoadduct formation with DNA. In
order to judge the reactivity, complex 5b (0.5 mM) was
incubated with a 10-fold excess of the model nucleotide 50-
guanosine monophosphate (50-GMP, 5 mM) in a phosphate
buffer (10 mM, pH 6) at 25 C. The reaction was monitored by
electrospray mass spectrometry (ESI-MS).
During the course of incubation, the intensity of the peaks cor-
responding to 5b (413 [M5bHClCl]+ and 450 [M5bCl]+)
was reduced with time in comparison to the peak related to
50-GMP (408 [M50-GMP + 2Na  H]+; Figure S4, Supporting
Information). A total of 8 h after the experiment was started, a peak
at 776 corresponding to the mono-50-GMP adduct was detected
and attributed to the positively charged species [M5bHClCl +
GMP]+ (C19H34N8O11PPt, calcd m/z 776.57; Figure S5, Support-
ing Information). Signals in the range where bisconjugates of 5b
with 50-GMP would be expected were not visible in the positive ion
mode.With the aim of proving that bifunctional adducts could be
detected under these conditions and for reasons of comparison,
an experiment was performed with [Pt(1R,2R-chxn)Cl2] in parallel.
The latter complex is an analogue to 5b, in which the monodentate
oxime ligand was exchanged for chloride, now featuring two
chlorido leaving groups [Pt(1R,2R-chxn)Cl2] was reacted with
1 equiv of AgNO3 in order to increase the aqueous solubility of
the complex). As could be expected, a peak related to the Pt-50-
GMP monoadduct at 708 [M[Pt(1R,2R-chxn)Cl2]  Cl + GMP]+
(C16H28ClN7O8PPt, calcd m/z 707.94) was detected 25 min
after the beginning of the incubation, whereupon two peaks
corresponding to Pt-50-GMP bisadducts were observed at 1034
[M[Pt(1R,2R-chxn)Cl2]HClCl + 2GMP]+ (C26H41N12O16P2Pt,
calcd m/z 1034.70) and 1056 [M[Pt(1R,2R-chxn)Cl2]  2HCl +
2GMP + Na]+ (C26H40N12O16P2PtNa, calcd m/z 1056.68) after
24 h, increasing with time.
A second experiment was performed with complex 5b and
[Pt(1R,2R-chxn)Cl2] under the same conditions, but at 37 C and
with MS detection both in the positive and in the negative ion
mode (Figures S6 and S7, Supporting Information). In the positive
ion mode, bisconjugates of 5b with 50-GMP were not visible.
However, bisadduct formation of 5b after 1 week of incubation
with 50-GMP could be proven by detection of a doubly negatively
charged peak at 515.6 corresponding to [M5b  2Cl  oxime +
2GMP4H]2C26H38N12O16P2Pt, calcdm/z 515.84), although
to a signiﬁcantly lesser extent compared to [Pt(1R,2R-chxn)Cl2].
On the basis of these results, the oxime group may be classiﬁed
as a leaving ligand. However, whether such a ligand is easily
exchangeable in a physiologically relevant time frame cannot be
answered yet.
’CONCLUSIONS
The results of this work may be considered from two
perspectives. In a narrow sense, four novel (3-hydroxy-
2-(oxidoimino)propan-1-olato-k2N,O)platinum(II) complexes
were prepared and completely characterized, along with the
protonated and open-chain species in the case of two complexes
featuring a bidentate ethane-1,2-diamine or (R,R)-cyclohexane-
1,2-diamine ligand. The cytotoxicity of the investigated com-
pounds in human cancer cells was found in the medium or even
low micromolar range, which is remarkable for nonclassic
platinum complexes with three coordinated N donor atoms.
Interestingly, similar structureactivity relationships were found
for two series of complexes featuring ethane-1,2-diamine and
(R,R)-cyclohexane-1,2-diamine ligands. Chelate ring opening im-
proved the IC50 values 8 and 15 times, respectively, in CH1
ovarian cancer cells. Time-dependent NMR studies at physiolo-
gically relevant pH values, performed for the most water-soluble
ethane-1,2-diamine-containing series, showed that zwitterionic
oximato complex 4 is stable toward ring opening both at pH 7.4
and at pH 6.0. Diﬀerently, protonated form 4a is being depro-
tonated to analogue 4 at pH 7.4, while tending to chelate ring-
opening in an acidic medium. As discussed above, this diﬀerent
behavior of complex 4a in comparison to 4 at a given pH value is
most probably the result of the presence of one equivalent of
chloride ions in the case of 4a. In contrast, open-chain species 4b,
stable at pH 6.0, was completely converted into the ring-closed
form 4 at pH 7.4. Comparative investigation of the cytotoxic
potency of complexes 4a and 4b under standard cell line
screening conditions (pH 7.4) and in an acidiﬁed cell culture
medium (pH 6.0) showed a signiﬁcant increase of antiprolifera-
tive activity under slightly acidic conditions. Whether this pH-
dependent activation is of relevance for the in vivo situation will
be the subject of our future research program.
In a wider sense, this research is an important contribution to the
development of inert and unreactive complexes (prodrugs) which
can be activated in the tumor tissue. From this point of view, a
number of novel oxime-based pH-sensitive potential platinum
prodrugs have been prepared. Moreover, in this work, we have
demonstrated the possibility of reversible pH-dependent intra-
molecular chelation and ring-opening reaction for the novel com-
plexes as well as an increase of their cytotoxic potency under the
Table 3. Comparison of the Cytotoxicities of 4a and 4b in
SW480 and A549 Cancer Cells at pH 7.4 and 6.0 (Drug
Exposure Time 24 h)
GI50 [μM]
SW480 A549
compound pH 7.4 pH 6 pH 7.4 pH 6
4a >640 590 ( 57 >640 373 ( 103
4b 231 ( 42 127 ( 22 438 ( 51 113 ( 31
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slightly acidic conditions characteristic for many solid tumor tissues.
However, the prepared 3-hydroxy-2-(oxidoimino)propan-1-olato
species proved to be less accessible to protonation at slightly acidic
pH values than, for instance, the previously reported aminoalco-
holato or O-alkyldithiocarbonato complexes. A promising strategy
to facilitate the chelate ring opening under acidic conditions could
be introducing, e.g., an alkyl substituent into the 1,3-dihydrox-
yacetone oxime ligand, which should result in a decrease of acidity of
the side-chain hydroxo group due to its positive inductive eﬀect.
As a consequence, complexes of a weaker acid are probably easier
to protonate, which should favor the formation of the open-chain
species. Investigation of these aspects is ongoing.
’EXPERIMENTAL SECTION
General Procedures. Potassium tetrachloridoplatinate and 1,3-
dihydroxyacetone oxime were supplied by Johnson Matthey and TCI,
respectively. Ammonium hydroxide solution (25% in water), ethylamine
solution (70% in water), and (R,R)-cyclohexane-1,2-diamine [(1R,2R)-
chxn] were purchased from Fluka, while ethane-1,2-diamine (en) was
obtained from Aldrich. All of these chemicals were used as received
without further purification. The complexes cis-[PtI2(NH3)2], cis-[PtI2-
(EtNH2)2], [PtCl2(en)], and [PtCl2{(1R,2R)-chxn}] were prepared
according to standard literature procedures starting fromK2[PtCl4].
43,44
Bidistilled water was used. The synthetic procedures were carried out in
a light-protected environment due to the known photosensitivity of
some platinum species.50 For HPLC separation, a semipreparative
250  20 mm Kromasil 100 Å C18 10 μm column was used. C, H, and
N elemental analyses were carried out by the elemental analyses laboratory
of the University of Vienna using a Perkin-Elmer 2400 CHN elemental
analyzer. ESI-MS spectra were obtained with a Bruker Esquire 3000 instru-
ment. IR spectra were obtained by using an ATR unit with a Perkin-
Elmer 370 FTIR 2000 instrument (4000400 cm1). 1H, 13C{1H},
195Pt, and two-dimensional NMR spectra were measured with a Bruker
Avance III 500 MHz NMR spectrometer at 500.32 (1H), 125.81 (13C),
and 107.55 MHz (195Pt), correspondingly, at 298 K. 195Pt chemical
shifts are referenced relative to K2[PtCl4], and the half-height line width
is given in parentheses.
Synthesis of the Platinum(II) Complexes with Chelated
1,3-Dihydroxyacetone Oxime. (SP-41)-Bis(3-hydroxy-2-
(hydroxyimino)propan-1-olato-j2N,O)platinum(II) (1). K2-
[PtCl4] (121.0 mg, 0.29 mmol) was dissolved in 2.5 mL of H2O; then
1,3-dihydroxyacetone oxime (61.0 mg, 0.58 mmol) was added. The
reaction mixture was stirred at room temperature overnight. Formation
of a colorless precipitate was observed, which was filtered off. Then, 1M
NaOH solution (160 μL, 0.16 mmol) was added to the yellow filtrate
(pH value changed from 2.0 to 5.5), and the reaction mixture was stirred
at room temperature for 24 h. An additional portion of the colorless
precipitate formed was filtered off, combined with the first portion,
washed twice with 0.5 mL of ice-cold water, and dried in vacuo at room
temperature. Yield: 73 mg (62%). Anal. Calcd. for C6H12N2O6Pt: C,
17.87; H, 3.00; N, 6.95. Found: C, 18.02; H, 2.82; N, 6.89%. ESI-MS
(H2O/MeOH),m/z: 402 [MH]. IR in KBr (selected bands), cm1:
3474 s, 3422 s ν(OH), 1615 m ν(CdN). 1HNMR (D2O): δ 4.59 (s, br,
OCH2,), 4.28 (s, br, HOCH2).
13C{1H}NMR (D2O): δ 166.2 (CdN),
71.8 (OCH2), 55.3 (HOCH2).
195Pt NMR (D2O): δ 137 (780 Hz).
General Synthesis of (SP-43)-Diam(m)ine(3-hydroxy-
2-(oxidoimino)propan-1-olato-j2N,O)platinum(II). [PtX2A2]
(0.50 mmol) and AgNO3 (1.0 mmol) were mixed and suspended in
10 mL of H2O, whereupon the mixture was stirred at room temperature
overnight. The precipitate of AgX was filtered off, and a solution of 1,3-
dihydroxyacetone oxime (0.50 mmol) in 2 mL of H2Owas added slowly
(dropwise within 12 h). After the reaction mixture was stirred at the
same temperature for 12 h, it was diluted with 50 mL of H2O and
subsequently mixed with approximately 3 g of a preconditioned basic
anion exchange resign, Amberlite IRA 402 (the commercially available
chloride form was treated with 30 mL of 2M NaOH for 30 min and
washed with deionized water until a pH of 7), and themixture was stirred
for several minutes. After the ion-exchanger turned from slightly yellow
to dark-gray (pH∼910), it was filtered off, and the fine precipitate of
platinum black (formed in small amount) was removed by filtration
through a Glass Microfibre 696. In the case of 24, the resulting yellow
solution was evaporated to dryness, and 15 mL of acetone was added.
The yellow solid formed was filtered off, washed with acetone (2 
1 mL), and dried in vacuo. After that, the crude product was purified
through semipreparative HPLC (H2O/MeOH 98/2 for 2 and 4, H2O/
MeOH 95/5 for 3) and lyophilized. In the case of 5, the yellowish filtrate
was reduced to 0.5 mL and placed into the fridge (+5 C) for 2 h. The
colorless precipitate formed was filtered off, washed twice with a few
drops of ice-cold H2O, and dried in vacuo. The yields were 25% (2), 20%
(3), 58% (4), and 32% (5).
(SP-43)-Diammine(3-hydroxy-2-(oxidoimino)propan-1-
olato-j2N,O)platinum(II) (2). Anal. Calcd. for C3H11N3O3Pt 3 2
H2O: C, 9.78; H, 4.11; N, 11.41. Found: C, 10.18; H, 3.77; N,
11.05%. ESI-MS+ (H2O/MeOH), m/z: 333 [M + H]
+, 355 [M +
Na]+. IR in KBr (selected bands), cm1: 3092 s, 2987 s, 2808 m ν(OH)
and ν(NH), 1630 m ν(CdN). 1H NMR (D2O): δ 4.51 (m, 2H,
OCH2), 4.23 (m, 2H, HOCH2).
13C{1H} NMR (D2O): δ 168.1
(CdN), 73.6 (OCH2), 56 (HOCH2).
195Pt NMR (D2O): δ 527
(800 Hz).
(SP-43)-Bis(ethylamine)(3-hydroxy-2-(oxidoimino)propan-
1-olato-j2N,O)platinum(II) (3). Anal. Calcd. for C7H19N3O3Pt 31/
2H2O: C, 21.16; H, 5.07; N, 10.58. Found: C, 20.90; H, 4.66; N, 10.21%.
ESI-MS+ (H2O/MeOH),m/z: 344 [M EtNH2+H]+, 389 [M+H]+, 411
[M + Na]+. ESI-MS (H2O/MeOH), m/z: 433 [M  Cl]. IR in KBr
(selected bands), cm1: 3200 s, 3128 s, 3068 s ν(OH) and ν(NH), 1606
ν(CdN). 1HNMR(D2O):δ4.57 (m, 2H,OCH2), 4.30 (m, 2H,HOCH2),
2.66 (m, 4H, 2CH3CH2), 1.17 (t, 6H, 2CH3,
3JH,H = 6.9 Hz).
13C{1H}
NMR (D2O): δ 176.2 (CdN), 73.1 (OCH2), 56.3 (HOCH2), 41.9
(CH3CH2), 41.3 (CH3CH2), 15.6 (2CH3).
195Pt NMR (D2O): δ 589
(720 Hz).
(SP-43)-(Ethane-1,2-diamine)(3-hydroxy-2-(oxidoimino)
propan-1-olato-j2N,O)platinum(II) (4). Anal. Calcd. for
C5H13N3O3Pt 3H2O: C, 16.35; H, 3.84; N, 11.44. Found: C, 16.68;
H, 3.45; N, 11.14%. ESI-MS+ (H2O/MeOH),m/z: 359 [M +H]
+. IR in
KBr (selected bands), cm1: 3177m, 2935 s, 2889 s ν(OH) and ν(NH),
1618 m ν(CdN). 1H NMR (D2O): δ 4.50 (m, 2H, OCH2), 4.22 (m,
2H, HOCH2), 2.55 (m, 4H, 2CH2).
13C{1H} NMR (D2O): δ 168.3
(CdN), 73.6 (OCH2), 55.9 (HOCH2), 46.43 (CH2), 46.36 (CH2).
195Pt NMR (D2O): δ 663 (600 Hz).
(SP-43)-{(R,R)-Cyclohexane-1,2-diamine}(3-hydroxy-2-
(oxidoimino)propan-1-olato-k2N,O)platinum(II) (5). Anal.
Calcd. for C9H19N3O3Pt 3H2O: C, 25.12; H, 4.92; N, 9.76. Found: C,
24.78; H, 4.71; N, 9.49%. ESI-MS+ (H2O/MeOH),m/z: 413 [M +H]
+.
IR in KBr (selected bands), cm1: 3184 s, 3100 s, 2937 m ν(OH) and
ν(NH), 1602 m ν(CdN). 1H NMR (MeOD): δ 4.66 (m, 2H, OCH2),
4.34 (m, 2H, HOCH2), 2.32 (m, 2H, 2CH), 2.03 (m, 2H, CH2), 1.64
(m, 2H, CH2), 1.33 (m, 2H, CH2), 1.23 (m, 2H, CH2).
13C{1H} NMR
(MeOD): δ 167.5 (CdN), 74.2 (OCH2), 61.2 (CH), 60.9 (CH), 56.5
(HOCH2), 32.7 (CH2), 32.5 (CH2), 24.3 (CH2), 24.2 (CH2).
195Pt
NMR (MeOD): δ 610 (630 Hz). Crystals for X-ray study were
obtained by slow evaporation of a water solution at room temperature.
Protonation of the Chelated Platinum(II) Oximato Spe-
cies. In a typical experiment, 1 equiv of 1.2M HCl was added to a
solution/suspension of 4 or 5 (0.1 mmol) in 10 mL of H2O, resulting in
the change of the solution color from pale- to bright-yellow. The
reaction mixture was immediately frozen and lyophilized. The products
4a and 5a were isolated as colorless solids in almost quantitative yield.
62
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(SP-43)-(Ethane-1,2-diamine)(3-hydroxy-2-(hydroxyimino)
propan-1-olato-j2N,O)platinum(II) Chloride (4a). Anal. Calcd. for
C5H14N3O3ClPt 31/2H2O:C, 14.87; H, 3.74;N, 10.41. Found: C, 15.06;H,
3.78; N, 9.98%. ESI-MS+ (H2O/MeOH), m/z: 359 [M Cl]+, 396 [M +
H]+. ESI-MS (H2O/MeOH), m/z: 394 [M H], 430 [M + Cl]. IR
(selected bands), cm1: 3353m, 3224 s, 3055 s, 2966 s ν(OH) and ν(NH),
1675 m ν(CdN). 1H NMR (D2O): δ 5.16 (m, 4H, 2NH2), 4.67 (s, 2H,
OCH2), 4.33 (s, 2H, HOCH2), 2.55 (m, 4H, 2CH2).
13C{1H} NMR
(D2O): δ 160.2 (CdN), 73.8 (OCH2), 56.2 (HOCH2), 46.7 (CH2), 46.5
(CH2).
195Pt NMR (D2O): δ 666 (960 Hz).
(SP-43)-{(R,R)-Cyclohexane-1,2-diamine}(3-hydroxy-2-
(hydroxyimino)propan-1-olato-k2N,O)platinum(II) Chloride
(5a). Anal. Calcd. for C9H20N3O3ClPt 3 1/2H2O: C, 23.61; H, 4.62; N,
9.18. Found: C, 23.57; H, 4.49; N, 8.91%. ESI-MS+ (H2O/MeOH), m/z:
413 [M  Cl]+, 435 [M  HCl + Na]+, 450 [M + H]+. IR in KBr
(selected bands), cm1: 3394 s, 3191 s, 3067 s, 2938 s ν(OH) and
ν(NH), 1613m ν(CdN). 1HNMR (D2O): δ 4.60 (s, 2H, OCH2), 4.28
(s, 2H, HOCH2), 2.32 (m, 2H, 2CH), 1.97 (m, 2H, CH2), 1.51 (m, 2H,
CH2), 1.22 (m, 2H, CH2), 1.09 (m, 2H, CH2).
13C{1H}NMR (D2O): δ
174.9 (CdN), 73.8 (OCH2), 61.1 (CH), 61.0 (CH), 56.1 (HOCH2),
32.3 (CH2), 32.2 (CH2), 24.0 (CH2), 23.9 (CH2).
195Pt NMR (D2O): δ
636 (870 Hz).
OximeChelate RingOpening. In a typical experiment, 4 equiv of
HClconc was added to a solution/suspension of 4 or 5 (0.2 mmol) in
5 mL of H2O, and the reaction mixture was stirred for 24 h at room
temperature. A small amount of a brownish-yellow solid formed was
filtered off through a Glass Microfibre 696. The resulting clear yellow
solution was lyophilized, giving hygroscopic pale-yellow solids of 4b and
5b. Yields of 4b and 5b were 65% and 72%, respectively.
(SP-43)-Chlorido(1,3-dihydroxoacetone Oxime-jN)-
(Ethane-1,2-diamine)platinum(II) Chloride (4b). Anal. Calcd.
for C5H15N3O3Cl2Pt 3H2O: C, 13.37; H, 3.81; N, 9.35. Found: C,
13.74; H, 3.59; N, 9.04%. ESI-MS+ (H2O/MeOH), m/z: 359 [M 
HCl Cl]+, 396 [MCl]+. IR (selected bands), cm1: 3380 s, 3249
s, 3193 s, 3094 s, 2994 m ν(OH) and ν(NH), 1647 m ν(CdN). 1H
NMR (D2O): δ 5.57 (m, 2H, 2NH2), 5.37 (m, 2H, 2NH2), 4.97 (s,
2H, HOCH2), 4.60 (s, 2H, HOCH2), 2.61 (m, 4H, 2CH2).
13C{1H}
NMR (D2O): δ 169.2 (CdN), 60.6 (HOCH2), 57.3 (HOCH2), 48.2
(CH2), 47.7 (CH2).
195Pt NMR (D2O): δ 978 (670 Hz).
(SP-43)-Chlorido{(R,R)-cyclohexane-1,2-diamine}(1,3-
dihydroxyacetone Oxime-kN)platinum(II) Chloride (5b).
Anal. Calcd. for C9H21N3Cl2O3Pt: C, 22.28; H, 4.36; N, 8.66. Found:
C, 22.10; H, 4.23; N, 8.26%. ESI-MS+ (H2O/MeOH), m/z: 413 [M
HClCl]+, 450 [MCl]+. IR in KBr (selected bands), cm1: 3183 s,
3083 s, 2937 s, 2862m ν(OH) and ν(NH), 1647m ν(CdN). 1HNMR
(D2O): δ 5.91 (m, 1H, NHH), 5.62 (m, 1H, NHH), 5.04 (m, 2H,
2NHH), 4.98 (s, 2H, HOCH2), 4.60 (s, 2H, HOCH2), 2.46 (m, 1H,
CH), 2.38 (m, 1H, CH), 1.99 (m, 2H, CH2), 1.53 (m, 2H, CH2), 1.26
(m, 2H, CH2), 1.09 (m, 2H, CH2).
13C{1H} NMR (D2O): δ 169.1
(CdN), 62.8 (HOCH2), 62.2 (HOCH2), 60.7 (CH), 57.3 (CH), 32.0
(CH2), 31.8 (CH2), 23.8 (CH2), 23.7 (CH2).
195Pt NMR (D2O): δ
945 (670 Hz).
1H NMR (DMF-d6): δ 12.44 (s, 1H, HON), 6.91 (m, 1H, NHH),
6.22 (m, 1H, NHH), 5.99 (m, 1H, NHH), 5.57 (m, 1H, NHH), 5.08 (d,
1H, HOCHH, 3JH,H = 12.8 Hz), 5.00 (d, 1H, HOCHH,
3JH,H = 12.8
Hz), 4.60 (s, 2H,HOCH2), 2.54 (m, 2H, 2CH), 2.10 (m, 2H, CH2), 1.57
(m, 2H, CH2), 1.49 (m, 2H, CH2), 1.15 (m, 2H, CH2).
13C{1H} NMR
(DMF-d6): δ 170.5 (CdN), 62.8 (HOCH2), 62.3 (HOCH2), 60.8
(CH), 57.1 (CH), 32.3 (CH2), 31.7 (CH2), 24.5 (CH2), 24.3 (CH2).
15N NMR (DMF-d6): δ 22.6 (NH2), 10.7 (NH2). 195Pt NMR
(DMF-d6): δ 933 (500 Hz).
Crystal Structure Determination. X-ray diffraction measure-
ment for 5 3 2H2O was performed on a Bruker X8 APEXII CCD diffract-
ometer. A single crystal was positioned at 35 mm from the detector, and
1330 frames were measured, each for 60 s over 1 scan width. The data
were processed using SAINT software.51 Crystal data, data collection
parameters, and structure refinement details are given in Table 1. The
structure was solved by direct methods and refined by full-matrix least-
squares techniques. Non-H atoms were refined with anisotropic dis-
placement parameters. H atoms were inserted in calculated positions
and refined with a riding model. The structure solution was achieved
with SHELXS-9752 and refinement with SHELXL-97,53 and graphics
were produced with ORTEP-3.54
Cell Lines and Culture Conditions. The human cancer cell lines
CH1 (ovarian carcinoma), kindly provided by Lloyd R. Kelland (CRC
Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton,
UK), as well as A549 (nonsmall cell lung cancer) and SW480 (colon
carcinoma), both provided by Brigitte Marian (Institute of Cancer
Research, Department of Medicine I, Medical University of Vienna,
Austria), were used for the experiment. Cells were grown in 75 cm2
culture flasks (Iwaki/Asahi Technoglass, Gyouda, Japan) as adherent
monolayer cultures in a complete medium [i.e., Minimal Essential
Medium (MEM) supplemented with 10% heat-inactivated fetal bovine
serum, 1 mM sodium pyruvate, 2 mM L-glutamine, and 1% nonessential
amino acids for the standard condition experiments and bicarbonate-free
Dulbecco’sModified EaglesMedium (DMEM) supplemented with 10%
heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 4 mM
L-glutamine, 1% nonessential amino acids, and 8.8 mM (pH 6.0) or
39.6 mM (pH 7.4) sodium bicarbonate for pH-dependent experiments
(all purchased from Sigma-Aldrich, Austria)]. Cell cultures were incubated
at 37 C in a moist atmosphere containing 5% CO2 (standard conditions)
or 8% CO2 (pH-dependent experiments).
Cytotoxicity Tests in Cancer Cell Lines. The cytotoxic activity
of the compounds was determined by means of a colorimetric micro-
culture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide). A549, CH1, and SW480 cells were
harvested from culture flasks by trypsinization and seeded in 100 μL
aliquots inMEM into 96-well plates (Iwaki/Asahi Technoglass, Gyouda,
Japan) in cell densities of 3 103, 1 103, and 2.5 103 cells per well,
respectively. After 24 h of preincubation of the cells, the test compounds
were dissolved in a complete medium and then added in aliquots of
100 μL per well. After continuous exposure for 96 h, drug solutions were
replaced with 100 μL of RPMI 1640 medium (supplemented with 10%
heat-inactivated fetal bovine serum and 2 mM L-glutamine) plus 20 μL
of MTT solution in phosphate-buffered saline (5 mg/mL). After
incubation for 4 h, the medium/MTT mixtures were removed, and
the formazan crystals formed by viable cells were dissolved in 150 μL of
DMSO per well. Optical densities at 550 nm were measured with a
microplate reader (Tecan Spectra Classic), using a reference wavelength
of 690 nm to correct for unspecific absorption. The quantity of viable
cells was expressed in terms of T/C values by comparison to untreated
control microcultures, and 50% inhibitory concentrations (IC50) were
calculated from concentration-effect curves by interpolation. Evaluation
is based on means from at least three independent experiments, each
comprising three replicates per concentration level. For pH-dependent
experiments, A549 and SW480 cells were harvested from culture flasks
by trypsinization and seeded in 100 μL aliquots in DMEM (pH 7.4) into
96-well plates in cell densities of 3  103 and 4  103 cells per well,
respectively. After 24 h, the medium from adherent microcultures was
removed, and cells were exposed to the drug solutions (200 μL per well)
for another 24 h in a moist atmosphere containing 8%CO2 at 37 C (for
drugs dissolved in DMEM pH 6) and 5% CO2 at 37 C (for drugs
dissolved in DMEM pH 7.4), followed by incubation in drug-free
DMEM (pH 7.4) for a further 72 h. Further incubation and measure-
ments were performed as described above.
Binding of Complex 5b to 50-GMP. For investigating the time-
dependent binding of 50-GMP to complex 5b, the complex (0.5 mM)
was incubated with 50-GMP (5mM) in a phosphate buffer (10 mM, pH 6)
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at 25 C. In parallel, an experiment was performed with [Pt(1R,2R-
chxn)Cl2] under the same conditions. A second experiment was
performed with complex 5b under the same conditions, but at 37 C.
The progress of the reaction was monitored by electrospray mass
spectrometry (ESI-MS) in the positive as well as in the negaive
ion mode.
’ASSOCIATED CONTENT
bS Supporting Information. Figures with concentration-
eﬀect curves of complexes 15, 4a, 4b, 5a, and 5b in CH1 cells.
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Synthesis, characterization and cytotoxic activity of novel potentially pH-
sensitive non-classical platinum(II) complexes featuring 1,3-
dihydroxyacetone oxime ligands 
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Figure S1. Concentration-effect curves of complexes 1–5 in CH1 cells. 
Figure S2. Concentration-effect curves of complexes 4, 4a and 4b in CH1 cells. 
Figure S3. Concentration-effect curves of complexes 5, 5a and 5b in CH1 cells. 
Figure S4. ESI-MS+ spectra (m/z range 380 − 480) of 5b incubated with 5’-GMP 
Figure S5. ESI-MS+ spectra (m/z range 750 − 840) of 5b incubated with 5’-GMP 
Figure S6. ESI-MS+ spectrum (m/z range 700 −1200) of 5b incubated with 5’-GMP  
Figure S7. ESI-MS− spectrum (m/z range 500−530) of [Pt(1R,2R-chxn)Cl2] and 5b incubated 
with 5’-GMP 
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Figure S1. Concentration-effect curves of complexes 1–5 in CH1 cells, obtained by the MTT assay 
(96 h exposure). 
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Figure S2. Concentration-effect curves of complexes 4, 4a and 4b in CH1 cells, obtained by the MTT 
assay (96 h exposure). 
67
 S3 
 
 
 
0
20
40
60
80
100
0,1 1 10 100 1000
concentration (µM)
T/
C
5
5a
5b
 
Figure S3. Concentration-effect curves of complexes 5, 5a and 5b in CH1 cells, obtained by the MTT 
assay (96 h exposure). 
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Figure S4. ESI-MS+ spectra (m/z range 380 −480) of 5b incubated with 5’-GMP in the molar ratio of 
1:10 at pH 6.0 and 25ºC recorded over a period of ca. 9 days. 
69
 S5 
 
Figure S5. ESI-MS+ spectra (m/z range 750 −840) of 5b incubated with 5’-GMP in the molar ratio of 
1:10 at pH 6.0 and 25ºC recorded over a period of ca. 9 days (after the 4th day no change was 
observed). 
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Figure S6. ESI-MS+ spectrum (m/z range 700 −1200) of 5b incubated with 5’-GMP in the molar ratio 
of 1:10 at pH 6.0 and 37ºC recorded after 7 days incubation. 
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Figure S7. ESI-MS− spectrum (m/z range 500−530) of [Pt(1R,2R-chxn)Cl2] (left) and 5b (right) 
incubated with 5’-GMP in the molar ratio of 1:10 at pH 6.0 and 37ºC recorded after 7 days incubation. 
The intensity of Pt-5’-GMP bisadduct ([PtC26H38N12O16P2]2−, calcd. 1031.68) is expressed in percent 
relative to the intensity of a peak corresponding to deprotonated 5’-GMP ([C10H13N5O8P]−, 362.21). 
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ABSTRACT: Novel platinum complexes of trans-geometry 
[PtCl2{(Z)-R(H)C=NOH}2] [R = Me (1), Et (3)] and [PtCl2{(E)-
R(H)C=NOH}{(Z)-R(H)C=NOH}] [R = Me (2), Et (4)] as well as 
the classic trans-[PtCl2(R2C=NOH)2] [R = Me, Et] were reacted 
with an equivalent amount of silver acetate in acetone solution 
at ambient temperature, resulting in the formation of unprece-
dented head-to-tail oriented oximato-bridged dimers [PtCl{μ-(Z)-
R(H)C=NO}{(Z)-R(H)C=NOH}]2 [R = Me (5), R = Et (7)], 
[PtCl{μ-(Z)-R(H)C=NO}{(E)-R(H)C=NOH}]2 [R = Me (6), R = Et 
(8)], and [PtCl(μ-R2C=NO)(R2C=NOH)]2 [R = Me (9), R = Et 
(10)], correspondingly. The dimeric species feature a unique six-
membered diplatinacycle and represent the first example of 
oxime ligands coordinated to platinum via the oxygen atom. All 
complexes were characterized by elemental analyses, electrospray 
ionization mass spectrometry, IR and multinuclear (1H, 13C, and 
195Pt) NMR spectroscopy, as well as X-ray diffraction in the cases 
of dimers 6 and 9. Furthermore, the crystal and molecular 
structures of a trimeric oximato-bridged complex 11 comprising 
three platinum units connected in a chain way were established. 
The cytotoxicity of both dimers and the respective monomers 
was comparatively evaluated in three human cancer cell lines: 
cisplatin-sensitive CH1 cells as well as cisplatin-resistant SW480 
and A549 cells, whereupon structure-activity relationships were 
established. Thus, it was found that dimerization results in a 
substantial (up to 7-fold) improvement of IC50 values of (aldox-
ime)PtII compounds, whereas for the analogous complexes fea-
turing ketoxime ligands the reverse trend was observed. Re-
markably, the novel dimers proved to be not cross-resistant with 
cisplatin in SW480 cells, exhibiting up to two-fold enhanced 
cytotoxicity in comparison with the CH1 cell line and thereby 
possessing a promising potential to overcome resistance toward 
platinum anticancer drugs.  
INTRODUCTION 
Great efforts have been undertaken to develop novel anticancer 
platinum-based drugs breaking the classic structure-activity rela-
tionships.1,2 This is being done with the expectation that the 
novel species would be capable of forming DNA adducts com-
pletely dissimilar to those deriving from clinically approved 
platinum agents.3−6 Moreover, others may show a radically dif-
ferent mode of action, e.g., with respect to alternative cellular 
targets. Among reported nonclassic platinum-based complexes 
exhibiting extraordinary cytotoxic properties, there are a few 
classes of multinuclear platinum(II) compounds, viz., (i) di- and 
triplatinum(II) complexes with bridging aliphatic7−18 and aro-
matic19 diamine ligands, where the platinum units are linked in 
a linear fashion (with trinuclear complex BBR346420−26 
representing the most promising anticancer agent that reached 
phase II clinical trials); (ii) azole-bridged platinum(II) dimers, 
yielding high uptake levels as well as a high extent of interstrand 
cross-links;27−35 (iii) dinuclear platinum(II)-bisphosphonate com-
plexes, featuring medium cytotoxicity but capable of specific 
accumulation in the bone;36,37 and (iv) a dimeric carboplatin 
analogue, showing greater in vitro antitumor activity and lower 
toxicity in mice than carboplatin.38 All above listed species are 
able to circumvent cisplatin resistance in vitro. 
Recently, some fascinating results concerning a novel class of 
nonclassic platinum(II) complexes, i.e., ketoxime-containing 
platinum(II) species, were reported. It was demonstrated that 
trans-[PtCl2(Me2C=NOH)(NH2CHMe2)], unlike its cis-analogue, 
causes cell death via an apoptotic mechanism.39 Furthermore, 
the complexes [PtX2(R2C=NOH)2] (X = Cl, Br, I; R = Me, Et) 
exhibiting trans-configuration were shown to possess a higher 
cytotoxicity,40,41 enhanced cellular accumulation, and elevated 
DNA platination, compared to their cis-isomers.42 Hence, (ke-
toxime)PtII complexes of trans-geometry represent a new and 
promising class of platinum-based antitumor agents clashing the 
classic Cleare&Hoeschele’s structure-activity rules.1,2  
Conducting the project on synthesis and antitumor activity of 
(oxime)PtII complexes,40−42 we attempted to elucidate a solution 
behavior of these species in the course of the hydrolysis studies 
insofar as the displacement of the so-called leaving groups 
(mostly chlorido or carboxylato ligands) by water molecules is 
believed to be a prerequisite for anticancer activity of the plati-
num-based drugs. As a starting point, we determined their acidi-
ty constants by 1H NMR titration. However, we were able to 
establish only pKa1 (ca. 7.2;
43 the acid-base equilibrium is revers-
ible), whereas further titration at pH over 8 indicated a partial 
irreversibility of the system due to a chemical reaction. Being 
interested in deep understanding of possible conversions of the 
oxime complexes in aqueous solutions, we carried out a synthet-
ic experiment and isolated novel-type oximato-bridged di- and 
trinuclear species generated as a result of association of the 
oximato complexes. 
Herein, we report on the synthesis and characterization of un-
precedented di- and triplatinum(II) oximato-bridged species 
derived from classic trans-configured ketoxime platinum(II) 
complexes40,41 as well as from newly prepared aldoxime analo-
75
 gues. Furthermore, the cytotoxicity of the novel monomeric and 
dimeric compounds was comparatively evaluated in three hu-
man tumor cell lines originating from cisplatin-sensitive (CH1) 
or resistant (SW480 and A549) cancer cells. 
 
RESULTS AND DISCUSSION 
Recently, we reported on the promising cytotoxic properties of 
trans-configured platinum(II) ketoxime complexes.40−42 In line 
with these results, we now have focused on the development of 
new aldoxime analogues featuring (E)- or (Z)-R(H)C=NOH (R = 
Me, Et) ligands in trans-configuration. As expected, the novel 
agents exhibit considerably higher aqueous solubility as com-
pared to their ketoxime congeners with ligated R2C=NOH (R = 
Me, Et). As a next step of the project, we performed dimeriza-
tion of both aldoxime- and ketoxime-containing complexes, 
yielding head-to-tail oriented oximato-bridged dimers of the 
general formula [PtCl(μ-RR’C=NO)(RR’C=NOH)]2 (R = Me, Et; 
R’ = H, Me, Et) and verified their cytotoxic properties. In addi-
tion, for R = R’ = Et a novel structure consisting of three linked 
in a linear fashion platinum units bridged by oximato ligands 
was established. 
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 Figure 1. Platinum(II) oxime complexes used in this study. 
 
Synthesis, Characterization and X-ray Structure Determina-
tion of trans-Bis(aldoxime)platinum(II) Complexes. Genera-
tion of 1–4 (Figure 1) was carried out by a conventional 
route44−46 via the reaction of K2[PtCl4] with 2 equivs of a E/Z-
R(H)C=NOH (R = Me, Et) in an aqueous solution at room 
temperature followed by thermal isomerization in MeNO2 and 
column separation of isomers (yields are 31–35%). The com-
plexes were characterized by elemental analyses, electrospray 
ionization mass spectrometry (ESI-MS), IR, and 1H, 13C{1H}, and 
195Pt NMR spectroscopy, and also by X-ray crystallography (for 1 
and 4, Figure S1, Table S1). Trans-configuration of the com-
plexes and E/Z-configurations of the ligands were established by 
X-ray diffraction. Detailed description of syntheses and charac-
terizations of 1–4 is given in the Supporting Information, whe-
reas synthetic experiments are reported in the Experimental 
Section.  
Synthesis, Characterization, and X-ray Structure Determina-
tions of Oximato-Bridged Platinum(II) Dimers/Trimer. The 
corresponding dimeric species derived from 1–4 which were 
obtained in this work as well as originated from the previously 
reported trans-[PtCl2(R2C=NOH)2] (R = Me,
46 Et41) were pre-
pared by abstraction of a chlorido ligand with 1 equiv of silver 
acetate. The reaction was carried out in acetone at room tem-
perature for a limited time (1–3 h) in order to minimize the 
probability of acetato complex formation; final products 5–10 
(Figure 1) were purified by column chromatography, and iso-
lated in moderate yields (31–36%). 
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Figure 2. Plausible route for generation of the trimer. 
 
Interestingly, slow evaporation of a solution of complex 10 in a 
mixture of undried ethanol, ethylacetate, and acetone resulted 
in formation of trimer 11. The obtained crystals were characte-
rized by X-ray crystallography (see below), as well as by ESI-MS 
spectrometry ([M + Na]+ and [M + K]+ peaks were detected). A 
plausible mechanism of the trimer formation could be asso-
ciated with a dimer-monomer equilibrium (Figure 2). 
Complexes 5–10 gave satisfactory elemental analyses and ap-
propriate molecular ion/fragmentation patterns in the ESI-MS+ 
spectra ([M + H]+ and [M + Na]+ peaks were found). Further-
more, 5–10 were characterized by IR spectroscopy, exhibiting 
characteristic strong ν(OH) [3143–3377 cm–1] and ν(NO) [958–
970 cm–1] stretching vibrations, as well as two ν(C=N) [1609–
1625 and 1651–1681 cm–1] bands of medium intensity. Expec-
tedly, two sets of oxime proton signals were observed in the 1H 
NMR spectra of all prepared dimers, corresponding to the 
bridging and nonbridging ligated oximes. Starting with Z/E 
monomeric complexes 2 and 4, the respective dimers [PtCl{µ-
(Z)-R(H)C=NO}{(E)-R(H)C=NOH}]2 (R = Me (6), Et (8)), featur-
ing bridging Z-oximato ligands, were formed as major products. 
However, traces of Z,E- (6a/8a) and E,E-oximato bridged dimers 
(6b/8b) were detected by NMR spectroscopy. Moreover, disso-
lution of 6 and 8 in CD3OD led to an increase of the signals of 
the latter species with time, resulting in the following equili-
brium ratios: 6 : 6a : 6b ≈ 7 : 2 : 1 and 8 : 8a : 8b ≈ 3 : 2 : 1. 
This fact could be explained by equilibrium possibly established 
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 Table 1. Crystal Data and Details of Data Collection for 1, 4, 6, 9, and 11 
 1 4 6 9 11 
empirical formula C4H10Cl2N2O2Pt C6H14Cl2N2O2Pt C8H18Cl2N4O4Pt2 C12H26Cl2N4O4Pt2 C30H62Cl2N6O6Pt3 
fw 384.13 412.18 695.34 751.45 1259.03 
space group P-1 Pn P21/c P-1 P-1 
a, Å 4.2101(3) 4.3305(3) 11.1533(6) 8.4994(8) 9.2330(3) 
b, Å 6.5803(6) 10.0784(6) 10.7869(6) 9.7473(10) 9.5490(3) 
c, Å 8.7596(7) 13.1600(7) 13.1609(7) 13.5101(15) 11.2825(4) 
α, deg 75.388(4)   79.033(3) 85.637(3) 
β, deg 82.707(5) 98.440(4) 95.596(3) 79.998(3) 82.020(2) 
γ, deg 78.825(4)   67.676(2) 80.387(2) 
V, Å3 229.59(3) 568.14(6) 1575.84(15) 1010.11(18) 969.84(6) 
Z 1 2 4 2 1 
λ, Å 0.71073 0.71073 0.71073 0.71073 0.71073 
ρcalcd, g cm
−3 2.778 2.409 2.931 2.471 2.156 
crystal size, mm 0.50 × 0.04 × 0.01 0.30 × 0.05 × 0.05 0.13 × 0.13 × 0.04 0.20 × 0.20 × 0.15 0.20 × 0.10 × 0.05 
T, K 100 100 100 100 100 
μ, cm−1 158.16 127.92 180.90 141.21 10.976 
R1a 0.0185 0.0336 0.0369 0.0287 0.0302 
wR2b 0.0407 0.0659 0.0951 0.0719 0.0736 
GOFc 1.033 1.024 1.005 1.081 1.031 
aR1 = Σ||Fo| − |Fc||/Σ|Fo|. bwR2 = {Σ[w(Fo2 − Fc2)2]/Σ[w(Fo2)2]}1/2. cGOF = {Σ[w(Fo2 − Fc2)2] /(n − p)}1/2, where n is the number of reflec-
tions and p is the total number of parameters refined. 
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Figure 3. Equilibrium in CD3OD solution of 6 and 8.  
 
between a dimer and its corresponding monomer in solution, 
resulting in a mixture of dimers (Figure 3). 
In the 195Pt NMR spectra, the platinum signals of aldoxime-
containing dimers 5–8 appear in a narrow range between –208 
and –251 ppm, while δPt of corresponding ketoxime complexes 
9 and 10 resonate at a lower field (–35 and –152 ppm, respec-
tively). 
The crystal structures of dimers 6 and 9, and trimer 11 were 
determined by X-ray diffraction (Tables 1, 2 and 3, Figures 4 
and 5). The three compounds feature pairs of head-to-tail 
oriented oximato ligands, which bind the platinum centers via 
the oximic nitrogen and the oxygen of the deprotonated hy-
droxo group. In 11, three platinum atoms are connected to 
each other via bridging ligands in a chain manner. Apart from 
the bridging ligands, the coordination sphere of each platinum 
center in 6 and 9 and the terminal Pt’s in 11 is completed by 
the corresponding aldoxime (6) or ketoxime (9 and 11) and a 
chlorido ligand. 
 
 
Figure 4. ORTEP view of 6 (left) and 9 (right) with the atom labe-
ling scheme; the thermal ellipsoids have been drawn at the 50% 
probability level. 
 
A comparison of selected geometric features of oximato-bridged 
platinum complexes 6, 9, and 11 is presented in Table 4. Inte-
restingly, the Pt···Pt distances in 6 and 11 (3.1872(6) and 
3.2094(2) Å, respectively) are considerably longer compared to 
that in 9 (2.8668(5) Å), that is probably due to an increased 
steric effect exerted by the alkyl substituents of the nonbridging 
oxime ligand directed to the platinum-platinum core. Contrary 
to 6 and 11, in 9, the methyl substituents of the coordinated 
acetoxime are turned away from the bisoximato bridge. Moreo-
ver, the two hydrogen bonds between the oximic hydroxo group 
of one platinum unit and chlorido ligand of the second one 
could favor the approaching of two platinum centers and result 
in an additional stabilization of the dimeric structure of 9. The 
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 O4···Cl1 and O2···Cl2 distances are at 3.301 and 3.303 Å, 
respectively. These distances fall into the range of typical O···Cl 
contacts when OH···Cl hydrogen bonding takes place 
[2.95−3.40 Å],47 representing relatively weak interactions com-
pared to the reported values. The angles O4−H4···Cl1 and 
O2−H2···Cl2 are 145.3 and 162.3º, correspondingly. 
 
 
Table 2. Selected Bond Lengths (Å) and Angles (deg) for 
Complexes 6 and 9 
 6 9 
Pt(1)−N(1) 1.992(9) 2.009(6) 
Pt(1)−N(2) 2.032(9) 2.019(7) 
Pt(1)−Cl(1) 2.282(2) 2.2962(19) 
Pt(1)−O(3) 2.023(7) 2.030(5) 
Pt(2)−N(3) 1.974(8) 2.012(6) 
Pt(2)−N(4) 2.024(9) 2.026(6) 
Pt(2)−Cl(2) 2.291(3) 2.2981(19) 
Pt(2)−O(1) 2.036(8) 2.016(5) 
N(1)−C(1) 1.260(14) 1.294(10) 
N(2)−C(3) 1.264(14)  
N(3)−C(5) 1.278(14)  
N(4)−C(7) 1.268(15)  
N(2)−C(4)  1.273(10) 
N(3)−C(7)  1.289(10) 
N(4)−C(10)  1.272(10) 
   
N(1)−Pt(1)−N(2) 176.2(3) 177.0(3) 
N(1)−Pt(1)−Cl(1) 91.6(3) 90.88(19) 
N(2)−Pt(1)−Cl(1) 89.8(2) 91.09(18) 
N(3)−Pt(2)−N(4) 177.5(4) 176.0(3) 
N(3)−Pt(2)−Cl(2) 91.0(3) 90.26(19) 
N(4)−Pt(2)−Cl(2) 90.4(3) 92.04(19) 
 
 
Generally, the distances between the adjacent platinum atoms 
in 6, 9, and 11 are shorter than a double van der Waals radius 
for Pt [1.72 × 2 = 3.44 Å]. Compared to the reported Pt···Pt 
distances in the platinum(II) dimeric complexes featuring two 
bridging ligands, e.g., (i) α-pyridonate [2.88−2.90 Å],48 (ii) 1-
methyluracilate or 1-methylthyminate [2.927−2.986 Å],49 (iii) 
amidate [2.993−3.060 Å],50 (iv) amidinate [3.381 Å],51 and (v) 
carboxylate [2.952−2.990 Å],52 the Pt···Pt distances in 6 and 11 
correspond to a rather weak nonbonded interaction between 
the platinum centers. On the contrary, the Pt···Pt distance in 9 
is one of the shortest known for platinum(II) dimers. Being in 
good agreement with literature data,53,54 the tilt angle (τ) be-
tween the neighboring platinum coordination planes is directly 
related to the Pt···Pt distance. Thus, the shortest Pt···Pt dis-
tance in 9 corresponds to the lowest τ value (57.2º versus 81.4º 
and 85.3º for 6 and 11, respectively), additionally confirming 
the lowest repulsive interactions in case of the acetone oxime-
containing platinum(II) dimer. The coordination planes in 6 
and 9 are twisted only slightly (ω = 9.9 and 2.5º, corresponding-
ly), while in 11 the twist angle was proved to be substantially 
higher (ω = 19.2º), serving to minimize the steric interactions 
between the ethyl substituents of the bridging oximato and 
nonbridging oxime ligands. 
 
 
 
Figure 5. ORTEP view of 11 with the atom labeling scheme; the 
thermal ellipsoids have been drawn at the 30% probability level. 
 
The platinum ions in 6, 9, and the terminal Pt’s in 11 nearly 
adopt a square-planar geometry, being slightly displaced out of 
the coordination plane by 0.02−0.06 Å, whereas Pt1 in 11 lies 
ideally within the corresponding N1−O2−N1'−O2' plane. The 
Pt−Cl bond lengths [2.282(2)−2.3169(13) Å] correspond to 
previously reported distances for platinum(II) chlorido com-
pounds.55,56 The Pt−N and Pt−O bond lengths appear in the 
range normally found in related platinum(II) complexes,51,57,58 
namely: 1.974(8)−2.032(9) Å and 2.005(3)−2.047(3) Å, respec-
tively. The values of C=N distances [1.260(14)−1.294(10) Å] are 
similar within 3σ and correspond to previously published dis-
tances of C=N double bonds in metal-bound oximes.59−61  
Comparative Studies of the Cytotoxic Activity of Novel Plati-
num(II) Oxime Complexes and Corresponding Oximato-
Bridged Dimers. In view of our previous findings on antitumor 
activity of trans-(oxime)PtII complexes,40,41 the cytotoxicity of 1−9 
was evaluated in comparison with cisplatin and transplatin by 
means of a colorimetric microculture assay (MTT) in three hu-
man cancer cell lines: cisplatin-sensitive ovarian carcinoma 
(CH1), as well as intrinsically cisplatin-resistant colon carcinoma 
(SW480) and nonsmall cell lung cancer (A549) cell lines, yield-
ing IC50 values listed in Table 5. The cytotoxic potency of dimer 
10 could not be examined because of its insufficient aqueous 
solubility. 
Generally, CH1 and SW480 cancer cell lines showed similar 
response toward both monomeric (1−4) and dimeric (5−9) 
complexes, as it was also reported for (ketoxime)PtII species.41 
However, in case of 1 and 3 nearly 2-fold improvement of the 
cytotoxic potency in cisplatin-resistant SW480 cells compared 
to cisplatin-sensitive CH1 cells could be observed. Differently, 
the A549 cell line exhibited a somewhat lower sensitivity to the 
novel oxime complexes, yielding IC50 values increased by factors 
of 2.2−4.0 for monomers 1−4 and 4.3−12 for dimers 5−9 in 
comparison with those in the CH1 cell line. 
Unexpectedly, an enlargement of the alkyl chain length of the 
oxime ligand by using propionaldehyde oxime (in 3, 4, 7, and 8) 
instead of acetaldehyde oxime (in 1, 2, 5, and 6) did not result 
in an increase of cytotoxicity in the case of monomers 1−4 and 
only slightly reduced IC50 values of dimers 5−8 (by factors 
1.1−2.3). Interestingly, some influence of E- and Z-configurati- 
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Table 3. Selected Bond Lengths (Å) and Angles (deg) for Complex 11 
Pt(1)−N(1) 2.028(4) Pt(2)−O(1A) 2.005(3) 
Pt(1)−O(2) 2.047(3) N(1)−C(1) 1.290(6) 
Pt(2)−N(2) 1.997(4) N(2)−C(6) 1.280(6) 
Pt(2)−N(3) 2.020(4) N(3)−C(11) 1.284(6) 
Pt(2)−Cl(1) 2.3169(13)   
    
N(1A)−Pt(1)−N(1) 180.000(1) N(2)−Pt(2)−N(3) 177.00(16) 
N(1)−Pt(1)−O(2) 87.66(14) N(2)−Pt(2)−Cl(1) 93.46(12) 
N(1A)−Pt(1)−O(2) 92.34(14) N(3)−Pt(2)−Cl(1) 89.46(12) 
 
 
Table 4. Selected Geometric Parameters of the Oximato-
Bridged Platinum Complexes 
 Pt···Pt, Å 
dihedral angle,a 
deg Pt···Pt···Pt angle, 
deg 
τ ω 
6 3.1872(6) 81.4 9.9 – 
9 2.8668(5) 57.2 2.5 – 
11 3.2094(2) 85.3 19.2 180.0 
a τ is the tilt angle between the adjacent platinum coordination 
planes, and ω is the average torsion angle about the Pt(1)···Pt(2) 
vector. 
 
on of the coordinated aldoximes on the IC50 values was ob-
served. Thus, monomeric complexes 2 and 4 featuring both E-
and Z-aldoximes proved to be by a factor of 2 more cytotoxic in 
CH1 cells compared to their isomers 1 and 3, containing two Z-
ligands. 
Comparing aldoxime-containing monomeric complexes 1−4 
and the corresponding dimers 5−8, it should be pointed out 
that dimerization results in 1.8- to 6.7-fold enhancement of the 
cytotoxic potency in CH1 cells. However, dimer 9 featuring a 
ketoxime ligand exhibited 13 and 11 times higher IC50 values in 
CH1 and SW480 cells, respectively, as compared to the corres-
ponding monomer trans-[PtCl2(Me2C=NOH)2],
40 reversing the 
structure-activity relationships valid for (aldoxime)PtII complex-
es. 
With respect to cisplatin, monomeric species 1−4 proved to be 
significantly less cytotoxic in CH1 (24−47 times) and A549 
(10−16 times) cell lines, while in SW480 cells the IC50 values 
were similar to that of cisplatin. Remarkably, dimers 5−9 exhi-
bited 1.3−3.0-fold improved cytotoxicity in SW480 cells com-
pared to cisplatin, being however less potent both in CH1 and 
A549 cell lines (by factors of 3.9 to 13). In comparison to 
transplatin, novel (oxime)PtII complexes 1−9 were found to 
display up to 17 times enhanced cytotoxic potency. 
Behavior of Monomer 1 and Dimer 5 in Aqueous Solution 
under Physiological Conditions. In order to reveal the beha-
vior of the prepared monomeric and dimeric species in aqueous 
solutions under the conditions used for cell culture experi-
ments, time-dependent 1H NMR measurements of monomer 1 
and the respective dimer 5 were carried out in phosphate buf-  
Table 5. Cytotoxicity of Monomeric (1–4) and Dimeric (5–9) 
(oxime)PtII Complexes in CH1, SW480, and A549 Cancer 
Cells (Exposure Time 96 h) 
Compound 
IC50 (µM), 96h 
CH1 SW480 A549 
1 6.6 ± 0.2 3.5 ± 0.1 14 ± 1 
2 3.3 ± 0.1 3.3 ± 0.1 13 ± 1 
3 6.2 ± 0.3 3.6 ± 0.1 21 ± 3 
4 3.4 ± 0.2 3.3 ± 0.04 13 ± 1 
5  0.95 ± 0.1 1.2 ± 0.1 12 ± 0.4 
6 1.8 ± 0.2 1.9 ± 0.1 12 ± 1 
7  0.94 ± 0.09 1.0 ± 0.1  5.1 ± 0.5 
8 0.96 ± 0.09 1.3 ± 0.1 5.7 ± 0.3 
9 2.2 ± 0.4 2.5 ± 0.3 9.5 ± 1.6 
trans-
[PtCl2(Me2C=NOH)2]a 
0.17 ± 0.09 0.22 ± 0.05  
cisplatin 0.14 ± 0.03 3.3 ± 0.4 1.3 ± 0.4 
transplatina 15 ± 2 19 ± 3  
a Data taken from ref. 44 
 
fered D2O solutions (10 mM, pH 7.4) containing NaCl (0.125 
M), with concentrations of complexes being ca. 400 and 200 
μM, correspondingly. Figure 6 shows a selected range of 1H 
NMR spectra (6−8 ppm) where the signals of N=CH protons 
are detected. Keeping dimer 5 or monomer 1 under these con-
ditions over three days resulted in a nearly identical peak pat-
tern (spectra (2) and (4), respectively), consisting of five N=CH 
proton signals corresponding to the dimer (black), the mono-
mer (red), the hydrolyzed monomer (green), and an additional 
so far unknown species (blue). 
These results are in good agreement with IC50 values of 1 and 5 
in SW480 cell line, showing a 2-fold improvement of the cyto-
toxicity in the case of dimer 5 as compared to monomer 1. 
However, the ratio IC50(1)/IC50(5) in two other cell lines used 
in this work deviate from a factor of 2, being 6.6 in CH1 and 
1.25 in A549 cells, indicating a slightly different behavior in 
these cell lines. 
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Figure 6. The 1H NMR spectra of monomer 1 and corresponding dimer 5 in the range 6−8 ppm: dimer 5 five min (1) and ca. three 
days (2) after dissolution in 10 mM phosphate buffered D2O solution (pH 7.4), containing 0.125 M NaCl; monomer 1 five min (3) 
and ca. three days (4) after dissolution in 10 mM phosphate buffered D2O solution (pH 7.4), containing 0.125 M NaCl; monomer 1 
five min (5), five h (6) and ca. three days (7) after dissolution in 10 mM phosphate buffered D2O solution (pH 7.4) in the absence of 
NaCl. 
 
 
Spectra (5)−(7) (Figure 6) additionally represent time-dependent 
hydrolysis studies of complex 1. For this purpose no sodium 
chloride was added to the phosphate buffered D2O solution of 
1 (pH 7.4), resulting in an enhanced aquation of the complex. 
Five minutes after dissolution of the compound, a peak corres-
ponding to the N=CH proton of the hydrolyzed species (green) 
could be observed (spectrum (5)). A total of 5 h after the expe-
riment was started, the dichlorido complex (red) was completely 
converted into the aqua species (green) (spectrum (6)). In addi-
tion, small signals related to the dimeric species (black) were 
detected. Finally, three days later, the mixture of N=CH proton 
signals turned into one single peak (blue) (spectrum (7)). With 
the intention to elucidate which species was formed as a result 
of the conversions taking place in the aqueous solution, 195Pt 
NMR spectrum was recorded. A signal at 316.7 ppm was ob-
served, which correlate well with the δPt values for trans-
configured platinum(II) species having [N2O2] ligand donor set 
reported in the literature in the range between 209 and 366 
ppm.62 Further, in ESI-MS+ spectrum a peak at m/z 956 was 
detected that could be attributed to a sodiated trimeric complex 
[Pt3(C2H4NO)6 + Na]
+ (C12H24N6O6Pt3Na, calcd m/z 956.06). 
Due to the fact, that only one set of N=CH proton signals was 
observed in the 1H NMR spectrum (7), a ring-shaped trimeric 
structure containing six equivalent oximato bridges can be sug-
gested (Figure 7). 
Geometry Optimization. Full geometry optimization for a ring-
shaped Z-acetaldoximato-bridged trimer was performed at the 
DFT B3LYP theoretical level. In the optimized structure (Figure 
7), three platinum atoms display square-planar geometries de-
viating only slightly (by 0.075−0.080 Å) from their respective 
N−O−N−O coordination planes. The optimized Pt−O 
[2.068−2.075 Å] and Pt−N [2.041−2.048 Å] distances appeared 
to be somewhat longer as compared to those bond lengths ob-
served in the X-ray structures of dimers 6 and 9, and trimer 11 
(Pt−O [2.005(3)−2.047(3) Å] and Pt−N [1.974(8)−2.032(9) Å]). 
As the Pt···Pt distances are concerned, they were found be-
tween 3.019 and 3.033 Å in the optimized structure, correlating 
well with the values measured for 6, 9, and 11 
[2.8668(5)−3.2094(2) Å]. 
 
 
 
Figure 7. An optimized structure of a ring-shaped trimer. 
 
CONCLUSIONS 
A possibility of di- and trimerization of (oxime)PtII complexes 
leading to the formation of a six-membered diplatinacycle has 
been demonstrated. The oximato-bridged platinum(II) dimers 
were isolated and completely characterized, including X-ray 
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7 
diffraction in case of two dimers. Additionally, a crystal struc-
ture of a novel oximato-bridged platinum(II) trimer featuring 
platinum units connected to each other in a chain manner was 
determined.  
Although the bridging properties of oximic ligands have been 
extensively studied, e.g., nearly exhaustively in the case of group 
VIII metals (Fe,63,64 Ru,65 Os,66 Co,67,64 Ni,63,64,68−70 and Pd69), and 
partially for some representatives of group I (Cu63,68,70−84,), II 
(Zn,63,64,85 Cd85), III (Gd64), IV (Ti,86 Zr86), VI (Cr64) and VII 
(Mn63,64,87−89), there are no reports on oximato-bridged platinum 
complexes. Moreover, to the best of our knowledge the novel di-
/trimer(s) exhibit a unique six-membered diplatinacycle as well 
as represent the first example of oxime/oximato ligands coordi-
nated to the platinum atom via the oxygen.  
In general, the di-/trimerization observed in this work on the 
kinetically inert platinum(II) center could give a possible ratio-
nale for various polymerizations involving oxime/oximato spe-
cies based on more labile metals. Considering these results, 
previous work on the synthesis of polymeric oximato-bridged 
complexes should be thoroughly revisited and the possibility of 
the consecutive association of the monomeric oximato units 
should be taken into account in further studies. 
Additionally, the cytotoxic properties of the novel dimers were 
examined in three human cancer cell lines (CH1, SW480, and 
A549) in comparison with the corresponding monomeric com-
plexes of trans-geometry and structure-activity relationships were 
established. It was found that dimerization improves significant-
ly the cytotoxic potency of the aldoxime-containing complexes, 
whereas the dimer bearing ketoxime ligands proved to be consi-
derably less potent than the respective monomer. Notably, the 
novel oximato-bridged dimers display appreciably enhanced 
cytotoxicity in the intrinsically cisplatin-resistant SW480 cell 
line as compared to cisplatin, indicating in perspective a prom-
ising potential to overcome cisplatin resistance. 
 
EXPERIMENTAL 
General Procedures. Potassium tetrachloridoplatinate and 2-
propanone oxime were supplied by Johnson Matthey and Fluka, 
respectively. 3-Pentanone, acetaldehyde oxime (a mixture of syn 
and anti forms) and propionaldehyde oxime (a mixture of syn 
and anti forms) were purchased from Aldrich. All these chemi-
cals were used as received without further purification. 3-
Pentanone oxime was synthesized from the corresponding ke-
tone by a standard text-book procedure.90,91 Complexes trans-
[PtCl2(Me2C=NOH)2]
46 and trans-[PtCl2(Et2C=NOH)2]
41 were 
prepared accordingly to the previously published methods start-
ing from K2[PtCl4]. Synthetic procedures were carried out in a 
light-protected environment when platinum was involved. Fluka 
silica gel 60 (220−440 mesh) was used for column chromato-
graphy. C, H, and N elemental analyses were carried out by the 
elemental analyses laboratory of the University of Vienna using 
a Perkin-Elmer 2400 CHN elemental analyzer. ESI-MS spectra 
were obtained with a Bruker Esquire 3000 instrument. IR spec-
tra were obtained by using an ATR unit with a Perkin-Elmer 
370 FTIR 2000 instrument (4000–400 cm−1). 1H, 13C{1H}, and 
195Pt NMR spectra were measured with a Bruker Avance III 500 
MHz NMR spectrometer at 500.32 (1H), 125.81 (13C), and 
107.55 MHz (195Pt), correspondingly, at 298 K. 195Pt chemical 
shifts are given relative to K2[PtCl4], and the half-height line 
width is given in parentheses. 
Reaction of K2[PtCl4] with Z/E-R(H)C=NOH (R = Me, Et). 
K2[PtCl4] (0.7 mmol) was dissolved in 15 mL of H2O and a so-
lution of Z/E-R(H)C=NOH (1.4 mmol) in 2 mL of H2O was 
added dropwise. The reaction mixture was stirred for 24 h at 
room temperature. A small amount of undefined reddish preci-
pitate formed was filtered off, washed with H2O and dried in 
vacuo. The filtrate was evaporated to dryness and 10 mL of 
MeOH added. A colorless precipitate of KCl was filtered off. 
Then MeOH was removed on a rotary evaporator and 5 mL of 
CHCl3 or Et2O (for R = Me or Et, respectively) was added, whe-
reupon a yellow precipitate of K[PtCl3{R(H)C=NOH}] was fil-
tered off, washed with CHCl3 or Et2O (2×2 mL) and dried in 
vacuo (yield was 23–26%). The filtrate was evaporated to dryness 
and the crude product was stored for purification with column 
chromatography, see below. 
To a solution (K[PtCl3{R(H)C=NOH}], 0.16−0.18 mmol) in 10 
mL of H2O an equivalent amount of Z/E-R(H)C=NOH was 
added and the reaction mixture was stirred at room temperature 
for 24 h. The solvent was removed, 10 mL of MeOH were add-
ed and a colorless precipitate of KCl was filtered off, whereupon 
MeOH was removed on a rotary evaporator, the solid residue 
was combined with the crude products synthesized previously 
(see above) and 15 mL of MeNO2 was added, whereupon the 
reaction mixture was refluxed for 1 h. After that the solvent was 
removed and products 1 (1st fraction) and 2 (2nd fraction), or 3 
(1st fraction) and 4 (2nd fraction) were separated by column 
chromatography (CHCl3 : Me2C=O 8:1 (v/v) for R = Me and 
10:1 (v/v) for R = Et). Yields of 1–4: 31–35%. 
(SP-4-1)-Dichloridobis((1Z)-N-hydroxyethanimine-
ĸN)platinum(II) (1). Anal. Calcd. for C4H10N2Cl2O2Pt: C, 
12.51; H, 2.62; N, 7.29. Found: C, 12.90; H, 2.46; N, 7.03%. 
ESI-MS+ (MeOH), m/z: 407 [M + Na]+, 423 [M + K]+. TLC (8:1 
(v/v) CHCl3/Me2C=O): Rf = 0.73. IR in KBr (selected bands), 
cm–1: 3202 s ν(OH), 1667 m ν(C=N), 970 s ν(NO). 1H NMR 
(CD3OD), δ: 7.39 (q, 1H, CH, 
3JH,H = 5.8 Hz), 2.05 (d, 3H, 
CH3, 
3JH,H = 5.7 Hz). 
13C{1H} NMR (CD3OD), δ: 156.4 (C=N), 
12.7 (CH3). 
195Pt NMR (CD3OD), δ: –479 (500 Hz). Crystals for 
X-ray study were obtained by slow evaporation of an ace-
tone/toluene solution. 
(SP-4-1)-Dichlorido((1E)-N-hydroxyethanimine-ĸN)((1Z)-N-
hydroxyethanimine-ĸN)platinum(II) (2). Anal. Calcd. for 
C4H10N2Cl2O2Pt: C, 12.51; H, 2.62; N, 7.29. Found: C, 12.79; 
H, 2.60; N, 7.22%. ESI-MS+ (MeOH), m/z: 407 [M + Na]+, 466 
[M + Me(H)C=NOH + Na]+, 482 [M + Me(H)C=NOH + K]+. 
ESI-MS– (MeOH), m/z: 287 [M – Me(H)C=NOH – HCl – H]–. 
TLC (8:1 (v/v) CHCl3/Me2C=O): Rf = 0.52. IR in KBr (selected 
bands), cm–1: 3215 s ν(OH), 1677 m ν(C=N), 980 s ν(NO). 1H 
NMR (CD3OD), δ: 7.51 (q, 1H, CH, 
3JH,H = 6.1 Hz), 7.50 (q, 
1H, CH, 3JH,H = 5.7 Hz), 2.49 (d, 3H, CH3, 
3JH,H = 6.1 Hz), 2.05 
(d, 3H, CH3, 
3JH,H = 5.7 Hz). 
13C{1H} NMR (CD3OD), δ: 156.0 
(C=N), 155.4 (C=N), 16.1 (CH3), 12.7 (CH3). 
195Pt NMR 
(CD3OD), δ: –532 (550 Hz). 
(SP-4-1)-Dichloridobis((1Z)-N-hydroxypropane-1-imine-
ĸN)platinum(II) (3). Anal. Calcd. for C6H14N2Cl2O2Pt: C, 
17.48; H, 3.42; N, 6.80. Found: C, 17.77; H, 3.11; N, 6.65%. 
ESI-MS+ (MeOH), m/z: 435 [M + Na]+, 451 [M + K]+. TLC (10:1 
(v/v) CHCl3/Me2C=O): Rf = 0.54. IR in KBr (selected bands), 
cm–1: 3338 s ν(OH), 1671 m ν(C=N), 985 s ν(NO). 1H NMR 
(CD3OD), δ: 7.29 (t, 1H, CH, 
3JH,H = 5.8 Hz), 2.52 (m, 2H, 
CH2), 1.09 (t, 3H, CH3, 
3JH,H = 7.7 Hz). 
13C{1H} NMR (CD3OD), 
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δ: 161.9 (C=N), 20.9 (CH2), 8.6 (CH3). 
195Pt NMR (CD3OD), δ: 
–490 (510 Hz).  
(SP-4-1)-Dichlorido((1E)-N-hydroxypropane-1-imine-ĸN)(1Z)-N-
hydroxypropane-1-imine-ĸN)platinum(II) (4). Anal. Calcd. for 
C6H14N2Cl2O2Pt: C, 17.48; H, 3.42; N, 6.80. Found: C, 17.73; 
H, 3.13; N, 6.66%. ESI-MS+ (MeOH), m/z: 435 [M + Na]+, 451 
[M + K]+. ESI-MS– (MeOH), m/z: 301 [M – Et(H)C=NOH – 
HCl – H]–. TLC (10:1 (v/v) CHCl3/Me2C=O): Rf = 0.41. IR in 
KBr (selected bands), cm–1: 3246 s ν(OH), 3204 s ν(OH), 1676 
m ν(C=N), 1666 m ν(C=N), 983 s ν(NO). 1H NMR (CD3OD), 
δ: 7.42 (t, 1H, CH, 3JH,H = 6.9 Hz), 7.39 (t, 1H, CH, 
3JH,H = 5.8 
Hz), 3.04 (m, 2H, CH2), 2.52 (m, 2H, CH2), 1.21 (t, 3H, CH3, 
3JH,H = 7.6 Hz), 1.11 (d, 3H, CH3, 
3JH,H = 7.7 Hz). 
13C{1H} NMR 
(CD3OD), δ: 161.5 (C=N), 160.0 (C=N), 24.6 (CH2), 20.9 
(CH2), 9.3 (CH3), 8.6 (CH3). 
195Pt NMR (CD3OD), δ: –529 (500 
Hz). Crystals for X-ray study were obtained by slow evaporation 
of a methanol/toluene solution. 
Dimerization of trans-Bis(aldoxime)- and trans-
Bis(ketoxime)platinum(II) Complexes. Monomers 1–4 and 
trans-[PtCl2(R2C=NOH)2] (R = Me
46, Et41) (0.1 mmol) were dis-
solved in 2–3 mL of acetone and an equivalent amount of 
AgOAc (0.1 mmol) was added. The reaction mixture was stirred 
at room temperature for 1–3 h (followed by TLC), then the 
precipitate of AgCl was filtered off and the resulting yellow 
solution was reduced to dryness. The product was isolated by a 
column chromatography as the first fraction using a mixture of 
CHCl3 and Me2C=O as mobile phase with a ratio of 20:1 for 5, 
8:1 for 6 and 9, 30:1 for 7, and 10:1 for 8 and 10. Yields were 
31–36%. 
(SP-4-2)-Di-µ-((1Z)-N-oxyethanimine-ĸN,ĸO)bis[chlorido((1Z)-
N-hydroxyethanimine-ĸN)platinum(II)] (5). Anal. Calcd. for 
C8H18N4Cl2O4Pt2: C, 13.82; H, 2.61; N, 8.06. Found: C, 13.87; 
H, 2.36; N, 7.65%. ESI-MS+ (MeOH), m/z: 542 [M – 2 
Me(H)C=NOH – Cl]+, 600 [M – 2 Me(H)C=NOH + Na]+, 718 
[M + Na]+, 734 [M + K]+. TLC (20:1 (v/v) CHCl3/Me2C=O): Rf 
= 0.58. IR in KBr (selected bands), cm–1: 3247 s ν(OH), 1678 
and 1619 m ν(C=N), 970 s ν(NO). 1H NMR (CD3OD), δ: 7.59 
(q, 1H, CH, 3JH,H = 5.8 Hz), 6.99 (q, 1H, CH, 
3JH,H = 5.8 Hz), 
2.07 (d, 3H, CH3, 
3JH,H = 5.7 Hz), 1.94 (d, 3H, CH3, 
3JH,H = 5.8 
Hz). 13C{1H} NMR (CD3OD), δ: 153.8 (C=N), 151.3 (C=N), 
12.3 (CH3), 12.1 (CH3). 
195Pt NMR (CD3OD), δ: –208 (480 Hz). 
(SP-4-2)-Di-µ-((1Z)-N-oxyethanimine-ĸN,ĸO)bis[chlorido((1E)-
N-hydroxyethanimine-ĸN)platinum(II)] (6). Anal. Calcd. for 
C8H18N4Cl2O4Pt2: C, 13.82; H, 2.61; N, 8.06. Found: C, 14.02; 
H, 2.42; N, 7.72%. ESI-MS+ (MeOH), m/z: 600 [M – 
Me(H)C=NOH – Cl]+, 676 [M – 2 Me(H)C=NOH + K]+, 718 
[M + Na]+, 734 [M + K]+. TLC (8:1 (v/v) CHCl3/Me2C=O): Rf = 
0.48. IR in KBr (selected bands), cm–1: 3248 s ν(OH), 1676 and 
1618 m ν(C=N), 964 s ν(NO). 1H NMR (CD3OD), δ: 7.78 (q, 
1H, CH, 3JH,H = 5.8 Hz), 7.38 (q, 1H, CH, 
3JH,H = 6.2 Hz), 2.33 
(d, 3H, CH3, 
3JH,H = 6.2 Hz), 2.09 (d, 3H, CH3, 
3JH,H = 5.8 Hz),. 
13C{1H} NMR (CD3OD), δ: 154.1 (C=N), 152.0 (C=N), 15.8 
(CH3), 12.4 (CH3). 
195Pt NMR (CD3OD), δ: –251 (490 Hz). 
Crystals for X-ray study were obtained by slow evaporation of a 
methanol/toluene solution at room temperature. 
(SP-4-2)-Di-µ-((1Z)-N-oxypropane-1-imine-
ĸN,ĸO)bis[chlorido((1Z)-N-hydroxypropane-1-imine-
ĸN)platinum(II)] (7). Anal. Calcd. for C12H26N4Cl2O4Pt2: C, 
19.18; H, 3.49; N, 7.46. Found: C, 19.11; H, 3.25; N, 7.22%. 
ESI-MS+ (MeOH), m/z: 628 [M – 2 Et(H)C=NOH + Na]+, 716 
[M – Cl]+, 752 [M + H]+, 774 [M + Na]+. TLC (CHCl3): Rf = 
0.59. IR in KBr (selected bands), cm–1: 3232 s ν(OH), 1660 and 
1625 m ν(C=N), 961 s ν(NO). 1H NMR (CD3OD), δ: 7.50 (t, 
1H, CH, 3JH,H = 5.7 Hz), 6.88 (t, 1H, CH, 
3JH,H = 5.8 Hz), 2.55 
(m, 2H, CH2), 2.43 (m, 2H, CH2), 1.13 (t, 3H, CH3, 
3JH,H = 7.6 
Hz), 1.06 (t, 3H, CH3, 
3JH,H = 7.7 Hz). 
13C{1H} NMR (CD3OD), 
δ: 160.0 (C=N), 157.9 (C=N), 20.6 (CH2), 20.5 (CH2), 8.9 
(CH3), 8.7 (CH3). 
195Pt NMR (CD3OD), δ: –212 (440 Hz). 
(SP-4-2)-Di-µ-((1Z)-N-oxypropane-1-imine-
ĸN,ĸO)bis[chlorido((1E)-N-hydroxypropane-1-imine-
ĸN)platinum(II)] (8). Anal. Calcd. for C12H26N4Cl2O4Pt2: C, 
19.18; H, 3.49; N, 7.46. Found: C, 19.21; H, 3.43; N, 7.16%. 
ESI-MS+ (MeOH), m/z: 628 [M – 2 Et(H)C=NOH + Na]+, 716 
[M – Cl]+, 752 [M + H]+, 774 [M + Na]+. TLC (20:1 (v/v) 
CHCl3/Me2C=O): Rf = 0.71. IR in KBr (selected bands), cm
–1: 
3250 s ν(OH), 1681 and 1624 m ν(C=N), 958 s ν(NO). 1H 
NMR (CD3OD), δ: 7.70 (t, 1H, CH, 
3JH,H = 5.7 Hz), 7.31 (t, 1H, 
CH, 3JH,H = 6.8 Hz), 2.89 (m, 2H, CH2), 2.58 (m, 2H, CH2), 
1.161 (t, 3H, CH3, 
3JH,H = 7.6 Hz), 1.160 (t, 3H, CH3, 
3JH,H = 7.7 
Hz). 13C{1H} NMR (CD3OD), δ: 159.6 (C=N), 157.2 (C=N), 
24.2 (CH3), 20.7 (CH3), 9.8 (CH3), 8.6 (CH3). 
195Pt NMR 
(CD3OD), δ: –243 (450 Hz). 
(SP-4-2)-Di-µ-(N-oxypropane-2-imine-ĸN,ĸO)bis[chlorido(N-
hydroxypropane-2-imine-ĸN))platinum(II)] (9). Anal. Calcd. 
for C12H26N4Cl2O4Pt2: C, 19.36; H, 3.27; N, 7.06. Found: C, 
19.54; H, 3.29; N, 7.43%. ESI-MS+ (MeOH), m/z: 752 [M + 
H]+, 774 [M + Na]+. TLC (8:1 (v/v) CHCl3/Me2C=O): Rf = 
0.53. IR in KBr (selected bands), cm–1: 3143 s ν(OH), 1666 and 
1620 m ν(C=N), 969 s ν(NO). 1H NMR (CDCl3), δ: 8.67 (s, 
2H, OH), 2.72 (s, 6H, CH3), 2.55 (s, 6H, CH3), 2.29 (s, 6H, 
CH3), 2.09 (s, 6H, CH3). 
13C{1H} NMR (CDCl3), δ: 165.4 
(C=N), 157.4 (C=N), 25.0 (CH3), 23.7 (CH3), 18.4 (CH3), 17.7 
(CH3). 
195Pt NMR (CDCl3), δ: –35 (400 Hz). Crystals for X-ray 
study were obtained by slow evaporation of an acetone solution 
at room temperature. 
(SP-4-2)-Di-µ-(N-oxypentane-3-imine-ĸN,ĸO)bis[chlorido(N-
hydroxypentane-3-imine-ĸN))platinum(II)] (10). Anal. Calcd. 
for C20H42N4Cl2O4Pt2: C, 27.81; H, 4.90; N, 6.49. Found: C, 
27.42; H, 4.73; N, 6.27%. ESI-MS+ (MeOH), m/z: 828 [M – 
Cl]+, 864 [M + H]+, 886 [M + Na]+. TLC (20:1 (v/v) 
CHCl3/Me2C=O): Rf = 0.43. IR in KBr (selected bands), cm
–1: 
3377 s ν(OH), 1651 and 1609 m ν(C=N), 966 s ν(NO). 1H 
NMR (CD3OD), δ: 3.59 (m, 2H, 2CHH), 3.36 (m, 2H, 2CHH), 
3.22 (m, 2H, 2CHH), 3.11 (m, 2H, 2CHH), 2.65 (m, 4H, 
4CHH), 2.52 (m, 2H, 2CHH), 2.36 (m, 2H, 2CHH), 1.34 (t, 
6H, 2CH3, 
3JH,H = 7.6 Hz), 1.21 (t, 6H, 2CH3, 
3JH,H = 7.6 Hz), 
1.16 (t, 6H, 2CH3, 
3JH,H = 7.6 Hz), 1.00 (t, 6H, 2CH3, 
3JH,H = 7.6 
Hz). 13C{1H} NMR (CD3OD), δ: 173.2 (2C=N), 168.5 (2C=N), 
29.1 (CH2), 28.9 (CH2), 28.3 (CH2), 28.1 (CH2), 22.4 (2CH2), 
22.1 (2CH2), 10.3 (4CH3), 9.17 (2CH3), 9.0 (2CH3). 
195Pt NMR 
(CD3OD), δ: –152 (510 Hz). Crystals of the trimer for X-ray 
study were obtained by slow evaporation of an EtOH, EtOAc 
and acetone mixture solution at room temperature. 
Crystal Structure Determinations. X-ray diffraction measure-
ments were performed with Bruker X8 APEX II CCD diffrac-
tometer at 100 K. Single crystals were positioned at 35 mm 
from the detector, and 1557, 1865, 1853, 3003, and 1194 
frames were measured, each for 60, 30, 5, 20, and 50 s over 1° 
scan width for 1, 4, 6, 9, and 11, respectively. The data were 
processed using SAINT software package.92 Crystal data, data 
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collection parameters, and structure refinement details for 1, 4, 
6, 9, and 11 are given in Table 1. The structures were solved by 
direct methods and refined by full-matrix least-squares tech-
niques. Non-hydrogen atoms were refined with anisotropic 
displacement parameters. H atoms were placed at calculated 
positions and refined as riding atoms in the subsequent least-
squares model refinements. The isotropic thermal parameters 
were estimated to be 1.2 times the values of the equivalent iso-
tropic thermal parameters of the non-hydrogen atoms to which 
hydrogen atoms were bonded. SHELXS-9793 was used for struc-
ture solution and SHELXL-9794 for refinement, molecular dia-
grams were produced with ORTEP.95 
Cell Lines and Culture Conditions. Human cancer cell lines: 
CH1 (ovarian carcinoma) kindly provided by Lloyd R. Kelland 
(CRC Centre for Cancer Therapeutics, Institute of Cancer 
Research, Sutton, UK), A549 (non-small cell lung cancer) and 
SW480 (colon carcinoma), both provided by Brigitte Marian 
(Institute of Cancer Research, Department of Medicine I, Med-
ical University of Vienna, Austria) were used for the experi-
ment. Cells were grown in 75 cm2 culture flasks (Iwaki/Asahi 
Technoglass, Gyouda, Japan) as adherent monolayer cultures in 
complete medium [i.e., Minimal Essential Medium (MEM) 
supplemented with 10% heat-inactivated fetal bovine serum, 1 
mM sodium pyruvate, 2 mM L-glutamine, and 1% nonessential 
amino acids (all purchased from Sigma-Aldrich, Austria)]. Cell 
cultures were incubated at 37 °C in a moist atmosphere con-
taining 5% CO2. 
Cytotoxicity in Cancer Cell Lines. The cytotoxic activity of the 
compounds was determined by means of colorimetric microcul-
ture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide). A549, CH1 and SW480 
cells were harvested from culture flasks by trypsinization and 
seeded in 100 μL aliquots in MEM into 96-well plates (Iwa-
ki/Asahi Technoglass, Gyouda, Japan) in cell densities of 3×103, 
1×103 and 2.5×103 cells per well, respectively. After 24 h prein-
cubation of the cells, the test compounds were dissolved in 
MEM, and 100 µL of solution was added per well. Compounds 
5–9, which are insufficiently soluble in medium, were dissolved 
in dimethyl sulfoxide and then diluted in MEM not to exceed 
the concentration of 0.5% DMSO in the applied solution. Af-
ter continuous exposure for 96 h, drug solutions were replaced 
with 100 µL RPMI 1640 culture medium (supplemented with 
10% heat-inactivated fetal bovine serum and 2 mM L-
glutamine) plus 20 µL MTT solution in phosphate-buffered 
saline (5 mg/ml). After incubation for 4 h, the RPMI/MTT 
mixtures were removed, and the formazan crystals formed in 
viable cells were dissolved in 150 μL of DMSO per well. Optical 
densities were measured at 550 nm with a microplate reader 
(Tecan Spectra Classic), using a reference wavelength of 690 nm 
to correct for unspecific absorption. The quantity of viable cells 
was expressed in terms of T/C values by comparison to un-
treated control microcultures, and 50% inhibitory concentra-
tions (IC50) were calculated from concentration–effect curves by 
interpolation. Evaluation is based on means from at least three 
independent experiments, each comprising three replicates per 
concentration level. 
Theoretical Calculations. All calculations were performed us-
ing the Gaussian 09 software package.96 Geometry optimization 
and frequency calculations of the complex were carried out 
using the hybrid DFT method using B3LYP functional97,99 
combined with LANLDZ basis set. No solvation models were 
employed: the results described are in the gas phase. Frequency 
calculation verified the absence of imaginary values. 
Solution Behavior. For investigation of the behavior of mono-
mer 1 and respective dimer 5 in aqueous solution, time-
dependent 1H NMR measurements were carried out in a 10 
mM phosphate buffered D2O solution at pH of 7.4 containing 
0.125 M NaCl over three days. The concentrations of complex-
es were ca. 400 and 200 μM, correspondingly. Additionally, the 
hydrolysis experiment for 1 was performed at analogous condi-
tions in the absence of NaCl. All NMR measurements were 
performed at ambient temperature. 
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1. Synthesis and Characterization of trans-Bis(aldoxime)platinum(II) Complexes. 
Generation of the target bis(aldoxime)dichloridoplatinum(II) complexes of trans-configuration 
(1–4, Figure 1) was carried out by a reaction of potassium tetrachloridoplatinate with two 
equivalents of E/Z-R(H)C=NOH (R = Me, Et) in aqueous solution at room temperature. When 
the reaction was complete, a small amount of reddish undefined precipitate insoluble in common 
solvents was filtered off, water was removed and the mixture was suspended in chloroform (for R 
= Me) or diethyl ether (in case of R = Et), whereupon K[PtCl3{R(H)C=NOH}] (23–26%) was 
isolated by filtration. Then, the filtrate was evaporated to dryness and the residue (a mixture of 
cis- and trans-[PtCl2{R(H)C=NOH}2]) was refluxed in nitromethane for 1 h in order to convert 
the cis-species into the trans-analogues. Although the reported thermal isomerization of 
acetoxime-containing platinum(II) complexes was performed in aqueous solution.
1,,2
 MeNO2 was 
used as solvent due to its inertness in order to avoid possible side-reactions/decomposition. As a 
result, a mixture of trans-[PtCl2{(Z)-R(H)C=NOH}2] and trans-[PtCl2{(E)-R(H)C=NOH}{(Z)-
R(H)C=NOH}] was obtained and the isomers were then separated by column chromatography. 
An additional amount of target species 1–4 was isolated after the reaction of 
K[PtCl3{R(H)C=NOH}] with a further equiv of the corresponding aldoxime in aqueous solution, 
resulting in overall yields of 31–35% for complexes 1–4.  
Compounds 1–4 were characterized by elemental analyses, 1H, 13C{1H}, and 195Pt NMR and IR 
spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and also by X-ray 
crystallography (for 1 and 4). C, H, and N elemental analyses were satisfactory for all complexes. 
ESI-MS spectra displayed in the positive ion mode the fragments [M + Na]
+
 and [M + K]
+
 having 
isotopic patterns that were in agreement with calculated ones. In the IR spectra of 1–4 strong 
ν(OH) [3202–3338 cm–1], medium ν(C=N) [1666–1677 cm–1] and strong ν(NO) [970–985 cm–1] 
                                                          
1
 Kukushkin, V. Yu.; Belsky, V. K.; Aleksandrova, E. A.; Konovalov, V. E.; Kirakosyan, G. A. Inorg. 
Chem. 1992, 31, 3836−3840. 
2
 Kukushkin, V. Yu.; Tudela, D.; Izotova, Y. A.; Belsky, V. K.; Stash, A. I. Polyhedron 1998, 17, 
2455−2461. 
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stretching vibrations were detected. As expected, in the 
1
H NMR spectra one set of oxime proton 
signals was observed for symmetric complexes 1 and 3, while for complexes 2 and 4, bearing two 
isomeric oxime ligands, two sets of corresponding signals were detected. It is worth mentioning 
that the signals related to the E-ligands were shifted to lower field as compared to those of the 
coordinated Z-isomers. Concerning 
195
Pt NMR spectra, a significant difference in chemical shifts 
was observed between symmetric species 1 and 3, containing two Z-ligands (δPt = –479 and –490 
ppm, respectively) and their isomers 2 and 4, featuring both E- and Z-aldoximes (δPt = –532 and –
529 ppm, correspondingly). 
2. X-ray Structure Determination for Complexes 1 and 4. The structures of trans-[PtCl2{(Z)-
Me(H)C=NOH}2] (1) and trans-[PtCl2{(E)-Et(H)C=NOH}{(Z)-Et(H)C=NOH}] (4) were 
determined by X-ray diffraction (Tables 1 and 1S, Figure 1S). The coordination geometries of the 
two complexes are slightly distorted square-planar. The deviation of the platinum atom in 
complex 4 from the mean plane through N1–Cl1–N1–Cl1 is 0.02 Å, while 1 lies ideally within 
the corresponding N1–Cl1–N2–Cl2 plane. In both compounds, the platinum center is coordinated 
by two oximic nitrogen atoms and two chlorido ligands, exhibiting trans configuration. The Pt–
Cl bond distances are in the range from 2.3046(19) to 2.307(2) Å, and these distances are in a 
good agreement with the reported dichlorido platinum(II) species of trans geometry [2.282–2.321 
Å].
3,4,5
 The Pt–N bond lengths [2.002(3)–2.019(6) Å] correlate well with the corresponding bond 
distances in previously characterized trans-bis(oxime)platinum(II) complexes [1.974–2.016 Å].2,6 
In the coordinated aldoximes, the values of C=N bond lengths are between 1.277(9) and 1.281(4) 
                                                          
3
 Scaffidi-Domianello, Yu. Yu.; Meelich, K.; Jakupec, M. A.; Arion, V. B.; Kukushkin, V. Yu.; Galanski, 
M.; Keppler, B. K. Inorg. Chem. 2010, 49, 5669–5678. 
4
 Scaffidi-Domianello, Yu. Yu.; Nazarov, A. A.; Haukka, M.; Galanski, M.; Keppler, B. K.; Schneider, J.; 
Du, P.; Eisenberg, R.; Kukushkin, V. Yu. Inorg. Chem. 2007, 46, 4469–4482. 
5
 Scaffidi-Domianello, Yu. Yu.; Haukka, M.; Kelly, P.F.; Galanski, M.; Keppler, B. K.; Kukushkin, V. 
Yu. Z. Krystallogr. NCS 2006, 221, 226–228. 
6
 Kaplan, S. F.; Kukushkin, V. Yu.; Shova, S.; Suwinska, K.; Wagner, G.; Pombeiro, A. J. L. Eur. J. 
Inorg. Chem. 2001, 1031−1038. 
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Å being in good agreement with distances of the C=N double bond in platinum(II)-bound oxime 
ligands [1.268–1.302 Å] reported recently.2,5,6 
90
5 
 
 
 
Figure S1. ORTEP view of 1 (left) and 4 (right) with the atom labeling scheme; the thermal 
ellipsoids have been drawn at the 50% probability level.  
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Table S1. Selected Bond Lengths (Å) and Angles (deg) for Complexes 1 and 4 
 1 
 
4 
Pt(1)−N(1) 2.002(3) 2.019(6) 
Pt(1)−N(2)  2.006(6) 
Pt(1)−Cl(1) 2.3066(8) 2.307(2) 
Pt(1)−Cl(2)  2.3046(19) 
N(1)−C(1) 1.281(4) 1.277(9) 
N(2)−C(4)  1.279(10) 
   
N(1)−Pt(1)−Cl(1) 89.53(8) 90.28(18) 
N(1)−Pt(1)−N(1A) 180.0  
N(1)−Pt(1)−Cl(1A) 90.47(8)  
N(2)−Pt(1)−N(1)  178.6(3) 
N(2)−Pt(1)−Cl(1)  89.55(19) 
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III. CONCLUSIONS 
 
 
In this thesis a series of novel platinum(II) complexes featuring diverse oxime ligands was prepared, 
characterized and their biological activity was investigated in vitro. 
 
In the first project, various structural modifications of cis- and trans-platinum(II) compounds with 
coordinated acetone oxime were carried out. With the aim of setting up and optimizing structure-activity 
relationships for platinum(II)(oxime) compounds, cis-/trans-[PtX2(R2C=NOH)2] [X = Cl, Br, I; R = Me, Et, n-
Pr, i-Pr] as well as  cis-/trans-[Pt(NH3)2(R2C=NOH)2](NO3)2 [R = Me, Et, n-Pr] were generated and 
characterized by elemental analysis, IR and electrospray mass spectrometry (ESI-MS), 1H, 13C, and 195Pt 
NMR spectroscopy and, in five cases, by X-ray crystallography.  
Interestingly, two of the prepared complexes, namely, trans-[PtI2(Me2C=NOH)2] and trans-[Pt(NH3)2(n-
Pr2C=NOH)2](NO3)2, were proved to exist in solution as a mixture of two temperature-dependent 
conformations. This phenomenon could be explained by a hindered rotation of the coordinated oximes 
around the Pt−N bond due to the sterically demanding iodido ligands or n-propyl groups, respectively. 
All synthesized platinum(II)(oxime) complexes were evaluated in vitro in cisplatin-sensitive ovarian 
carcinoma (CH1) and intrinsically cisplatin-resistant colon carcinoma (SW480) cell lines. Unlike cisplatin 
itself, cis-/trans-[PtX2(R2C=NOH)2] complexes showed comparable IC50 values in both cell lines, which 
indicates a powerful potential to circumvent cisplatin resistance. As expected, the lower reactive bromido 
species were found to be less cytotoxic than the chlorido analogues. Differently, the iodido compounds 
exhibited enhanced cytotoxicity as compared to the bromido species, probably based on a higher 
lipophilicity favoring cellular uptake of the complexes. Considering cis-/trans-[PtCl2(R2C=NOH)2], the 
complexes containing acetone oxime, 4-heptanone oxime and 2,4-dimethyl-3-pentanone oxime ligands 
proved to be similarly cytotoxic, whereas the pentanone oxime species were significantly less active. As 
the cationic complexes cis-/trans-[Pt(NH3)2(R2C=NOH)2](NO3)2 are concerned, no considerable 
cytotoxicity was observed, as it could be expected for the charged species exhibiting four N-donor ligands. 
Importantly, a behavior clashing the early structure-activity rules postulated by Cleare and Hoeschele, 
namely, a superior cytotoxicity of trans-complexes as compared to their cis-analogues, was observed for 
two additional cis-/trans-oximeplatinum(II) couples. 
 
In the second part of the thesis, four zwitterionic diam(m)ine(3-hydroxy-2-(oxidoimino)propan-1-olato-
к
2
N,O)platinum(II) complexes [diam(m)ine = (ammonia)2, (ethylamine)2, ethane-1,2-diamine, and (R,R)-
cyclohexane-1,2-diamine] were prepared as potential prodrugs activatable under slightly acidic conditions, 
as characteristic for many solid tumors. Further, the oximato group in the compounds comprising ethane-
1,2-diamine or (R,R)-cyclohexane-1,2-diamine ligands was protonated by a reaction with hydrochloric acid 
and consequently a chelate ring opening was performed.  
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All complexes were characterized by elemental analysis, IR and electrospray mass spectrometry (ESI-
MS), and multinuclear (1H, 13C, and 195Pt) NMR spectroscopy. Additionally, 1H, 195Pt-HMQC NMR spectra 
of the zwitterionic species were recorded, proving the N,O-chelate formation. Furthermore, the crystal 
structure of (SP−4−3)-{(R,R)-cyclohexane-1,2-diamine}(3-hydroxy-2-(oxidoimino)propan-1-olato-
к
2
N,O)platinum(II) was determined by X-ray diffraction, providing a further confirmation for the double 
deprotonation of the 1,3-dihydroxiacetone oxime ligand.  
Cytotoxic activity of the prepared complexes was evaluated by means of the MTT assay in three human 
cancer cell lines: ovarian carcinoma (CH1), colon carcinoma (SW480), and nonsmall-cell lung cancer 
(A549). Among the zwitterionic chelated species, compounds featuring two monodentate amine ligands 
proved to be more cytotoxic in CH1 cells as compared to those comprising a bidentate diamine, showing 
IC50 values in the medium or even low micromolar range. An analogous tendency was observed in 
inherently cisplatin-resistant SW480 and A549 cells, with exception of an enhanced cytotoxicity of 
(SP−4−3)-{(R,R)-cyclohexane-1,2-diamine}(3-hydroxy-2-(oxidoimino)propan-1-olato-к2N,O)platinum(II). 
The latter complex showed a completely different activity profile reminding that of oxaliplatin.  
The solution behavior of compounds featuring the ethane-1,2-diamine ligand was investigated via 
acquisition of time-dependent 1H NMR spectra at physiologically relevant proton concentrations. It was 
found that the zwitterionic complex stayed unchanged both at pH 7.4 and 6.0, whereas the protonated 
species were deprotonated at pH 7.4 and partially converted to an open-chain complex in a slightly acidic 
milieu (pH 6.0). As the open-chain compound is concerned, it was found to stay unchanged at pH 6.0, 
while at pH 7.4 a complete ring-closure was observed.  
Evaluation of the pH dependent cytotoxic potency for two latter complexes showed up to 4-fold 
improvement of the IC50 values at pH 6.0 as compared to those obtained at pH 7.4.  
In order to reveal if the monodentately bound 1,3-dihydroxiacetone oxime could act as a leaving group 
producing bisadducts with DNA, binding of (SP−4−3)-chlorido{(R,R)-cyclohexane-1,2-diamine}(1,3-
dihydroxiacetone oxime-кN)platinum(II) chloride towards a model nucleotide 5’-GMP was investigated 
using ESI-MS. Formation of the Pt-5’-GMP bisadduct was proven, although it was produced to a 
significantly lower extend as compared to bifunctional [PtCl2{(R,R)-cyclohexane-1,2-diamine}] used as a 
control. Thereby, the oxime ligand could be rated as a leaving group.  
 
In the third project, platinum(II)(aldoxime) complexes trans-[PtCl2{(Z)-R(H)C=NOH}2] and trans-[PtCl2{(E)-
R(H)C=NOH}{(Z)-R(H)C=NOH}] [R = Me, Et] featuring an enhanced aqueous solubility as compared to 
the ketoxime analogues were prepared by a reaction of K2[PtCl4] with E/Z-isomeric mixture of the 
corresponding aldoximes, followed by a thermal cis→trans-isomerization in MeNO2 solution and column 
separation of the isomers.   
Further, oximato-bridged dimers of the novel platinum(II)(aldoxime) species and trans-[PtCl2(R2C=NOH)2] 
complexes of general formula [PtCl(μ-RR’C=NO)(RR’C=NOH)]2 [R = Me, Et; R’ = H, Me, Et] were 
generated by addition of an equivalent amount of silver acetate to the respective monomer. To the best of 
our knowledge, the dimeric complexes represent the first example of oxime/oximato ligands coordinated to 
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platinum via the oxygen atom and feature a unique six-membered diplatinacycle. No oximato-bridged 
platinum complexes have been reported by now. 
Monomeric and dimeric species were completely characterized by elemental analysis, IR and electrospray 
mass spectrometry (ESI-MS), 1H, 13C, and 195Pt NMR spectroscopy and, in four cases, by X-ray 
crystallography. Additionally, the crystal structure of a pentanone oximato-bridged trimer comprising three 
platinum coordination units connected in a chain manner was determined. 
Behavior of trans-[PtCl2{(Z)-Me(H)C=NOH}2] and its corresponding dimer in aqueous solution was 
investigated under simulated physiological conditions (pH 7.4, 0.125 M NaCl) by 1H NMR spectroscopy, 
leading to the formation of practically identical equilibrium mixtures, including the monomer, its hydrolized 
product, the dimer, and an additional species, supposed to have a ring-shaped trimeric structure. 
Hydrolysis of trans-[PtCl2{(Z)-Me(H)C=NOH}2] was studied in aqueous solution at pH 7.4 in the absence of 
NaCl, leading firstly to formation of the hydrolyzed product, followed by a partial dimerization, finally being 
completely converted into the previously mentioned trimeric compound. 
Structure optimization for the ring-shaped acetaldoximato-bridged trimer was performed, demonstrating 
only a slight deviation of the geometric parameters from those in oximato-bridged dimeric structures 
determined by X-ray diffraction. 
The cytotoxic activity of the prepared monomers and dimers was investigated in vitro in three human 
cancer cell lines (CH1, SW480, and A549), showing significantly lower IC50 values (up to 6.6 times) for the 
dimers as compared to the corresponding monomers. All complexes exhibited similar cytotoxicity in 
cisplatin-sensitive CH1 and intrinsically cisplatin-resistant SW480 cell lines, indicating capability to 
circumvent cisplatin resistance. 
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